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ABSTRACT
Epithelial ovarian cancer (EOC) accounts for over 80% of ovarian carcinomas.
More than two-thirds of patients present with metastatic disease resulting in a
poor five year survival of 25%. Surgery is the mainstay of treatment;
subsequently the majority of patients receive platinum based chemotherapy
regimes. Although chemotherapy may improve progression free survival, it has
little impact on overall survival.
CA125 has an established role in monitoring response to chemotherapy and
providing a lead time to clinical relapse. Its value in prognosis, however,
requires clarification. Not all patients express CA125, therefore complementary
tumour markers have been intensively sought. The most promising antigenic
molecule to date is polymorphic epithelial mucin, against which numerous
monoclonal antibodies have been raised. Using several of these antibodies, this
thesis investigated the role of the following mucin antigens in EOC; HMFG2,
CA153, CA724 and CA199. In addition, tumour-associated trypsin inhibitor
(TATI), and p185, the glycoprotein encoded for by the neu (c erb B2/HER 2)
oncogene, were evaluated. Double-determinant immunoassay was the most
common method of antigen quantitation. An ELISA was developed for HMFG2
"in-house", while the remaining markers were measured using commercial
assay kits.
1237 blood samples were collected post-operatively from April 1984 to July
1989 from 250 EOC patients. After retrospective clinical documentation, a
database consisting of each patient's case history and serial serum marker
levels was developed in collaboration with Unilever Research to perform
statistical analyses. CA125 was elevated in a greater proportion of patients with
all FIGO stages and histological tumour types than all the other markers. Whilst
serum p185 was elevated in very few patients, there were insufficient data (the
major restriction being cost) to assess the clinical correlates of CA153, CA199,
CA724 and TATI. HMFG2 showed most promise and was therefore evaluated
in more detail.
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Both CA125 and HMFG2 correlated significantly with tumour burden. CA125
correlated significantly with response to first-line chemotherapy, but could not
distinguish complete from partial responders. HMFG2 levels fell in the majority
of responders, but did not show a significant correlation. Consequently, both
markers had poor sensitivity for microscopic and small volume macroscopic
disease at second-look laparotomy. This remains the only accurate method of
determining response in patients with no clinically evaluable disease, although
its value is questionable. HMFGa gave similar lead times to relapse as CA125,
but in fewer patients. The value of a marker lead time depends ultimately on
remaining therapeutic options; only prospective randomised trials will determine
the impact pre-clinical "serological diagnosis" of relapse has on outcome.
CA125 and HMFG2 were significant predictors of total and progression free
survival after the first cycle and throughout primary chemotherapy. Prognostic
information that may influence treatment strategy is desirable as early as
possible; in patients with a poor expected outcome continuation of aggressive
chemotherapy would not be justified. By dividing the patient group with
samples taken after the first cycle of treatment into quartiles on the basis of
marker levels, it was possible to identify different prognostic groups. The
survival curves for each quartile were not significantly different for HMFG2 but
were for CA125. It was possible to divide patients into groups with relatively
good, intermediate and poor progression free survival and survival based on
CA125 levels at this time. However, CA125 was not independent of
performance status in predicting survival. No single parameter will accurately
predict outcome in all patients, and although CA125 was an important
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Epithelial Ovarian Cancer (EOC) and its Management
2
1.1 INTRODUCTION
Epithelial ovarian cancer (EOC) presents one of the most challenging problems
to gynaecologists and oncologists. It is the sixth most common cancer in
women, accounting for 4% of all female cancers by incidence, and 6% of all
female cancer deaths (Deppe and Lawrence, 1988). The incidence is less than
that of carcinoma of the uterine cervix and corpus combined, and yet it remains
the leading cause of death due to gynaecological malignancy (Booth and Beral,
1985). More than 4000 women die of ovarian cancer each year in Britain.
The insidious onset, together with its propensity for intra-abdominal metastasis,
results in approximately two-thirds of women presenting with disseminated
disease at the time of initial diagnosis. Once the disease has spread beyond
the ovary, the prospect of cure is remote and long-term survival disappointingly
poor. Overall, the 5 year survival rate is approximately 30%. Stages I, II, III, and
IV have 5 year survival rates in the order of 61 %, 40%, 5%, and 3% respectively
(Tobias and Griffiths, 1976). Within each stage survival depends upon the
tumour grade and histopathological type. The mortality rate has remained
unaltered despite advances in surgical and staging techniques and the intro¬
duction of cisplatin containing chemotherapeutic regimes. The lack of a reliable
screening test for early diagnosis almost certainly contributes to this dismal
picture.
Surgery is the mainstay of treatment, with today's procedures among the most
involved in gynaecological surgical practice. Complete surgical resection in
patients with advanced disease is usually impossible, hence the majority require
post-operative therapy with systemic chemotherapy. About 50% of patients with
advanced disease respond to first-line chemotherapy, but responses are
usually short-lived, and second-line treatments are far less effective and less
well tolerated. Thus, most patients enter a cycle of disease remissions and
exacerbations involving multiple treatment attempts and failures.
A number of prognostic factors have been identified, including; stage, tumour
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grade and histological type, tumour ploidy, age at diagnosis, performance
status, and presence of ascites. Virtually all studies, however, have
demonstrated that the amount of residual disease left after surgery is the single
most important determinant of prognosis (for review, see Webb, 1989).
Post-operative follow-up remains a significant problem for all patients. At
present the most effective means of determining true response to therapy in
patients deemed clinically free of disease is by recourse to surgery. Numerous
reports have questioned whether second-look surgery is of benefit to patients,
given that it carries a significant morbidity and mortality rate in subjects already
compromised by disease, prior surgery and often intensive chemotherapy.
Recently, Luesley et at. (1988) have conclusively shown in a prospective
randomised trial that second-look surgery has no impact on survival.
Traditionally, oncologists have focused on the dynamics of treatment and
disease response, with increased remission rates, extension of the disease free
interval and survival being their ultimate goals. Management of advanced
disease remains a significant problem, and while earlier diagnosis may be
critical in reducing the mortality rate this has yet to be proven experimentally.
The ability to recognize and treat persistent residual or recurrent disease
effectively will undoubtedly have more immediate impact on survival. Until
recently the quality of life for these patients has rarely been examined. Perhaps
equally important in determining which patients will benefit from chemotherapy
is the identification of those who do not stand to benefit in terms of improved
disease free survival and survival, and the subsequent saving or re-allocation
of resources gained from a reduction in ineffective therapy. More emphasis
should then be placed on palliation and improving the quality of life of these
patients.
This chapter will examine the problems that ovarian cancer and its management
using conventional methods of treatment presents. Finally, it will introduce the





EOC accounts for 90% of all primary malignant ovarian cancer (Fox, 1985) and
has an average incidence of 15 new cases per 100,000 of the female
population per year (Piver, 1987). It has been estimated that 1 in 70 women are
likely to develop EOC during their lifetime (Cutler and Young, 1975), compared
to 1 in 12 for breast cancer. The incidence increases with age, peaking at 40
years for benign disease and 55-60 years for malignant ovarian disease. This
has led to the suggestion that benign disease may be a precursor to malignant
disease (Anderson, 1990). However, the evidence is largely circumstantial and
anecdotal (Scully, 1982). The true proportion that progress in this manner is
unknown.
1.2.2 Geographical distribution
EOC is a disease of Western industrialized society, like the majority of
degenerative illnesses. Japan, however, has the lowest incidence in the world
(Waterhouse, 1976). Environmental factors seem to be more important than
ethnic, although to date there are no clues as to whether diet or other
environmental agents may be carcinogenic for the ovary.
1.2.3 Genetic factors
Three types of ovarian cancer may arise: sporadic, where no family history is
seen through two generations; familial, where two or more first degree relatives
have, or have had, the disease (Lynch type II), and; hereditary, where the
familial pattern shows an autosomal dominant trait (Lynch type I). Family
history, recognised as the most easily identifiable and greatest of risk factors,
accounts for about 5% of all cases (Ponder et al., 1990). Estimates of the
relative risk vary from 3-fold (Lynch et al., 1990, Ponder et al., 1990) to 20-fold
(Franceschi et al., 1982). A preliminary report of the U.K. Office of Population
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Census and Surveys study shows the relative risk of death is substantially
increased for a first degree relative when the index case is diagnosed before
50 years of age (Ponder et al., 1990). The most common familial occurrence
of ovarian cancer is in association with breast cancer (Lynch et al., 1978).
Ovarian cancer is also linked to carcinoma of the endometrium and colon. The
short interval between diagnosis or simultaneous occurrence suggests a
common aetiology.
Hereditary ovarian cancer, characterised by early age at onset, a high
incidence of bilaterality, and vertical transmission, has been estimated to
account for 5-10% of all cases (Lynch et al., 1990). The increased risk is
believed to be due to the inheritance of a single autosomal dominant gene;
which has yet to be proven by demonstration of linkage between ovarian
cancer and a known genetic marker. Strong ethical pressure exists to perform
prophylactic oophorectomy on such women; however, this is no guarantee of
total protection against future development of intraperitoneal carcinomatosis.
Tobacman et al. (1982) described 28 women from 16 ovarian cancer prone
families who had prophylactic oophorectomy, three of whom later developed
intraperitoneal carcinomatosis. They concluded that EOC may arise from any
tissue derived from coelomic epithelium. Chen et al. (1985) later reported the
case of a 38 year old woman who developed peritoneal carcinomatosis three
years after oophorectomy because of a strong family history. Retrospective
pathological assessment of her resected ovaries revealed occult foci of
malignant cells. A third possible explanation for the development of peritoneal
carcinomatosis after prophylactic oophorectomy could be that fragments of
ovarian tissue had been left behind at operation. Lynch et al. (1990) offer the
k hypothesis that a subset of patients in hereditary ovarian cancer families may
manifest a so-called "familial peritoneal ovarian carcinomatosis syndrome" in
whom prophylactic oophorectomy would be ineffective.
Until 1970 there were only five cases of familial ovarian cancer reported in the
literature (Piver et al., 1982). By 1985, the Familial Ovarian Cancer Registry
established in 1981 (Piver et al., 1984) had accumulated over 100 cases. The
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registry at King's College Hospital, London, now has over 300 ovarian cancer
families (Bourne,T., personal communication). Studies on such families may
throw more light on the biological nature and natural history of the disease.
Perhaps most importantly they may help to determine the gene(s) involved in
the transmission of hereditary ovarian cancer, thus enabling the definition of a
high risk group suitable for targeting surveillance and management strategies.
To date, experimental evidence does not lead strongly to any particular
chromosomal location, although there is much interest in the tumour
suppressor gene, p53, found on chromosome 17 (Eccles etaL, 1990).
Lynch et at. (1990) were the first to report prophylactic oophorectomy in two
patients, from breast/ovarian cancer families, who both had markedly elevated
levels of the tumour marker CA125 which returned to normal post-operatively.
Histological examination revealed ovarian cancer in both women, demonstrating
the possibility of using CA125 to screen ovarian cancer prone families (see
chapter 3, section 3.5.2, p 74).
1.2.4 Reproductive factors
Many studies have reported the association of ovarian cancer with reproductive
and menstrual history and the use of exogenous hormones. Beral (1987) noted
an inverse correlation between ovarian cancer mortality and family size; such
that low death rates were seen in Spain, Bulgaria, and Japan where large
families are common, and high death rates were seen in Sweden and Denmark
where family sizes are small. It has been consistently reported that nulliparous
women are at an increased risk of developing the disease compared with
parous women, the risk declining progressively with the number of children a
woman has (Booth, 1986).
Fathalla (1971) first introduced the idea of "incessant ovulation", and hence
trauma to the ovary as a promoting factor in ovarian carcinogenesis. This has
been supported by other investigators (Casagrande etal., 1979, La Vecchia et
al., 1983). Events which shorten the number of ovulations or suppress them,
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have been shown to have a protective effect; late menarche, early menopause,
first pregnancy before the age of 25, and use of oral contraceptives.
In 1977, Newhouse et al. reported that oral contraceptive use was associated
with a reduced risk of ovarian cancer. Since then, a decline in incidence of EOC
and functional cysts amongst users has been detected (Vessey et al., 1987,
Booth etal., 1989). Booth etal. (1989) have estimated that 28 laparotomies per
100,000 women are avoided each year as a consequence of pill use. Other
than prophylactic oophorectomy in women from ovarian cancer prone families,
this is the only clear example of ovarian cancer prevention to date. The Oxford
Family Planning Association study showed a 50% decrease in risk amongst
those who have ever taken oral contraceptives, consistent with the results of
recent U.S. case-control studies (The Cento for Disease Control, Cancer and
Steroid Hormone Study, 1983). More data is required to confirm or refute the
findings that protection increases with increasing duration of use and persists
after stopping (Vessey et al., 1987).
A reduction in risk has also been seen in women who have had a previous
hysterectomy with ovarian conservation (Booth, 1986). Post-menopausal
oestrogen use for symptom relief has been associated with increased risk in
America (Hoover et al., 1977), and in Britain, although hormone replacement
therapy is less prevalent in the U.K. (Beral, 1987).
1.2.5 Dietary and other environmental factors
It has been suggested that diets typical of Western society, with a high
consumption of animal fats, may be important in the aetiology of ovarian
cancer. Byers et al. (1983) conducted a systematic survey of the dietary habits
of women with ovarian cancer and found no clear association with consumption
of fats, protein, vitamin C, alcohol or tea, but did suggest a high fibre intake
and a diet rich in vitamin A might afford some protection. There is, however, no
consensus as to what dietary measures should be taken to avoid or reduce the
risk of EOC.
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No epidemiological or experimental evidence exists to incriminate viruses in
ovarian neoplasia, although the mumps virus was suspected due to its
gonadotrophic properties (Cramer et al., 1983a). Known carcinogens which
come into contact with the ovaries through the pelvis or vagina, such as
ionizing irradiation, asbestos and talc, may increase the risk, although the
evidence is controversial (Beral, 1987).
Although several protective factors have been identified, many are not of
immediate practical relevance. Insufficient aetiological factors are known to
allow primary prevention through their control. For reviews of the epidemiology
of ovarian cancer see Piver (1987) and Beral (1987).
1.3 SYMPTOMS
1.3.1 Early disease
Early symptoms of EOC are vague. Most women experience no symptoms or
mild symptoms unless a pathological accident occurs, such as torsion,
intracystic haemorrhage, rupture or infection. Insidious signs such as vague
abdominal discomfort, dyspepsia, flatulence, bloating and other gastrointestinal
disturbances may occur (Barber, 1984). All of these gastrointestinal symptoms
are non-specific and may precede diagnosis by several months.
1.3.2 Advanced disease
Symptoms of advanced disease include; abdominal distention due to
increasing tumour mass, and/or accumulation of ascites, abdominal pain due
to progressive compression of surrounding pelvic structures, dyspepsia, and
vaginal bleeding (Hudson and Curling, 1985). Barber (1984) proposed a triad
of suspicious features, including age greater than 35 years, persistent
unexplained gastrointestinal symptoms, and a history of ovarian imbalance and
malfunction, which should alert a physician to the possibility of ovarian cancer.
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1.4 PATHOGENESIS
The ovary appears deceptively innocuous on microscopic examination, yet it
has extraordinary metaplastic capabilities. Tumours derived from ovarian tissue
may mimic virtually any other tissue in the female genital tract (Fox, 1985). This
results from retention of the pluri-potentiality of the Mullerian duct by adult
ovarian serosa. Ovarian tumours therefore commonly resemble tumours of the
fallopian tube, uterus, and cervix (Fox, 1985).
Epithelial ovarian tumours are thought to arise in one of several ways from
ovarian serosa: from direct malignant change in the serosa, from prior
formation of a serosal inclusion cyst which represents a pinched-off invagination
of the surface epithelium, or from malignant change in a benign cyst which has
evolved from a serosal inclusion cyst (Anderson, 1990). In the experience of
Fox (1990), "malignant change is rarely, if ever, seen either in inclusion cysts
or in serous cystadenomas, occurs with extreme infrequency in mucinous
cystadenomas, but does occur with some frequency in endometriotic cysts".
Cramer and Welch (1983b) attempted to unite all known aetiological factors to
explain the mechanism(s) underlying ovarian cancer pathogenesis, but the
histogenesis of EOC remains obscure. This will have important implications for
screening programmes - until more is known about the natural history of
ovarian cancer, the benefits of detecting cysts cannot be determined.
1.5 CLASSIFICATION
DiSaia and Creaseman (1985) classified ovarian tumours according to the
tissue of origin, illustrating the great diversity of ovarian tumour types. Thus,
ovarian tumours may be derived primarily from coelomic epithelium, germ cells,
specialized gonadal stroma, non-specific mesenchyme, and from metastatic
tumours of the breast, endometrium, gastrointestinal tract (Krukenberg
tumours) and lymphomas.
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Different tumour types occur with different frequencies in distinctive age ranges,
(see table 1.1), and each has different prognostic significance. Ovarian tumours
derived from coelomic epithelium predominate.
Table 1.1 Frequency of histogenetic tumour type with age
Tumour derived from: 0-20 years 20-50 years >50 years
Coelomic epithelium 29 % 71 % 81 %
Germ cells 59 % 14 % 6 %
Specialized gonadal stroma 8 % 5 % 4 %
Non-specific mesenchyme 4 % 10% 9 %
taken from DiSaia and Creaseman (1984).
The World Health Organisation (WHO) classification scheme (see table 1.2
overleaf) extends DiSaia and Creaseman's criteria to incorporate not only cell
type, but also the degree of malignancy and architectural growth characteristics
(exophytic or growing on the surface, and endophytic or growing into a cyst).
A given tumour may show varying combinations of these characteristics. For
a full description of the macroscopic and microscopic appearances of ovarian
tumours see Fox (1985).
1.6 TUMOUR GRADE
Each tumour is graded according to how closely its cells resemble their normal
counterparts. Four grades are recognised; well differentiated (grade 1),
moderately differentiated (grade 2), poorly differentiated (grade 3), and
undifferentiated (grade 4) in descending order of resemblance to their tissue
of origin. More than one grade may exist in the same tumour. Tumour grade
is one of the most important prognostic factors, with outlook worsening with
progressive loss of cell differentiation.
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Table 1.2 WHO classification of EOC
Histological type Variety
A Serous tumours 1. Benign (a) Cystadenoma and papillary cystadenoma
(b) Surface papilloma
(c) Adenofibroma and cystadenofibroma
2. Borderline (a) Cystadenoma and papillary cystadenoma
(b) Surface papilloma
(c) Adenofibroma and cystadenofibroma
3. Malignant (a) Adenocarcinoma, papillary adenocarcinoma
and papillary cystadenocarcinoma
(b) Surface papillary carcinoma
(c) Adenofibroma and cystadenofibroma
B Mucinous tumours 1. Benign (a) Cystadenoma and papillary cystadenoma
(b) Surface papilloma
(c) Adenofibroma and cystadenofibroma
2. Borderline (a) Cystadenoma and papillary cystadenoma
(b) Surface papilloma
(c) Adenofibroma and cystadenofibroma
3. Malignant (a) Adenocarcinoma and cystadenocarcinoma
(b) Adenofibroma and cystadenofibroma
c Endometrioid 1. Benign (a) Adenoma and cystadenoma
tumours (b) Adenofibroma and cystadenofibroma
2. Borderline (a) Adenoma and cystadenoma
(b) Adenofibroma and cystadenofibroma
3. Malignant (a) Carcinoma (i) Adenocarcinoma
(ii) Adenoacanthoma
(iii) Adenofibroma and cystadenofibroma
(b) Endometrioid stromal sarcomas
(c) Mixed mesodermal tumours
D Mesonephroid 1. Benign (a) Adenofibroma
(clear cell) 2. Borderline
tumours 3. Malignant (a) Carcinoma and adenocarcinoma









see Serov et at. (1983).
1.7 TUMOUR SPREAD
Ovarian cancer tends to remain within the peritoneal cavity throughout its
course, causing death by progressive inanition due to intestinal tract
12
obstruction. Intra-peritoneal implantation and contiguous growth are the most
common modes of spread, although lymphatic and haematogenous dissemina¬
tion may occur. There is often contiguous growth to the adjacent bowel, pelvic
peritoneum, bladder, rectosigmoid caecum, ileum and omentum. Ovarian
cancer, however, usually invades superficially and mucosal involvement of the
bladder and bowel is rare.
The spread pattern of ovarian cancer is primarily based on the flow of cells
within abdominal or ascitic fluid, and on the lymphatic drainage of the ovary.
Obstruction of diaphragmatic lymphatics by tumour cells contributes to the
development of ascites by impairing peritoneal lymphatic drainage, while
transdiaphragmatic spread to the lymph nodes on the thoracic surface of the
diaphragm leads to development of pleural effusion. Right pleural effusion is
frequently the first extraperitoneal manifestation. Spread is often more extensive
than expected, even when only the pelvic area seems to be grossly involved.
In the past, understaging was a frequently reported and serious problem that
resulted in selection of inappropriate therapy (Young, 1983).
1.8 FIGO STAGING
Staging of EOC is based on clinical and surgical findings, and is a prognostic
factor of major importance. The internationally recognised FiGO (F6d6ration
Internationale de Gyn§cologie et d'Obst£trique) staging system is shown in
table 1.3 overleaf.
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Table 1.3 FIGO staging of EOC
Stage Features
I Growth limited to the ovaries
la Growth limited to one ovary; no ascites; no tumour on the external surface; capsule intact
lb Growth limited to both ovaries; no ascites; no tumour on the external surface; capsule
intact
Ic Tumour either stage la or lb but with tumour on the surface of one or both ovaries; or
with capsule ruptured; or with ascites present containing malignant cells or with positive
peritoneal washings
II Growth involving one or both ovaries with pelvic extension
Ha Extension and/or metastases to the uterus and/or tubes
lib Extension to other pelvic tissues
lie Tumour either stage lla or lib, but with tumour on surface of one or both ovaries; or with
capsule(s) ruptured; or with ascites present containing malignant cells or with positive
peritoneal washings
III Tumour involving one or both ovaries with peritoneal implants outside the pelvis and/or
positive retroperitoneal or inguinal nodes; superficial liver metastasis equals stage III;
tumour limited to true pelvis but with histologically proven malignant extension to small
bowel or omentum
Ilia Tumour grossly limited to the true pelvis with negative nodes but with histologically
confirmed microscopic seeding of abdominal peritoneal surfaces
lllb Tumour of one or both ovaries with histologically confirmed implants of abdominal
peritoneal surfaces none exceeding 2cm in diameter; nodes negative
lllc Abdominal implants greater than 2cm on diameter and/or positive retroperitoneal or
inguinal nodes
IV Growth involving one or both ovaries with distant metastases; if pleural effusion present,





Diagnosis of malignancy ultimately rests with histological examination by the
pathologist of biopsy material taken at surgery. It is important that a woman
with suspected ovarian carcinoma should be referred to a specialist centre for
adequately planned optimal surgical debulking and staging to maximise her
chances of long-term survival.
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A pre-operative work-up of the patient is vital and should include the following:-
1. Complete history and physical examination
2. Papanicoloau (Pap) smear of cervix
3. Complete blood count
4. Renal function tests
5. Liver function tests
6. yS-hCG, AFP and CA125 serum assay for subsequent monitoring
7. Chest radiograph
8. Intravenous pyelogram to rule out ureteral obstruction and define mass
9. Proctosigmoidoscopy
10. Barium enema, upper gastrointestinal and small bowel series to identify
primary bowel cancer or impending bowel obstruction secondary to ovarian
cancer
The last three procedures are more often performed in America (Deppe and
Lawrence, 1988). Ultrasound, computed tomography and lymphangiography
cannot characterize tissue less than 0.5cm in diameter, but are useful to confirm
clinical impression. None of these techniques can replace exploratory
laparotomy as the definitive staging technique.
1.9.2 Primary surgery
Surgery is the cornerstone of management of EOC. It has three major roles.
The first is to establish a diagnosis, by determining the type and grade of the
tumour and the stage of the disease. The second role is therapeutic, by
performing cytoreduction and allowing provision of intraperitoneal access for
further therapy. Lastly, surgery has a palliative role in reducing tumour bulk and
relieving obstruction. The need for subsequent therapy and its selection is
determined by the findings and success of ablative surgery. Although many
prognostic factors have been identified, the only one the gynaecologist can
influence is the amount of post-operative residual disease, making adequate
surgical debulking the most important facet of patient management. There is,
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however, controversy concerning the precise influence surgery has on survival,
as will be seen later.
Laparotomy entails opening the abdomen with a midline vertical incision curved
around the umbilicus, and conducting a thorough exploration of the entire
abdominal cavity. All pelvic organs are inspected, suspicious sites biopsied and
frozen sections sent for histopathological examination. Ascites is aspirated if
present, if not, washings are taken with saline from the cul-de-sac, lateral and
paracolic gutters and subdiaphragmatic areas, most common sites of early
metastasis. Detailed accounts of surgical procedures in ovarian cancer may be
found in Griffiths (1986), and Hacker (1989).
After primary laparotomy, the volume, location, measurement, and number of
residual masses should be accurately recorded to enable response to future
therapy to be determined. The diameter of the largest residual mass has been
adopted as the best measurement, as attempts to estimate the volume of
disease and percentage debulk proved futile. Precise measurements are
impossible because of the multiplicity of deposits. Several studies have
established the upper limit for optimal debulking to be in the region 1-2cm
residual disease. The extent of residual disease has an impact on response to
therapy, time to progression and findings at second-look surgery, which
ultimately affect survival.
1.9.3 Primary surgery of early disease
Complete surgical resection is a relatively simple procedure when the disease
is confined to the ovaries. Patients with early stage disease (FIGO stages I and
II) are usually managed by total abdominal hysterectomy (TAH) and bilateral
salpingo-oophorectomy (BSO) because of the high incidence of spread to the
endometrium and bilaterality. The issue of ovarian conservation in young
nulliparous women remains unsettled, however, it is considered reasonable to
preserve childbearing capacity in women with stage 1a low grade or mucinous
tumours (Griffiths, 1986).
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The importance of accurate staging has been emphasised in several studies.
Young etal. (1983) reported results of restaging laparotomy in 100 women with
apparent stage la-llb disease inclusive referred to member institutes of the
Ovarian Cancer Study Group (set up in 1976 under the auspices of the National
Cancer Institute), in which 31 patients were "upstaged", 77% of those to stage
III. There was a strong association between the percentage of patients
"upstaged" and tumour grade, 46% with grade 3, 34% with grade 2, and 16%
with grade 1 tumours were "upstaged". It has since become apparent that
accurate surgical staging is reflected in a marked improvement in survival within
both stages I and II (Griffiths, 1986).
1.9.4 Primary surgery of advanced disease
The preferred operations are TAH, BSO, and, commonly, resection of the
greater omentum. Bowel resection or partial bladder resection with ureter re¬
implantation is often necessary. However, complete surgical resection in
patients with advanced disease is usually impossible. The options remaining
include biopsy only, limited resection of primary tumour, or aggressive
cytoreduction or "debulking". Optimal debulking is theoretically feasible in 85%
of patients, however, Hacker (1989) reported that this is only being achieved
in 31-48% of patients, reflecting the difficulties in making a pre-operative
diagnosis and scepticism regarding the need for extensive surgery.
At the beginning of the century, a number of gynaecological surgeons were
advocating complete removal of the primary tumour which, Miegs suggested,
would render the remaining tumour more susceptible to radiotherapy (Miegs,
1934). In 1968, Munnell advocated a "maximal surgical effort", and this was first
quantitated by Griffiths et al. in 1975. In a retrospective study from the Boston
Hospital for women, Griffiths et al. (1975) showed that survival in a group of
patients who had residual metastatic disease resected to less than 1.5cm in
diameter was no different to that in a group of patients in whom the largest
metastatic lesions were less than 1.5cm at the outset. Using multivariate
analysis, the authors found survival of patients who underwent optimal
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cytoreduction to be independent of the extent of spread, organ involvement,
grade or operation performed (Griffiths et al., 1975).
Hacker et al. (1983) found that the survival of patients, after debulking to less
than 1.5cm, in whom initial metastases were greater than 10cm was similar to
those who had suboptimal debulking, suggesting that excision of large tumour
masses failed to alter the prognosis. Heintz et al. (1988), however, showed that
survival could be improved by up to 12 months by aggressive resection of
large masses and subsequent intensive cisplatin combination chemotherapy.
The precise influence of surgical cytoreduction on survival is unclear. It is most
plausible that patients in whom optimal debulking was achieved had a
favourable prognosis in any case. The issue of the relative significance of
tumour resection versus tumour resectability has been raised by several
authors (Heintz et al, 1988, Zanaboni et al, 1988, and McDermott et al, 1988)
and is presently being addressed by the Gynaecological Oncology Group.
In a rare report of its kind, Blyth and Wahl (1982) showed that, contrary to
opinion, an aggressive surgical approach actually improved the quality of life
of patients. Webb (1989) has shown that the morbidity rate of such an
approach is acceptibly low, the most common post-operative complication is
pneumonia and this occurs in a small percentage of patients. Hence, current
philosophy dictates as aggressive an approach as possible without creating an
inordinate morbidity and mortality, despite controversy over the value of such
an approach in patients with advanced disease.
1.9.5 Interval debulking
Unfortunately, the biological aggressiveness and manner of spread renders
some tumours unamenable to debulking. Abdominal carcinomatosis presents
a formidable problem to the surgeon, pelvic debulking should be possible if this
can be overcome. Haematogenous dissemination resulting in parenchymal
organ involvement often renders the patient inoperable. In some cases,
secondary debulking following several courses of chemotherapy may be
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possible. According to Griffiths (1986) this is based on the erroneous belief that
chemotherapy can render inoperable tumours operable.
Secondary debulking is, however, a more difficult technical procedure. Berek
et al. (1983) were able to perform optimal cytoreduction in 69% of 39 patients
at primary operation and only 39% of 32 patients at secondary operation. It is
only feasible when the patient is able to continue with intensive chemotherapy
after primary surgery (Griffiths et al., 1979). Survival of patients debulked this
way is much poorer than those debulked at primary surgery. Lawton et al.
(1990) achieved macroscopic tumour clearance in 24% of 108 patients after
three or five cycles of cisplatin therapy. Median progression free survival in the
debulked group was 17 months compared to nine months in those who were
not debulked, while 88% of 16 patients debulked at primary laparotomy
remained in complete remission after 36 months of follow-up.
1.9.6 Post-operative therapy
The majority of EOC patients require post-operative treatment with
chemotherapy. Treatment is selected on the basis of the extent of disease or
stage, size and location of residual tumour, presence of ascites and general
condition of the patient. Until the early 1950s, surgery was considered the
optimal treatment, followed by radiotherapy if there was omental involvement
or when the patient relapsed. This was the only approach possible before the
advent of chemotherapy, however, survival rates were very poor. Whilst
excellent results have been achieved in patients with minimal residual disease
after surgery in recent years, in general there is a lack of reliable data with
which to assess the contribution to survival or palliation from most management
approaches. Prospective randomised controlled trials provide the best
opportunity to define clearly the value of a treatment strategy.
1.9.7 Radiotherapy - current status
There have been very few well designed prospective randomised trials with
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careful stratification of known important prognostic factors to assess the value
of radiotherapy in EOC. Usually radiotherapy is reserved for women with early
stage disease or those with minimal residual post-operative disease, accounting
for about one third of all patients. This is because the dosage required to
destroy a mass >2cm diameter exceeds normal tissue tolerance.
Schray et al.{1983) treated 53 advanced EOC patients with <2cm residual or
recurrent disease with whole abdominal salvage radiotherapy. No benefit was
seen in patients who had disease >2cm prior to chemotherapy or macroscopic
disease at second-look laparotomy. In patients with minimal residual disease,
radiotherapy is the one adjuvant method following surgery which has been
shown to improve long-term survival consistent with cure. Indeed, it has been
shown to double the proportion of patients cured when compared to surgery
alone (Bush 1984). Optimal use of radiotherapy yields a 10% improvement in
long-term survival for the total patient population. There is no evidence that
combination chemotherapy achieves the same survival advantage.
In summary, post-operative radiotherapy is regarded as being valuable: in
patients with stage I and II disease and no macroscopic residual disease; to a
whole abdominopelvic volume (because of the manner of spread); in other rare
tumours such as dysgerminoma; and so long as careful attention is paid to
dosimetry, technique and patient positioning. It is not indicated: in patients with
stages la(i) and lb(i); as a pre-operative therapy or; as a pelvic only volume as
a radical therapy (Spooner, 1986). The role of radiocolloid installation into the
peritoneal cavity remains to be more clearly defined.
1.9.8 Chemotherapy
Chemotherapy for ovarian cancer was first introduced in 1952. Triethyl-
melamine (TEM), a nitrogen mustard derivative, produced a favourable
response in 30% of patients (Sykes etal., 1955). Subsequently, other alkylating
agents were tested and by the end of the 1950s chemotherapy emerged as an
effective palliative treatment. Alkylating agents remained the major
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chemotherapeutic agents for a decade, melphalan being the most commonly
used due to its reliable activity. No single agent proved superior to another.
However, only 50% of patients responded to these agents and the majority of
those soon relapsed. This prompted the evaluation of new cytotoxic agents as
second-line therapy. Responses after alkylating agents failed were rare,
although second-line hexamethylmelamine and cisplatin showed sufficient
clinical activity to encourage their use as first-line treatments. Other non-
alkylating agents that have demonstrated activity included doxorubicin, 5-
fluorouracil and methotrexate.
The high relapse rate, poor response rate to second-line treatment and
encouraging activity of certain agents, coupled with the fact that different
agents had different sites of activity at the cellular level and different
mechanisms of toxicity encouraged the development of combination
chemotherapy - an approach that was working with Hodgkin's disease and
acute leukaemia in children.
One of the first non-alkylating agents tested was 5-fluorouracil, which proved
disappointing on its own but was initially promising in combination with
actinomycin D and cyclophosphamide as ACFUCY. This combination gave a
38% response rate (complete and partial) in 47 patients who had failed to
respond to first-line melphalan therapy (Smith and Rutledge, 1970). The
purpose of this and other similar studies was to demonstrate the potential
activity and evaluate the toxicity of the combination prior to use in a randomised
controlled trial against conventional first-line therapy. One of the first such trials,
reported by Smith et al.{1972) compared melphalan to the same ACFUCY
regime, and found similar response rates (42% and 45% respectively). The early
observation by Smith and Rutledge was not substantiated later when more
precise response criteria were applied, and had to be abandoned due to the
very high toxicity and high number of treatment related deaths in patients given
second-line ACFUCY.
Promising responses were later seen with other combinations. Young et al.
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(1978) reported a 75% first-line response rate to hexamethylmelamine,
methotrexate, 5-fluorouracil, and cyclophosphamide compared to 55% in
patients who received melphalan. Delgado et al. (1979) reported an 89%
response rate to hexamethylmelamine, 5-fluorouracil, and cyclophosphamide
compared to 58% using melphalan. Although increased response rates were
found, no associated increase in survival was seen.
Of many trials that have been performed, few have shown a statistically
significant survival advantage of combination over single agent therapy (Young
et al., 1978, and Trope, 1981). There has, however, been a trend in favour of
platinum containing regimes. The important contribution of cisplatin to
combination chemotherapy was shown in three studies, from the Mayo Clinic
(Decker et al., 1982), the Netherlands Cancer Institute (Neijt et al., 1984), and
the Gynaecological Oncology Group (Omura et al., 1986). Response rates of
60-80% can be expected in patients with advanced disease, of which about
25% will be complete responses. The introduction of platinum containing
regimes has, despite their increased activity, still not clarified the situation with
regards to improvement in survival (Lawton and Blackledge, 1986). Although
certain subgroups of patients appear to benefit in the short-term, long-term
benefit is unclear. Superior response rates do not necessarily lead to improved
survival.
Few studies report the duration of response. Schwartz and Smith (1980)
reported disease recurrence with a mean time to relapse of one year in 12% of
58 patients who each had a pathologically documented complete response.
Gershenson et al. (1985) report a relapse rate of 30% within five years of
complete response. Several studies have confirmed the importance of
prognostic factors in determining outcomes, especially the amount of residual
disease after surgery (Griffiths etal., 1975, Klein etal., 1985, and Swenerton et
al., 1985).
A major problem in treating patients with chemotherapy is the development of
drug resistance. Cisplatin is also limited by its toxicity, which commonly
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necessitates dose reduction or withdrawal. Other platinum analogues,
carboplatin and iproplatin, have similar activity but less toxicity. Evidence is
accumulating that resistance is less likely to develop by intensifying initial
therapy (Malpas, 1989). The use of "up-front" or initial high-dose therapy is still
in the early stages clinically. Kaye (1990) has contended that "up-front" therapy
might improve the quality of life for some patients simply by shortening the time
spent on therapy.
Alternatively, intraperitoneal (i.p.) chemotherapy may overcome this problem
and also that of systemic toxicity by enabling local dose intensification. It has
potential in patients with microscopic disease, and disease less than 2cm
remaining after surgery (Blackledge ef a/., 1990). Several requirements must
be met by candidate drugs, including: absence of local peritoneal toxicity, a
steep dose-response relationship, low peritoneal permeability, capability of
direct tumour kill, and rapid plasma clearance. Clinical trials have been
performed in small patient groups using 5-fluorouracil, methotrexate,
doxorubicin, melphalan, mitomycin C, and cisplatin (Brenner, 1986). A
randomised controlled trial by the EORTC (European Organisation for Research
into the Treatment of Cancer) Gynaecological Oncology Group is currently
underway to assess the effectiveness of i.p. chemotherapy in maintaining
pathological complete response.
1.9.9 Alternative therapy
Approximately two-thirds of ovarian epithelial tumours have functional oestrogen
and/or progesterone receptors (Leake and Owens, 1990). Endocrine therapy
is usually reserved for palliation of patients with advanced disease refractory to
chemotherapy as primary response rates are poor (Deppe and Lawrence,
1988). Biological response modifiers, such as interferons, monoclonal
antibodies, tumour necrosis factor, are thought to act by modifying host
behaviour to the tumour (Mihich et al., 1986). Several have been tested with
chemotherapy although the results are inconclusive.
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Several of the monoclonal antibodies used in this thesis to evaluate serum
tumour-associated antigens have also been used therapeutically. Radiolabeled
monoclonal antibodies are currently undergoing clinical trials in an attempt to
target tumour cells bearing the appropriate tumour-associated antigen. Thus,
it is hoped that this new anti-cancer treatment will be more effective by reducing
the toxicity associated with conventional chemotherapy and allowing dose
intensification. One of the major problems with this type of treatment at present
is host production of human anti-mouse antibodies "HAMAs" which prevent
effective repeat administration of antibody. Production of "humanised"
monolconal antibodies is expected to circumvent this problem. This area will be
described in more detail in chapter 3 (section 3.2.6, p 63).
1.9.10 Second-look surgery
Second-look laparotomy was first introduced in 1948 by Wangensteen to
diagnose early recurrence in asymptomatic colorectal carcinoma patients
(Wangensteen etal., 1949). Rutledge and Burns first used it in 1966 in ovarian
cancer patients to assess disease status following chemotherapy. Second-look
laparotomy may be defined as the surgical re-exploration of patients who have
completed a planned course of therapy after a definitive primary surgical
procedure, who have no clinical or radiographical evidence of disease. The aim
of second-look surgery is therefore to determine tumour status and plan future
treatment if necessary. The pre-operative work-up is similar to that of primary
surgery, and the procedure is essentially similar in its execution and aims. The
surgeon must examine previous sites of documented disease and make every
effort to rule out the presence of residual disease after operation. Thus, second-
look operation is a meticulous search for persistent disease and should be
made by the gynaecologist familiar with the history, mode of spread and
findings at primary laparotomy. Not all patients however will be eligible for the
procedure. It is mainly performed for one of the following reasons: to determine
whether non-palpable disease is responding to chemotherapy and to detect
early recurrence; when the patient develops an isolated resectable recurrence;
when initial surgery is limited and significant tumour regression with post-
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operative therapy renders the patient operable; and when initial laparotomy
findings are unclear and staging is incomplete.
Second-look laparoscopy is a useful diagnostic test for determining the
presence of resectable, unresectable or diffuse disease following chemo¬
therapy, but has a high false negative rate (20-75%) and is therefore not an
alternative to second-look laparotomy (Malviya and Deppe, 1988).
The timing of second-look operation is variable and must be individualised,
although most are performed between six months and one year after the first
operation when the patient has completed their first course of chemotherapy.
Optimal timing depends on the extent of residual disease after primary
laparotomy and the number of courses chemotherapy the patient has had.
1.9.11 Second-look outcome
The outcomes, or extent of disease present, at second-look laparotomy are
traditionally classified as: negative, when no histologic or cytologic evidence
of disease is found, in such circumstances the patient is said to have a
pathological complete response; microscopic, when no tumour is identified by
the surgeon but cytologic washings or biopsies demonstrate persistent
disease; macroscopic, when persistent disease is identified grossly by the
surgeon and confirmed by the pathologist; or deemed an inadequate
procedure, when surgical exploration is incomplete due to surgical or
anaesthetic mishap, or if extensive inoperable adhesions are present.
1.10 EVALUATION OF RESPONSE TO THERAPY
Evaluation of response to therapy has been severely hampered by the difficulty
in measuring tumour response, by using varying response criteria and by a
general lack of reporting of survival outcomes. It is performed using both
objective and subjective means (Miller et al., 1981).
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1.10.1 Endpoint evaluation
It is important to consider at what point treatment outcome is to be
documented. Ultimately, the success of a treatment regimen may be defined
using a number of different endpoint criteria. These include: the percentage of
patients with evaluable disease who respond to treatment: the findings at
second-look surgery: the length of time until recurrence/relapse (disease free
survival) or disease progression/relapse (progression free survival): and the
overall survival of a group of patients.
Negative second-look laparotomy is a frequently reported endpoint. Although
it confers survival advantage the risk of disease recurrence after a negative
second-look laparotomy is uncertain. Also, the majority of patients selected for
second-look laparotomy are clinically disease free and therefore represent a
better prognostic group. As mentioned earlier, Gershenson et al. (1985)
reported that up to 30% of patients with negative second-look laparotomy
relapse within a five year period.
1.10.2 Objective response criteria
Objective evaluation includes determination of tumour size, change in size,
change in number of lesions, and duration of response since the start of
therapy. Objective disease assessment is conventionally determined with the
aid of radiographical scanning techniques: ultrasound scanning and computed
tomography, and second-look surgical procedures: laparoscopy and laparo¬
tomy. Information gained using scanning techniques is not always unequivocal
and is often subject to wide variability in interpretation.
At each consultation, usually monthly at the outset of treatment (although scans
are performed less frequently), any change is evaluated. Solid tumours are
measured in centimetres and dimensions consist of the largest diameter and
perpendicular diameter at the widest portion of the tumour. Responses have
been defined by the International Union for the Control of Cancer (UICC),
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shown in table 1.4, below.









The achievement of disease free survival that extends without
treatment, beyond the period of risk of relapse.
The disappearance of all clinical evidence of active tumour for
a minimum of six weeks. Cytologic washings taken at second-look
must be consistently negative. A pathologic CR is when no histologic
or cytologic evidence of disease is found at laparotomy.
A 50% or greater reduction in the sum of diameters of all measured
lesions, with no new tumour manifestations appearing during therapy.
A steady state or a response less than PR or progression. There is no
appearance of any new lesion and no worsening of symptoms.
The unequivocal increase of at least 25% in the size of any measurable
lesion or the appearance of new lesions.
The appearance of new lesions or reapppearance of old lesions in
patients who have been in CR. For patients who have been in PR,
relapse is defined as an increase of 50% or more in the sum of
products of the diameters of all measured lesions over that which was
obtained at the time of maximum tumour regression.
The duration of response since the start of treatment (expressed in
days, weeks or months) until renewed increase in tumour size is more
than 25% of the product of two diameters, measured on two
consultations during therapy.
UICC, 1988.
1.10.3 Subjective response criteria
Subjective evaluation includes: determination of performance status using
internationally agreed nominal scales; changes in weight, appetite, pain, specific
organ symptoms; changes in initially pathological laboratory parameters of
kidney function, liver function, other organ functions, erythrocyte sedimentation
rate, and specific biochemical parameters of the disease; and evaluation of
treatment toxicities based on leucocyte and platelet counts, and haemoglobin
level. Other symptoms include nausea, vomiting, stomatitis, and alopecia.
27
Examples of two commonly used scales, the ECOG (European Committee on
Obstetrics and Gynaecology) performance status and toxicity are shown below.
ECOG Performance status
0 Able to carry on normal activity.
1 Patient able to live at home with tolerable tumour manifestations.
2 Patient with disabling tumour manifestations, but less than 50% of time in
bed.
3 Patient severely disabled and more than 50% of time in bed, but able to
stand up.
4 Patient very sick and bedridden.
5 Dead.
Toxicity
0-No symptoms, 1-Mild, 2-Moderate, 3-Severe, 4-Life threatening
1.11 ALTERNATIVE METHODS OF DETERMINING RESPONSE
Most gynaecological oncologists would like to see second-look surgery
replaced with a less traumatic but equally accurate, non-invasive or less
invasive method of determining response to chemotherapy and disease status.
Luesley et a/. (1988) have shown in a prospective randomised trial that second-
look surgery has no impact on overall survival, however, it is true that certain
patients will benefit from the procedure. It would be useful before operating to
be able to determine which patients will benefit, and thus save a number of
unnecessary operations. Chambers et a/.(1988) argue that second-look surgery
should be limited to experimental protocol situations in which precise
measurement of tumour size may be important. Not many surgeons would
disagree with this.
Several possible alternatives to second-look laparotomy have been investig¬
ated, such as ultrasound scanning, computed tomography, radioimmuno-
scintigraphy, magnetic resonance imaging, and tumour marker assay, but none
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as yet has proved an acceptable reliable alternative (Malviya and Deppe, 1988).
In the absence of second-look laparotomy, all available information, objective
and subjective together with clinical examination, is used to form a complete
picture of the disease status of a patient.
Aside from the difficulties in determining response to therapy, another major
difficulty in managing ovarian cancer patients with currently available
chemotherapy is deciding to stop or change treatment when drug resistance
develops, or to re-initiate treatment for progressive disease at a stage when the
patient may still respond. Most patients with stage III or IV disease will
eventually fail primary chemotherapy. Second-line treatment is far less
successful in patients who have already failed the most efficacious therapy.
The toxicity of chemotherapy mandates that it is terminated when it is clear that
the patient has become resistant to it or has not responded at all, and is
unlikely to gain benefit from further treatment. It is well known, however, that
patient satisfaction bears little correlation with objective tumour response (Cody
and Slevin, 1989). Thus, if response to treatment can be accurately determined,
the question of how to procede is not so simple given the currently available
options and patient desire for active therapy.
The need for a more rational approach to the selection of patients for phase II
trials is well recognised, and the work of Blackledge et at. (1989) represents a
welcome attempt to move in this direction. Prognostic factors that may aid
treatment decisions are sought intensively. In this respect, tumour markers (see
chapters 2 and 3) may help guide such clinical decision making. This thesis
investigates the role of several putative serological ovarian tumour markers in
monitoring response to therapy and aiding decision making in the management






Malignant transformation is accompanied by genotypic changes, resulting in a
diversity of phenotypic differences between normal and malignant cells
(Sidebottom, 1987). The major difficulty facing tumour immunologists is not so
much finding these differences, but determining their significance and
identifying ways of exploiting them to detect and destroy cancerous cells (see
chapter 3).
The search for tumour-associated antigens specific to ovarian cancer dates
back to 1956 (Witebsky et a!., 1956). Over 100 putative ovarian tumour-
associated antigens, encompassing a wide variety of molecules, have since
been reported in the literature. Most of these do not normally elicit an immune
response, hence the term "marker" is more appropriate, and will be used
throughout this thesis. Tumour markers are of enormous interest because they
may help refine diagnosis and rationalise therapy. Unfortunately, no absolutely
tumour-specific marker has been discovered for ovarian cancer, or any
spontaneous human malignancy, except for the special case of idiotypic
determinants of lymphoid malignancy (Glennie and Stevenson, 1987).
Not long after the development of the hybridoma technique by Kohler and
Milstein (1975), enabling better definition of tumour markers, doubt regarding
the existence of "tumour specific" markers emerged (Old, 1981). Woodruff
(1990) has argued more recently that "It is not surprising that a particular
marker which is present in a normal progenitor cell should be conserved
during transformation and be present in all neoplastic cells which are
descendents of this progenitor. It would, however, be remarkable if all the
neoplastic cells carrying such a marker also carried a unique marker of a kind
found only in neoplastic cells". The very fact that changes in a few genes,
among the hundred thousand or so genes present in a mammalian cell
genome, are sufficient to induce transformation implies that the occurrence of
proteins with tumour specificity must be extremely rare if they exist at all (see
section 2.2.1). Nevertheless, a distinguishable difference in relative
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concentration between normal and malignant cells affords a tumour-associated
antigen-bearing molecule marker potential. Although none is known to be
unique to a particular malignancy, some aims of tumour immunologists have
been realised (see chapter 3).
This chapter will give an overview of different types of tumour markers before
considering the requirements of an ideal marker. Ovarian tumour markers
discovered to date will be reviewed and, finally, the development, pattern of
expression and characteristics of tumour markers investigated in this thesis will
be examined in detail.
2.2 TYPES OF TUMOUR MARKER
Tumour markers are usually substances such as hormones, enzymes, glyco¬
proteins and proteins, which may be found on the tumour cell surface and/or
secreted into the circulation (Malkin, 1987). Daar and Lennox (1987) have
divided tumour markers into the six categories shown in table 2.1.
Table 2.1 Tumour marker classification
Type of tumour marker Features
1. Normal differentiation antigens
2. Major histocompatability antigens
These may be: appropriate to the differentiation stage of the
cell in which malignant transformation occurs; not appropriate
to this stage, but normally expressed at other stages in the
same tissue or other tissue, or; appropriate to the stage of
differentiation, but only found on dividing cells.
These may be: appropriate i.e. like those on normal tissue
of the individual in which the tumour arises, or; inappropriate
i.e. like those not normally expressed and indicative of new
specificities.
3. Viral antigens These may: belong to the transforming virus (for virally




6. Unusual glycoprotein and glycolipid antigens
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The majority of ovarian tumour markers investigated to date belong to the last
three categories, although none of these categories are exclusive. The last
three types of markers will therefore be described, for a full description of the
first three categories see Daar and Lennox (1987).
2.2.1 Oncogene antigens
In 1911, Rous correctly hypothesised that an infectious agent was involved in
the transmission of sarcomas in chickens infected with cell free extracts of
tumours (Rous, 1911). The causal agents were identified much later as RNA
retroviruses. Huebner and Todaro (1969) first proposed the existence of viral
oncogenes, and suggested that they could be integrated into the host's
genome and remain dormant or activate causing cancer. Viruses were later
shown to have acquired their oncogenes from normal mammalian cells they
had infected.
All multicellular eukaryotes have genes which very closely resemble viral
oncogenes. Clues to the functions of these cellular proto-oncogenes have
come from studies of proteins encoded by structurally similar viral oncogenes.
Four classes were originally identified; tyrosine protein kinases (class I), GTP
binding proteins (class II), growth factors (class III) and nuclear proteins (class
IV) (Daar and Lennox, 1987). Other classification schemes exist, e.g. based on
the cellular location - nuclear or cytoplasmic (Weinberg, 1989). Cellular proto-
oncogenes do not cause cancer, but may become transforming when activated
by one of the following mechanisms: point mutation in the proto-oncogene;
attachment of strong promoters/ enhancers to the proto-oncogene;
promoter/enhancer insertion near the proto-oncogene; rearrangement of the
proto-oncogene in the genome; defined chromosomal translocation of the
proto-oncogene, or; amplification of the proto-oncogene (Teich, 1988).
Three broad phases have been identified in the evolution of a tumour; initiation,
promotion, and progression, although the exact number of steps incurred in the
development of any tumour is unknown. Knudson (1985) hypothesised that two
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collaborating oncogenes must be activated in order to initiate transformation
(the "two-hit" hypothesis). Not all oncogenes fit this model however; activation
of a single oncogene may also cause transformation, e.g. Ha-ras transfection
of NIH/3T3 cells is sufficient to cause transformation (Weinberg, 1989).
Oncogenes and their products are potentially tumour markers of exquisite
specificity for the transformed state. It would be useful to identify cell surface
antigens specifically associated with this state especially if such markers were
directly linked with the mechanism responsible for transformation. While the
oncogene paradigm developed over the past decade provides a powerful
explanation of cancer at the molecular level it is far from complete. Hereditary
predisposition to cancer is a well documented phenomenon. Tumorigenesis
often involves loss of growth regulatory genes or anti-oncogenes. An anti-
oncogene or tumour suppressor gene may be defined as a gene whose
repression, inactivation, dysfunction or loss results in cell transformation (Rayter
et al., 1989). Currently there is much interest in one such gene, p53 found on
chromosome 17, which has been found to be deleted in a high proportion of
ovarian carcinomas (Eccles et al., 1990).
2.2.2 Oncofoetal antigens
During the development of multicellular organisms, cells divide and differentiate
to become functional organ systems. After they have acquired the metabolic
pathways for performing their specialized functions they undergo no further
change. In the process of differentiation cells not only acquire new specificities,
functions and morphological features but also new antigenic characteristics.
Differentiation is widely accepted to be under genetic control, although it is
uncertain whether the establishment and maintenance of all specialization
generally involves irreversible genetic changes. Normally, embryonic cells
produce a series of gene products which are replaced after birth by an adult
set of gene products, and are not expressed again in large amounts in
adulthood.
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The multistep nature of carcinogenesis (Bishop, 1987, and Weinberg, 1989)
originating in loss of genetic control and manifesting in multiple phenotypic
changes has already been mentioned in the previous section. These changes
are not infrequently pleiotropic, following from a single structurally or
functionally altered gene. Such gene alterations often result in derepression of
normally silent foetal genes and re-expression of their products. Malignant cells
are closely related to foetal states of differentiation in that they are less well
differentiated than their normal adult counterparts. This relationship, between
malignancy and the embryonic state, has been recognised for nearly a century
but only became established on a molecular basis with the discovery of a-
foetoprotein (AFP) in 1963 by Abelev et a!., and carcinoembryonic antigen
(CEA) two years later (Gold and Freedman, 1965).
2.2.3 Unusual glycoprotein and glycolipid antigens
Tumour cell surfaces have many altered carbohydrate structures, for review see
Feizi (1985). Such changes may have a considerable impact on cellular
recognition and communication. Mucus glycoproteins or mucins, of interest in
this thesis, which contain greater than 50% carbohydrate by weight are among
the most promising tumour markers to date. Other cell surface glycoproteins
and glycolipids also contain a high proportion of glycans. These may contain
1 -20 carbohydrate residues and can vary between tissues and within a tissue
giving rise to extensive heterogeneity. At least three types exist; containing
terminal fucose, sialic acid, or sulfate residues, the first being neutral and the
last two being acidic. Often more than one type of glycan is present in the
same mucin molecule. Addition of glycans during post-translational processing
which gives protection against proteolytic degradation, increases the apparent
molecular weight of the molecule on SDS polyacrylamide gel electrophoresis.
Change in the amounts of glycosyl-transferases and pool size of substrates
may alter post-translational processing of nascent proteins causing fairly major
changes in carbohydrate structures. Consequently, changes may occur in an
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antigenic determinant's structure and/or accessibility. Monoclonal antibodies
originally raised against specific carbohydrate determinants may no longer
recognise them after such changes have occurred. Apart from the use of
monoclonal antibodies and lectins, other biochemical techniques have been
used to detect such changes in antigen expression (Sidebottom, 1987). The
presence of alterations in the carbohydrate composition of mucins provides a
unique opportunity to study biochemical alterations in cell surface carbohydrate
composition during carcinogenesis. For review of the synthesis and
characterisation of mucins see Hilkens (1988).
2.3 THE IDEAL TUMOUR MARKER
The ideal properties for a tumour marker depend ultimately on its intended
application. Immunohistochemical detection, radioimmuno-scintigraphy, or
imaging, and immunotherapy require markers which are readily detectable on
the tumour cell surface, whilst serum markers are essential for non-invasive
diagnosis and monitoring. These applications will be dealt with in detail in
chapter 3.
2.3.1 Ideal properties of a serum tumour marker
The advantage of measuring secreted markers compared to the physical
measurement of a mass is the representation of viable tumour burden given by
a tumour cell product, rather than total tumour burden as imaged radiologically.
Daar and Lennox (1987) have identified several ideal properties of a serum
tumour marker. The ideal serum tumour marker should:-
1. be easy and inexpensive to measure.
2. be specific to and commonly associated with the tumour in question.
3. positively correlate with the tumour volume.
4. reflect the current disease status and change as the status of the tumour
changes over time.
5. precede and predict recurrences before they become clinically detectable.
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6. have stable levels which are not subject to wide fluctuations.
In addition, a serum tumour marker assay shoud be reproducible and the
antibodies should not cross-react with determinants found on other molecules.
It is extremely rare for a tumour marker to conform to all or even most of the
above criteria. Despite this, however, a few markers do have a well proven
place in clinical disease management. No discussion of tumour marker ideals
is complete without a mention of HCG and choriocarcinoma as an example.
Measurement of HCG, which is closest to the ideal serum marker, has had a
major impact on the clinical management and survival rates of choriocarcinoma,
described in the following section.
2.3.2 Human chorionic gonadotrophin
HCG is a glycoprotein composed of two subunits, a (molecular weight 14,900
D) which is almost identical to the a subunits of thyroid stimulating hormone
(TSH), follicle stimulating hormone (FSH), and luteinising hormone (LH); and/J
(molecular weight 23,000 D) which is similar to the /3 chain of other glycoprotein
hormones, except for the carboxy-terminal sequence which renders it
antigenically distinct. Early assays of HCG employed polyclonal antibodies
directed against the intact molecule and were unable to discriminate between
HCG and LH. Vaitukaitis et at. (1972) were the first to develop an assay using
a polyclonal antibody directed against the /3 subunit, enabling the more specific
detection of /3 HCG. Many monoclonal antibody assays to /3 HCG have been
developed since.
HCG is normally secreted by the placental syncytiotrophoblast to maintain
corpus luteum function and preserve progesterone secretion during the early
stages of gestation. It can be detected as early as five days after conception,
and reaches a peak at 8-10 weeks of pregnancy. Serum levels are found
elevated in the presence of germ cell tumours and gestational trophoblastic
malignancy (Bagshawe, 1978). Apart from pregnancy testing, /3 HCG assay is
primarily used in the diagnosis and monitoring of these tumours. The use of/3
HCG measurement to diagnose and monitor treatment of choriocarcinoma
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following evacuation of hydatidiform mole presents one of the more precise and
satisfying features of cancer management, described below.
2.3.3 Management of choriocarcinoma with /? HCG
Choriocarcinoma develops after evacuation of benign trophoblastic disease,
hydatidiform mole, in 5-10% of cases. It is among the most chemosensitive of
human solid tumours, responding to a variety of agents, particularly
methotrexate, which is the usual first-line treatment. The malignant form may
develop months or years after molar pregnancy, and for this reason women
treated for this condition are followed up for at least a year by serial serum /S
HCG measurement as part of a national screening programme (see chapter 3,
section 3.4, p65).
The criteria for active therapy include: high /3 HCG levels more than four weeks
after evacuation; progressively increasing /3 HCG values at any time after
evacuation, and; histological evidence of choriocarcinoma or evidence of
metastases (WHO, 1983). Patients may be divided into two prognostic groups
depending on levels of/3 HCG; those in the low risk group receive single agent
therapy, while those in the high risk group receive combination chemotherapy.
Serial measurements are used to monitor response to therapy and to follow-up
patients after treatment; as /3 HCG is highly specific, increasing levels are
indicative of relapse (Rustin, 1987). Adoption of/3 HCG serial measurement has
contributed to a substantial reduction in mortality in patients with non-metastatic
disease.
In summary, /3 HCG is ideal for monitoring choriocarcinoma because there is
a close linear relationship between /3 HCG and the number of choriocarcinoma
cells, and /3 HCG assay can detect as few as 105 cells. In addition,
choriocarcinoma is a particularly chemosensitive tumour. It must be
emphasized, however, that the success of /3 HCG in management of this
disease owes most to the existence of a well defined high risk group with a
relatively high disease prevalence.
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2.4 OVARIAN TUMOUR MARKERS
The vital need for tumour markers that will facilitate earlier accurate diagnosis,
monitoring, and development of more specific, less toxic therapy for women
with EOC was demonstrated in chapter 1. Bhattacharya etal. (1985a) identified
four major groups of molecules as potential markers for ovarian malignancy:
tumour associated antigens, oncofoetal antigens, carcinoplacentai glycoproteins
and, complex proteins or glycoproteins with enzymic activity. These correspond
roughly to the last two groups subsequently described by Daar and Lennox
(1987). Confusion may result from the different classification schemes used by
different authors; categorisation is difficult and is not absolute as there is
extensive overlap between categories.
Ovarian tumour markers have been identified using a variety of techniques.
Many were initially identified after raising antibodies to ovarian tumour tissue
extracts or other samples from patients with EOC, while other markers were
first associated with non-ovarian tumours, and were subsequently found to be
expressed in a high proportion of EOC patients. Table 2.2 lists ovarian tumour
markers reported in the literature to date. This list is by no means exhaustive,
new putative markers appear in the literature on an almost monthly basis, but
the list serves to illustrate the diversity of marker molecules associated with this
disease. Seven categories have been employed in this thesis: oncofoetal
antigens, carcinoplacentai antigens, enzyme antigens, proto-oncogene
antigens, polyclonal antibody defined antigens, chemically defined antigens,
and monoclonal antibody defined antigens, see table 2.2.
Many of the monoclonal antibodies listed are directed against determinants
upon the same PEM (polymorphic epithelial mucin) molecule, these will be
indicated by an asterisk. Most of these markers have not been fully
characterised. A description of the characteristics of the more promising "novel"
tumour markers investigated in this thesis will be given after table 2.2.
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Tumour-associated trypsin inhibitor (TATI)
Carcinoplacental antigens
Tissue polypeptide antigen (TPA)
Human chorionic gonadotrophin (/S HCG)
Enzyme antigens













van Nagell et al. (1978)
Stanhope ef al. (1979)
Stenman et al. (1982)
Bjorklund (1972)
Fishman et al. (1975)
Fishman ef al. (1968)
Awais et al. (1973)
Bhattacharya et al. (1976)
Sheid et al. (1977)
Blum and Sirota (1977)
Blum and Sirota (1977)
Chatterjee et al. (1978)
Chatterjee et al. (1978)
Khoo (1979)
Vankley (1981)
Barlow et al. (1981)
Chatterjee et al. (1981)
Chatterjee et al. (1982)
Proto-oncogene antigens
c-myc, c-fos (nuclear proteins)
c-fms (receptor tyrosine kinase)
c-HA-ras (membrane bound GTPase)
c-Ki-ras (membrane bound GTPase)
c-neu/c-erb-B2/HER-2 (receptor tyrosine kinase)
Slamon et al. (1984)
Slamon et al. (1984)
Krontiris et al. (1985)
Filmus & Buick (1985)

















Bhattacharya & Barlow (1973)
Order ef al. (1975)
Hamazaki & Hotta (1975)
Stolbach ef al. (1979)
Burton ef al. (1976)
Burton ef al. (1977)
Bara ef al. (1977)
Knauf and Urbach (1978)
Imamuraefa/. (1978)
Bhattacharya & Chatterjee (1980)
Dawson ef al. (1980)
Chemically defined antigens















Svanberg & Astedt (1975)
Pant ef al. (1978)
Hirsch-Marie ef al. (1978)
Goldenberg et al. (1978a)
Poulton ef al. (1978)
Khoo ef al. (1979)
Sanders ef al. (1980)
Wass ef al. (1981)
Stimson & Farqharson (1981)
Turner ef al. (1982)
Yabushita ef al. (1985)
Koebl ef al. (1988)
Goldhirsch ef al. (1988)
Aitokallio-Tallberg ef al. (1988)
Kacinski ef al. (1989)
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Table 2.2 continued.
MAb defined antigens Antigen Reference
Ovarian carcinoma
OC125 High Mr glycoprotein Bast et al. (1981)
NB/70K 70 KD glycoprotein Knauf & Urbach (1981)
GP48 48 KD glycoprotein Bhattacharya et al. (1982)
ID3 High Mr glycoprotein Bhattacharya et al. (1982)
MOV 2 High Mr glycoprotein Colnaghi et al. (1982)
OC133 80 KD protein Berkowitz et al. (1983)
MF 116 105 KD glycoprotein Mattes et al. (1984)
4F4,7A10 48 KD glycoprotein Bhattacharya ef al. (1984)
OVTL3 High Mr glycoprotein Epenetos et al. (1987)
OV632 High Mr glycoprotein Flueren et al. (1987)
MOV 8, MOV 19 Low Mr glycolipids Mottolese et al. (1987)
NB 12123 70 KD protein Knauf & Bast (1988)
CASA, OSA High Mr glycoprotein McGuckin et al. (19©0)
Breast carcinoma
*DF3 High Mr glycoprotein Abe & Kufe (1981)
*HMFG1, *HMFG2 High Mr glycoproteins Taylor-Papadimitriouefa/. (1981)
*AUAI High Mr glycoprotein Arklie et al. (1981)
*B72.3 High Mr glycoprotein Nuti et al. (1982)
*115 D8 High Mr glycoprotein Hilkens et al. (1984)
*NCRC 11 High Mr glycoprotein Ellis ef al. (1984)
F36/22 High Mr glycoprotein Croghan et al. (1984)
2G3 High Mr glycoprotein Frankel et al. (1985)
369 F10 High Mr glycoprotein Frankel et al. (1985)
200 F9 High Mr glycoprotein Frankel et al. (1985)
41 B4 230 KD glycoprotein Frankel et al. (1985)
520 C9 200 KD glycoprotein Frankel et al. (1985)
113 F1 200/100/60/40 KD protein Frankel et al. (1985)
454 A12, 454 E4, 96 KD transferrin receptor Frankel et al. (1985)
454 C11 200 KD glycoprotein Frankel et al. (1985)
493 D1 71 KD protein Frankel et al. (1985)
9C6 70 KD protein Frankel et al. (1985)
33 F8 66 KD protein Frankel et al. (1985)
677 B8 65/61 KD protein Frankel et al. (1985)
317 G5 43 KD glycoprotein Frankel et al. (1985)
90K 90 KD glycoprotein Scambiaefa/. (1988)
2C8.2F7 60 KD glycoprotein Bhattacharya et al. (1985)
*SM3 High Mr glycoprotein Burchell et al. (1987)
CA54/61 High Mr glycoprotein Nozawa et al. (1989)
Colon carcinoma
NS199 Low Mr glycolipid Koprowski et al. (1979)
Pancreatic carcinoma
DU-PAN-2 High Mr glycoprotein Metzgar et al. (1982)
Osteogenic sarcoma
791T/36 72 KD protein Embleton et al. (1981)
Laryngeal carcinoma
Ca 1 High Mr glycoprotein Woods et al. (1982)
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2.4.1 CA125
The OC125 monoclonal antibody was produced by Bast et al. (1981) using a
modified method of Kohler and Milstein (1975). BALB/c mice were immunized
using the cell line OVCA 433 established from a patient with stage III serous
cystadenocarcinoma of the ovary. After immunization, spleen cells from the
mice were fused with a plasmacytoma cell line, and the supernatants from
resultant colonies were screened using indirect immunofluorescence. OC125,
the most promising clone isolated, was selected for its reactivity with the OVCA
433 cell line and other EOC cell lines, but lack of reactivity with a B lymphocyte
line established from the same patient. OC125 defines an antigenic determinant
designated CA125, cancer antigen 125.
CA125 is found elevated in a number of pathological and physiological states,
particularly reproductive states. Kabawat et al. (1983a), using a variety of
immunofluorescence techniques, demonstrated expression of CA125 in first and
second trimester foetal tissues derived from coelomic epithelium (Mullerian
ducts, cells lining the foetal peritoneum, pleura, and pericardium) and amniotic
epithelium. CA125, however, was absent in cells lining the foetal ovary or any
other foetal tissues. CA125 also reacted with adult derivatives of coelomic
epithelium including cells from the Fallopian tubes, endometrium and
endocervix (Kabawat et al., 1983a). No reactivity was observed with normal
ovarian epithelium, although CA125 was expressed in cells lining inclusion
cysts, papillary excresences and adhesions where surface epithelial cells had
undergone metaplasia. Reactivity was also found in mesothelial cells lining adult
pleura, pericardium and peritoneum. From these observations, Kabawat et al.
(1983b) concluded that CA125 is a differentiation antigen associated with
coelomic epithelium and its normal and neoplastic derivatives. Subsequent
studies found CA125 expression in sections of normal ovarian epithelium in
addition to normal epithelium of the pancreas, colon, gall bladder, stomach,
lung and kidney (Dietel et al., 1986, Nouwen et al., 1986 and 1987).
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Of particular clinical interest were the findings of elevated serum CA125 in
patients with endometriosis (for review see Kenemans et al., 1988), during
menstruation (Pittaway etal., 1987) and early in pregnancy (Niloff etai, 1984a).
Jacobs et al. (1988a) investigated the compartmental distribution of CA125
activity in tissue homogenates from the female reproductive tract. The highest
tissue levels were detected in first trimester decidual homogenate and were
greater than those found in non-pregnant endometrium and term decidua.
These findings parallel the rise in serum CA125 during first trimester of
pregnancy, and are consistent with the hypothesis that CA125 is a product of
normal endometrium/decidua, suggesting that CA125 elevation during
pregnancy is of decidual origin (Quirk et al., 1988). CA125 is also elevated in
endometrial and cervical mucus (de Briujn et al., 1986) in agreement with the
above findings. Indeed, CA125 serial measurement has been advocated for
follow-up of patients with endometriosis.
The highest CA125 levels are found in patients with EOC. Elevated serum levels
of CA125 were originally reported in greater than 80% of EOC patients, and
reflected the course of disease in the majority of these patients (Bast et al.,
1983). Consequently, a large research effort has established the role of CA125
in several aspects of EOC management (Canney etal., 1984, Crombach etal.,
1985, Bast et al., 1985, Niloff et al., 1986, Lavin et al., 1987, Brioschi et al.,
1987, Schilthuis et al., 1987, Lambert et al., 1987). Kabawat et al. (1983b) first
demonstrated the association of CA125 in tumours of serous, endometrioid and
clear cell types but not mucinous tumours. Subsequent studies found increased
tissue expression in patients with all histological types of ovarian cancer, and
in a high proportion of malignancies arising in the lung, breast, stomach, liver,
gall bladder, pancreas, kidney and large bowel (Bast etal., 1983, Haga etal.,
1986). It is expressed by epithelial ovarian tumours and other tissues of
Mullerian origin, notably endometrial, endocervix, and fallopian tube
malignancies (Niloff etal., 1984b).
The determinant CA125 is found on a high molecular weight glycoprotein, the
function of which is unknown. Due to its complex nature, information regarding
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the physical and immunological nature of this antigen is limited. Studies of the
nature of CA125 are also hampered by the inability so far to clone the gene
that encodes it. Several investigators have determined the molecular weight of
the CA125-bearing molecule. Using Western blotting, CA125 activity in ovarian
cancer serum, amniotic fluid, human milk, and ovarian cancer cell line
supernatants was associated with a moiety of greater than 1000 KD and a
lower molecular weight moiety of 200 - 400 KD (Davis et al., 1986, O'Brien et
at., 1986). The nature of the determinant has been investigated using a variety
of chemical, physical and enzymatic treatments. CA125 activity was destroyed
by treatment with periodate, mild alkali and neuraminidase, suggesting that it
is a sialylated saccharide bound to protein by alkali-labile linkage (Hanisch et
al., 1985). However, Davis et al. (1986) found periodate treatment, at a
concentration sufficient to oxidize carbohydrate, to have no effect on CA125,
while heating to 100°c not surprisingly destroyed activity. They concluded that
the determinant must be proteinaceous in nature. The precise nature of the
CA125 determinant however remains unclear. Davis et al. (1986) found a
carbohydrate content of 26%, lower than that of a typical mucin (see section
2.4.3) In addition, CA125 contains N-linked saccharides, while mucins are
typically O-linked.
Whilst co-expression of CA125 with the antigenic determinants CA199, and DF3
and B72.3, have been found on the same molecular complex (Davis et al.,
1986), reports of serum levels indicate independent expression.
2.4.2 HMFG2
Fat globules found in milk are surrounded by a membrane which is acquired
as they are extruded from the acinar cells of the mammary gland by a process
of reverse pinocytosis (Dowben et al., 1967). The membrane should therefore
be representative of the apical cell membrane of the secretory mammary cell
and contain components appropriate for this stage of differentiation. It is
relatively easy to isolate the non-lipid components of the milk fat globule
membrane by extracting the fat globules with lipid solvents. Polyclonal antisera
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raised to delipidated Human Milk Fat Globule (HMFG) and made specific by
adsorption with various human cells (Ceriani eta!., 1977) proved to be a useful
tool for the identification of breast epithelial cells in culture and tissue sections.
It was also useful for localising mammary tumours in mice (Wilbanks et a!.,
1981). Such delipidated preparations have been used to raise monoclonal
antibodies in an attempt to obtain specific markers for the characterisation of
breast epithelial cells in vitro and in vivo, and also for defining differentiation
stages in normal and malignant breast epithelial cells (Taylor-Papadimitriou et
al., 1981).
Taylor-Papadimitriou etal. (1981) produced monoclonal antibodies by injecting
female BALB/c mice, first with delipidated HMFG, then with a booster injection
three weeks later with either the same delipidated HMFG or with milk epithelial
cells grown in culture for two weeks (HMFG, and HMFG2 respectively). Two
antibodies, 1.10.F3 (HMFG,) and 3.14.A3 (HMFG2), reacted strongly with 7/8
breast cancer cell lines but were unreactive with lymphoblastoid cell lines,
fibroblast cell lines, or other epithelial cell lines (except HeLa derivatives). Both
of these antibodies showed strong binding, by indirect immunoperoxidase
staining of paraffin-embedded and frozen tissue sections, to malignant breast
cells (Arklie et al., 1981). Both antibodies were strongly expressed in actively
secreting mammary epithelial cells, but not on most normal cells found in the
non-lactating breast (Arklie et al., 1981), and they exhibited a luminal binding
pattern. Primary breast cancer tissue of all cell types, including; ductal, lobular,
medullary, mucoid, and Pagets disease of the nipple, stained with both
antibodies (Arklie etal., 1981), whilst lymph node metastases stained positive
with 3.14.A3 (HMFG2). Well differentiated cells stained more strongly than poorly
differentiated cells. Of the small numbers of other tumour types initially
examined, only three stained positive; ovary, lung, and uterus (Arklie et al.,
1981). HMFG2 was also shown to stain bladder carcinomas positively (Conn et
al., 1988) and over 90% of epithelial ovarian tumours (Ward et al., 1987a).
The HMFG component produced by lactating mammary glands was originally
purified by Shimizu and Yamauchi (1982), and characterised as a mucin. Later,
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it was identified by Burchell et al. (1983) and Griffiths etal. (1987) as being the
antigenic component recognized by a range of monoclonal antibodies raised
against HMFG preparations (see table 2.1). It has been variously termed PAS-0
(Shimizu and Yamauchi, 1982), NPEP - non-penetrating glycoprotein (Ceriani
etal., 1983), EMA - epithelial membrane antigen (Ormerod etal., 1983), MAM-6
(Hilkens et al., 1984), PUM - polmorphic urinary mucin (Swallow et al., 1986),
ESM - epithelial sialomucin (Hilkens, 1988), and most recently PEM -
polymorphic epithelial mucin (Hilgers et al., 1989).
Mucus glycoproteins, commonly referred to as mucins, have been difficult to
analyse because of their complexity. PEM, however, is a "simple" non-gel
forming mucin that has been relatively well characterised biochemically. Mucins
have the following characteristic properties: a high molecular weight (usually
>400 KD); a high serine and threonine content in the protein backbone; mainly
O-linked glycans (attached via N-acetylgalactosamine to the hydroxyl oxygen
of serine and threonine, in contrast to the N-linkage via the amide nitrogen of
asparagine to N-acetlyglucosamine in most cell membrane and plasma
glycoproteins) which may comprise >50% of the weight of the molecule; an
apical localization in normal epithelia, and a density intermediate between those
of plasma glycoproteins and proteoglycans (Hilkens, 1988).
Burchell et al. (1983) showed several intermediate glycoproteins in Western
blots, using the monoclonal antibody HMFG2, of cell lysates of T47D breast
cancer cells. These were thought to represent long-lived intermediates in the
glycosylation process (Griffiths et al., 1987). The biosynthesis of O-linked
sugars has not been elucidated in great detail; there is no consensus on the
timing and localization of the initiation of O-linked carbohydrates, for review see
Hilkens, 1988. PEM exhibits extensive polymorphism (hence the name) which
has been detected by various monoclonal antibodies and lectins (Walker,
1990). This polymorphism, first noted at the glycoprotein level (Swallow et al.,
1986 and 1987), is a result of genetic polymorphism. Heterogeneity in the size
of the apomucin, shown by Burchell et al. (1983), occurs due to a variable
number (20-100) of tandem repeat units present in the gene (Gendler et al.,
47
1988). Initial sequencing of partial cDNA clones showed that the tandem repeat
sequence consisted of 60 base pairs, which were highly rich in guanine and
cytosine and coded for a peptide of 20 amino acids rich in serine, threonine
and proline (Gendler et a/., 1987 and 1988). The gene has been mapped to
band 22q of chromosome 1 (Swallow et at., 1987), and recently Gendler et al.
(1990) have reported the full sequence for PEM. The core protein was originally
estimated to be 68 KD after hydrogen fluoride deglycosylation of the mucin
purified by affinity chromatography from mixed samples of human milk (Burchell
et al., 1987). Over one quarter of all amino acids in PEM contain potential
glycosylation sites.
Some monoclonal antibodies raised against PEM are directed to the carbo¬
hydrate moiety or a combined protein-carbohydrate epitope, but most are
directed to the protein backbone, including HMFG2 (Price etal., 1991). HMFG2
recognises a synthetic peptide corresponding to the amino acid sequence
predicted by the tandem repeat sequence. The epitope consists of three amino
acid residues - asparagine - threonine - arginine (Price et al., 1991). The
monoclonal antibody SM-3 raised specifically against the core protein of PEM
(Burchell etal., 1987) does not react with the fully processed mucin but reacts
with the aberrantly processed PEM produced by breast cancer cells. This
antibody may therefore form the basis of a more cancer specific assay.
2.4.3 CA153
The tumour marker CA153 is defined by two monoclonal antibodies, DF3 (Kufe
et al., 1984) and 115D8 (Hilkens et al., 1985), raised against a membrane-
enriched fraction of the human breast cancer cell line MCF-7 and delipidated
HMFG (see previous section) respectively. Kufe etal. (1984) originally showed
differential reactivity of DF3 with malignant and benign breast tumours. Hilkens
et al. (1984) using a sandwich assay, which employed 115D8 as both catcher
and tracer antibodies, found elevated MAM-6 in a high proportion of patients
with metastatic breast, ovarian, prostate and cervical carcinomas. Tobias etal.
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(1985) were the first to develop a sandwich immunoassay using DF3 as catcher
and 115D8 as tracer antibodies to define the tumour marker designated CA153.
Using this assay, Tobias et al. (1985) found elevated serum CA153 levels in
79% of patients with metastatic breast cancer. Fewer than 10% of patients with
benign breast, liver, lung, ovarian or gastrointestinal tumours had elevated
serum CA153 (Tobias et al., 1985). Subsequently, Hilkens et al. (1985)
demonstrated CA153 overexpression by immunohistochemistry in 50% of
ovarian malignancies. Scambia etal. (1988), in a preliminary longitudinal study
of EOC patients, reported elevated CA153 in those with all histological types of
EOC, and 20% of those with benign ovarian tumours. The authors also report
no incidence of CA153 elevation in fibromyomatosis, endometriosis or
endometrial hyperplasia. Serum CA153 is also found raised in carcinomas of
the lung, colon, stomach, uterus and pancreas (Tobias et al., 1995). The
epitopes recognised by both DF3 and 115D8 are present on PEM described
in the previous section (section 2.4.3).
2.4.4 CA724
The monoclonal antibody B72.3 raised by Colcher et al. (1981), together with
cc49 (Muraro et al., 1988), a second generation MAb with greater affinity and
similar specificity to B72.3, form the basis of a double-determinant assay for
TAG72 (tumour-associated glycoprotein). Using immunohistochemical
techniques, TAG72 was found expressed in all types of EOC (Johnson et al.,
1985, Thor etal., 1986). Klug etal. (1986) found CA724 elevated in the serum
of EOC patients. Scambia et al. (1990) found CA724 elevated in the serum of
a higher proportion of patients with EOC than cervical or endometrial cancer.
CA724 was found not to be raised in breast cancer serum by Scambia et al.
(1990), in agreement with Klug et al. (1986). These findings were surprising
considering the monoclonal antibody B72.3 was generated using a membrane
enriched extract of metastatic breast tumour tissue, and was originally shown
to stain positive with 50% of all breast cancer tissue sections tested (Colcher
et al., 1981). Scambia et al. (1990) found CA724 serum elevation in fewer than
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10% of all benign ovarian tumours and patients with fibromyomatosis. No
incidence of CA724 serum elevation was found in patients with endometriosis
or endometrial hyperplasia (Scambia etal., 1990). In addition, Thor etal. (1986)
found CA724 elevation in fewer than 10% of patients with benign ovarian
tumours and normal ovaries, suggesting CA724 may have value in the
differential diagnosis of an adnexal mass. CA724 has also proved a useful
marker of digestive tract malignancies, notably stomach, colon, pancreas and
biliary tract tumours. The epitopes recognised by both B72.3 and cc49 are also
present on a high molecular weight glycoprotein complex of greater than 1000
KD.
Much interest has been focused on the surface expression of TAG72 in vitro
and in vivo. Preliminary studies have shown the usefulness of B72.3 in
radioimmunoscintigraphy (Surwit etai., 1989). The influence of a-interferon on
cell surface expression of CA724 has been investigated by several authors.
Greiner etal. (1986) demonstrated increased expression of CA724 in response
to a-interferon treatment, although Scambia et al. (1990) found no evidence of
increased CA724 in the circulation of patients receiving a-interferon therapy.
This type of therapy may facilitate imaging and targeting with B72.3 by
enhancing cell surface expression of TAG72.
2.4.5 CA199
The monoclonal antibody NS 199 that recognises the determinant CA199 was
originally raised against a human colon adenocarcinoma derived cell line
SW1116 (Koprowski et al., 1979). The distribution of CA199 in normal and
malignant tissues has been described by Atkinson et al. (1982) using
immunohistochemistal techniques. Positive staining was observed in the
majority of patients with adenocarcinomas of the pancreas, stomach, colon and
in fewer patients with gall bladder tumours. The authors also found positive
staining in normal pancreas, stomach, liver, gall bladder and lung (Atkinson et
al., 1982).
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CA199 is found elevated in the serum from patients with a wide range of
gastrointestinal malignancies, including gastric, colon, panceatic, and biliary
tract tumours (Del Villano and Zurawski, 1983). Elevation of CA199 in ovarian
cancer sera was first demonstrated by Ricolleau et al. (1983). In an earlier
study, Charpin et al. (1982) found positive staining of CA199 in a high
proportion of patients with mucinous EOC and advocated CA199 as a marker
of mucinous EOC. CA199 has however proved a disappointing marker of other
histological types of ovarian tumour (Bast et al., 1984, Canney et al., 1985).
Magnani et al. (1983) first identified CA199 as a mucin, after demonstrating that
the antibody was directed against a sialylated lacto-N-fucopentose II epitope,
an oligosaccharide which is biochemically related to Lewis3 blood group
determinant (Magnani et al., 1982).
2.4.6 TATI
Tumour-associated trypsin(ogen) inhibitor (TATI) was originally isolated from the
urinary peptide fraction of a patient with stage III serous cystadenocarcinoma
of the ovary (Stenman et al., 1982). The oncodevelopmental nature of TATI was
implied by findings of high concentrations in tissue extracts of ovarian,
endometrial, and cervical cancer, and early (14-16 weeks), but not late (32-40
weeks) amniotic fluid (Stenman et al., 1982). The authors also found trace
amounts of TATI in normal brain, liver, spleen, lung, and kidney (Stenman etal.,
1982). High serum levels were found in patients with gastric, oesophageal,
thyroid and breast cancers and hepatomas. High urinary levels were found in
patients with ovarian, endometrial and cervical carcinomas, uterine sarcoma,
and severe inflammatory diseases such as acute pancreatitis and broncho¬
pulmonary disease (Huhtala et al., 1983), but especially hepatobiliary disease
(Haglund et al., 1986).
Urinary TATI measurement has generally been found to be more sensitive than
serum assay in patients with EOC (Huhtala et al., 1983), however, Halila et al.
(1988) found serum TATI assay to be sufficiently sensitive for monitoring
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patients with mucinous EOC. Expression of TATI appears to decrease with
increasing degree of malignancy in patients with mucinous EOC (Halila et al.,
1988). They also found higher levels in mucinous cyst fluid than serous cyst
fluid (Halila etal., 1987). Several authors have suggested that TATI may add to
CA125 in monitoring mucinous EOC (Halila et al., 1987 and 1988, Mogensen
et al., 1990), however larger studies are needed to verify this.
Biochemical characterisation of TATI has been relatively easy in comparison to
the other ovarian tumour markers investigated in this thesis. TATI is a 6 KD
peptide, consisting of 56 amino acids, identical in composition, NH2 terminal
sequence and COOH terminal structure to pancreatic secretory trypsin inhibitor
(PSTI) (Stenman et al., 1982, Huhtala et al., 1982), although its origin was
extrapancreatic in the patient from whom TATI was originally isolated (Stenman
etal., 1982).
Halila et al. (1988) suggested that the role of TATI may be to protect normal
cells from trypsin autolysis, conversely it may serve a protective role in the
tumour. Production of proteolytic enzymes by malignant cells is believed to be
essential to the ability of the tumour to degrade extracellular matrix and invade
surrounding tissue (for review see Liotta et al., 1986). In a search for the target
protease for TATI, Koivunen et al. (1991) isolated TAT-2 (tumour-associated
trypsinogen 2) from mucinous ovarian cyst fluid. TATI was shown to inhibit TAT-
2 activity, thought to be involved in a protease cascade stimulating tumour cell
invasion and degradation of extracellular matrix (Koivunen et al., 1990). The
authors suggested TATI elevation may be in reponse to TAT-2 expression
(Koivunen et al., 1990). Co-ordinate expression of TATI and TAT-2 has also
been found by Stenman et al. (1990), who also suggest a protective role for
TATI. This is consistent with the association of TATI with better differentiated,
less invasive tumours (Halila et al., 1988).
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2.4.7 c-neu p185
Shih etal. (1981) first identified increased expression of the neu oncogene after
transfection of NIH/3T3 cells with DNA from ethylnitrosourea-induced rat
neurogiioblastomas. The gene was independently identified from normal
genomic and cDNA libraries respectively, and termed c-erb B2 (Yamamoto et
ai, 1986) and HER-2 (Coussens eta!., 1985).
C-neu expression has been found on the cell surface of normal adult and foetal
tissue from the gastrointestinal, respiratory, reproductive and urinary tracts
(Press et at., 1990), and overexpression has been commonly observed in
adenocarcinomas (Gullick and Venter, 1988). Neu has potent transforming
capabilities in NIH/3T3 cells when expressed in comparable amounts to those
observed in some human cancers (Di Fiore etal., 1987). The gene encodes a
cell surface glycoprotein of molecular weight 185KD, commonly known as p185,
which posseses tyrosine kinase activity (Padhy etal., 1982). C-neu p185 bears
extensive sequence homology to epidermal growth factor receptor (EGFR)
(Schechter etal., 1984), although the c-neu proto-oncogene is found on band
q21 of chromosome 17 (Coussens etal., 1985) and the EGFR proto-oncogene
is found on band p11-p13 of chromosome 7 (Meera Khan and Smith, 1984).
In the rat neuroblastoma, site directed mutagenesis has shown c-neu to be
activated by virtue of a point mutation at position 664, which changes valine to
glutamine in the transmembrane domain, resulting in constitutive expression of
activated p185 (Bargmann and Weinberg, 1988). Lemoine et al. (1990),
however, report no evidence of activating point mutations in the c-erb B2 proto-
oncogene in human breast cancer. Although c-neu p185 does not bind to
epidermal growth factor (Sefton, 1988), tyrosine phosphorylation of c-neu p185
is stimulated by epidermal growth factor (Connelly and Stem, 1990). Lupu et
al. (1990) have recently identified a 30 KD factor, gp30, which they claim to be
the natural ligand for p185.
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Increased expression of the neu oncogene is invariably due to gene
amplification, although overexpression has been observed in cancer cell lines
in the absence of gene amplification (Gullick, 1990). Tyson et al. (1988) first
reported neu amplification and overexpression in ovarian tumour tissue, and
overexpression in the cell line OVCA 429 in the absence of amplification. The
expression of neu has been studied most intensively in breast cancer (Naber
et al., 1990). Many similarities have been found between breast and ovarian
cancer; 25-30% of tumours at each site exhibit neu amplification and
overexpression (Slamon etal., 1989, Berchuck etal., 1990), and approximately
10% of each have single gene copies but overexpress neu (Slamon et al.,
1989).
Slamon et al. (1989) found neu amplification in 31/120 (26%) primary ovarian
tumours; 23 of which were amplified 2-5 fold, and eight were amplified greater
than 5-fold. They also found a highly significant correlation between gene
amplification and overexpression (Slamon etal., 1989). Patients were grouped
according to gene copy number and level of expression, and significant inverse
correlations were found between gene amplification and survival in 87 patients,
and immunohistochemical staining and survival in 72 patients - although this
association was far less significant than the inverse association between DNA
amplification and survival. The authors observed no significant correlation
between RNA and survival, although they suggest that the number of patients
in the study may have been insufficient.
A sandwich ELISA, designated the c-neu ELISA, has recently been developed
(Carney et al., 1989) using two monoclonal antibodies NB3 and TA1. These
antibodies recognize distinct epitopes on the extracellular domain of c-neu
p185, and show no cross reactivity with EGFR (McKenzie etal., 1989). Recent
studies have shown that the c-neu ELISA detects a 100 KD glycoprotein in
tissue culture supernatant of SK-BR-3 cells that overexpress the c-neu proto-
oncogene. This p100 is biochemically related to the c-neu product, and is
thought to represent the extracellular domain released from the cellular c-neu
protein (Zabrecky et al., 1991). Yuzhong and Clinton (1991) have recently
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reported release of a 130 KD glycoprotein, also representing the extracellular
domain of c-neu protein, in SK-BR-3 cells. Hayes etal. (1989), in a pilot study,
found elevated serum levels of c-neu p185, using this assay, in 15% and 23%
of patients with localised and metastatic breast cancer respectively. To date,
this assay has not been evaluated in ovarian cancer.
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CHAPTER 3




The overwhelming feature of ovarian tumour markers discovered pre-1975 is
that none has found a role in patient management, whilst monoclonal antibody
defined markers, notably CA125, have found roles albeit limited ones. Some of
the potential clinical applications of monoclonal antibodies directed against
ovarian tumour markers have already been mentioned in chapters 1 and 2.
They may be used in vitro for serological and immunohistological detection,
and in vivo for imaging and targeting cytotoxic agents to the tumour. All of
these techniques may be applied at one or more stages in the course of this
disease. It should perhaps be emphasized at this point that therapeutic
applications are still in the early research stages, while serological,
immunohistological, and immunoradiological applications are routine in many
centres. Many problems need to be resolved before general clinical application
of each becomes feasible. In addition to requiring more experience with each
technique, it will be a long time before the true benefits of any of these "novel"
management strategies can be determined.
Bodmer (1987) has outlined three major aims in the control of cancer, in
descending order of priority, as prevention, early detection, and development
of specific treatment. It is unrealistic however to expect complete success with
all or even any of these measures. In view of the difficulties in determining
response to treatment in EOC patients, as described in chapter 1, these aims
need to be extended to include a fourth; the ability to monitor response to
treatment and determine a patient's disease status without having to resort to
further and often unnecessary major surgery.
This chapter will examine each of the aforementioned problem areas. Table 3.1
lists potential clinical applications of MAbs in EOC management. Particular
attention will be given to screening and monitoring ovarian cancer, mainly
because screening has received much media attention recently and this thesis
is concerned with monitoring patients with histologically proven EOC. Many of
the principles concerning the use of tumour markers to screen for EOC also
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apply to monitoring patients with established disease. First, an overview of
imaging and therapy with monoclonal antibodies in ovarian cancer will be given.





Early detection of marker in serum, urine or other body fluid prior to clinical
presentation.
(i) Detection of marker in serum, urine or other body fluid.
(ii) Immunohistology (including cytology) using panels of monoclonal
antibodies to (a) determine the occult origin of metastases, (b) differentially
diagnose anaplastic tumours, (c) classify tumours morphologically,
(d) differentiate benign from malignant lesions, (e) determine prognosis, and
(f) predict which markers may be useful for follow-up.
(i) Determining levels of tumour markers in serum, urine or other body fluids.
(ii) Determination of tumour size and location, and any changes in these by
radioimmunoscintigraphy (see below).
4. Immunoimaging Detection of tumour masses and occult metastases by injection of radiolabeled
monoclonal antibody (radioimmunoscintigraphy), including lymphoscintigraphy.
5. Immunotherapy (i) Active immunotherapy (immunisation).
(ii) Systemic (including intralymphatic) using monoclonal antibodies alone, as
conjugates with cytotoxic drugs, radioisotopes, or interferons, or as
immunoliposomes.
(iii) bone marrow clearance using monoclonal antibodies alone, with
complement or as conjugates to (a) deplete malignant cells prior to autologous
bone marrow transplant, and (b) deplete cells to reduce graft versus host
disease in allogenic bone marrow transplant.
6. Modulation (i) Antibody directed antibody-dependent cell mediated cytolysis.
(ii) "Arming" of other effector cells, e.g. macrophages and monocytes.
(iii) Depletion of blocking factors and suppressor cells.
taken from Daar and Lennox (1987).
3.2 EOC TUMOUR MARKERS AS TARGETS FOR IMAGING AND
THERAPY WITH MONOCLONAL ANTIBODIES
Conventional imaging and therapy of EOC suffers many limitations (see chapter
1). Imaging using X-rays, computed tomography, ultrasound, and magnetic
resonance imaging can detect at best tumours of 0.5 to 1.0 cm in diameter,
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while conventional chemotherapy usually fails because of non-selective toxicity
and the development of drug resistance. The concept of a selective and highly
efficient "magic bullet" was introduced by Ehrlich last century (Ehrlich, 1898),
and was revived recently with the introduction of tumour markers. Several
clinical trials using monoclonal antibodies directed against ovarian tumour
markers are currently underway.
3.2.1 Route of administration
Whether or not a monoclonal antibody reaches a tumour deposit is dependent
on a number of factors, including; the accessibility of the antigen; the size of
the tumour deposit(s); the site of tumour deposit(s); the permeability of the
epithelium lining blood and lymphatic vessels near the tumour. Given the many
physical obstacles that have to be overcome, it is not surprising that the route
of antibody administration has an effect upon the outcome of targeting.
Systemic (i.v.) administration often results in the trapping of antibodies in
normal tissues, in particular the reticuloendothelial system. As ovarian tumours
are mostly localised within the peritoneal cavity, intraperitoneal (i.p.)
administration is the best route of administration for detection and therapy with
monoclonal antibodies.
Haisma et al. (1987) compared i.v. with i.p. administration using 131l labelled
OC125 F(ab')2 fragments in 10 patients with ovarian cancer. Rowlinson et al.
(1987) defined the advantage given by i.p. adminstration as the tumour:tissue
ratio following i.p. injection divided by the tumour:tissue ratio following i.v.
injection. The i.p./i.v. advantage for normal tissue uptake was, however, poor
ranging from only 1 to 10 in Haisma's study.
3.2.2 Immune response elicited by monoclonal antibodies
Although murine monoclonal antibodies are not toxic per se, they do elicit an
immune response in the majority of patients after both diagnostic and
therapeutic administration. One of the earliest groups to target ovarian
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carcinomas, the Hammersmith Oncology Group, injected 10 patients with
various monoclonal antibodies at a dosage of 250 p,g and subsequently
administered a therapeutic dose of 2 -15 mg (Courtney-Luck etal., 1986). Five
of their patients developed a human anti-mouse antibody (HAMA) response.
Later studies suggested that all patients injected with murine monoclonal
antibodies would develop such a response after one or more doses.
HAMAs not only interfere with antibody localisation and uptake by the tumour,
but may also cause falsely elevated serum marker levels (Janssen etal., 1989).
Several methods have been proposed to circumvent this problem to allow
effective repeat administration of antibodies. These include; use of human
monoclonal antibodies; use of hybrid antibodies that possess a human IgG
frame; host immunosuppression, and; plasmapheresis (for review see Verheijen
etal., 1988).
3.2.3 Radioimmunoscintigraphy
The first experiments were conducted by Goldenberg et at. (1974) using
polyclonal antibodies to CEA to localise xenografts of CEA-bearing human
colon carcinoma, and later in patients using 1311 labelled antibodies (Goldenberg
etal., 1978b). The quality of an immunoscintigram depends on several factors,
including the energy of emission, and the physical and biological half-life of the
isotope. It is important that the isotope does not emit /Jparfefcwhich would be
harmful to normal tissue.
3.2.4 Isotopes
In early studies, the most widely used isotope was 131iodine, which has a high
y emission, relatively long half-life of 8 days, but also significant emission.
Several isotopic labels have been tested, including 123iodine, 111indium,
67gallium, and "technetium. In vivo dehalogenation was a common problem
with iodine labelled antibodies resulting in excretion of free iodine and low
tracer accumulation in the tumour (Mach et a/., 1980). Technetium-99m has
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been advocated as the best label (Britton and Granowska, 1991) for imaging,
although the half-life is short (6h), therefore images must be produced within
12h of administration.
Background subtraction techniques are often necessary to reduce the amount
of background activity caused by accumulation of labelled antibody outside the
target tissue. These may be achieved by subtracting early from late images
when most of the antibody has been cleared from non-specific sites. The image
obtained using a non-specific antibody may be subtracted from the image
obtained with a more specific antibody, as demonstrated by Haisma et al.
(1984) using MAb 115D8 to localise tumour in mice bearing human breast
cancer xenografts. Alternatively, the "blood-pool" activity may be reduced by the
use of antibody fragments. Fab and F(ab')2 fragments can be prepared by
papain and pepsin digestion respectively of the whole IgG molecule.
3.2.4 Clinical radioimmunoimaging studies
Epenetos et al. (1982a and b) were the first to successfully image ovarian
cancer using 123l labelled monoclonal antibodies HMFGt and HMFG2 directed
against PEM. Since this report, HMFG2 has been extensively used to image
ovarian cancer (Granowska et al., 1984 and 1986, Patiesky et al., 1985,
Shepherd et al., 1987, Ward et al., 1987d). These early studies mostly
employed 123l and whole antibody. Granowska et al. (1986), in a prospective
study found a correlation of 95% between pre-operative scans using 123l labeled
HMFG2 and findings at primary laparotomy. Kalofonos and Epenetos (1987)
were the first to use F(ab')2 fragments of HMFG2 to image ovarian cancer in 14
patients with advanced disease.
Numerous studies have investigated the use of OC125 F(ab')2 fragments to
image ovarian cancer (Chatal et al., 1986, Hunter et al., 1987, and Haisma et
al., 1987). Positive scans were obtained in patients with normal serum CA125
levels and negative CT scans, suggesting a role for OC125 imaging in detection
of occult disease in EOC patients (Granowska et al., 1988).
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Other antibodies investigated in this thesis have been employed to image EOC
patients. Hnatowich et al. (1985) were the first to use an indium label; 111ln
labelled CA199 successfully visualised 67% of documented tumour sites in
patients with various tumours. Greiner et al. (1986) used B72.3 to image EOC
patients. The use of a-interferon therapy to enhance tumour cell surface
expression of TAG 72 was mentioned previously in chapter 2, section 2.4.4,
p 50.
3.2.5 immunotherapy
Unmodified antibodies may mediate their effects through two mechanisms;
complement activation and antibody-dependent cell mediated cytotoxicity
(ADCC) (see table 3.1, p 58). The first clinical therapeutic use of antibodies in
EOC patients involved the use of polyclonal human ovarian anti-tumour serum
(HOATS) in a randomised trial comparing its addition to abdominal irradiation,
melphalan, and i.p. colloidal 32P (Order et al., 1981). This study was not
extended because of the rapid introduction of monoclonal antibodies.
3.2.6 Monoclonal antibody conjugates
It is important that conjugation of monoclonal antibodies with either radiolabels
or other cytotoxic agents does not interfere with antibody-antigen interaction.
Verheijen et al. (1988) have identified several preferable features of monoclonal
antibodies for /'/7 vivo targeting. Thus, a candidate antibody must (1) be directed
to a cell surface antigen, (2) bind to its antigen with high affinity, (3) not form
immune complexes in the circulation, (4) internalize (for immunoconjugates),
(5) mediate ADCC (for unmodified antibodies), and (6) not accumulate in the
reticuloendothelial system. Antigen expression must be high on the tumour cell
surface and low on normal cells, i.e. it does not have to be "tumour specific".
Radiolabeled antibodies employing a wide variety of isotopes have been tested
therapeutically. Isotopes with a short path length and a short half-life are
prefered to minimise damage to normal tissue. /S emitters, e.g. 1311, ^ and 32P,
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which have a particle range of several cell diameters, are the most popular
radionuclides (Britton and Granowska, 1991). Yttrium-90 has several
advantages in that it is a pure /? emitter, eliminating hazards to normal tissue.
In a clinical study of 90Y labeled OC125, administered intraperitoneal^ in
patients with advanced EOC, Griffin et al. (1987) found tumour uptake to be
100 times that of normal tissue, and less than 3% of the dose was excreted in
the patients' urine. 90Y labeled HMFG2 has also been used to target ovarian
cancer (Snook et al., 1987).
The majority of targeting studies in EOC patients have been performed using
labelled OC125 or antibodies directed against epitopes found on PEM, mainly
HMFG, and HMFG2 (for review sees Verheijen et al., 1988, and Britton and
Granowska, 1991). The Flammersmith Oncology Group reported a response
rate of 25% (7/28) in patients with ovarian carcinoma using i.p. 1311 labelled
HMFG^ FIMFG2 or AUA1, selected by positive immunohistology (Stewart etal.,
1987). Poels etal. (1986) have recently developed a monoclonal antibody, OV-
TL3, directed against an antigen which is not found in the circulation.
Preliminary results using this antibody are promising; in vitro studies have
shown that the biodistribution of OV-TL3 antibody is superior to OC125
(Flaisma et al., 1987).
Monoclonal antibodies that have been "humanised" by grafting the
hypervariable regions of murine monoclonal antibodies, that determine the
antibody binding site, onto human IgG frames have been developed by
Verhoeyen etal. (1991) for HMFG^ and are currently undergoing clinical trials
at Flammersmith Hospital, London. Humanised anti-PLAP (MAb H17E2) has
also been genetically engineered in a similar manner (Verhoeyen et al., 1991).
Anti-PEM antibodies are directed against cell surface antigens and probably do
not internalise into the tumour cells; this is not a problem with
radioimmunotherapy but could be a disadvantage of immunoconjugates. ADCC
may be an important factor in the anti-tumour reaction, as most of these
antibodies do not bind complement. The problem of tumour antigen
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heterogeneity has already been alluded to in chapter 2. Several authors have
concluded that the most effective approach to targeting immunotherapy using
monoclonal antibodies may be to employ a "cocktail" of complementary
antibodies, analogous to the use of panels of antibodies in immunohisto-
chemistry and serology (see sections 3.6 and 3.7, pp. 76-82). The most
effective combination, however, remains to be determined.
3.3 PRIMARY PREVENTION
Primary prevention deals with the control of factors known to cause disease.
Several risk factors for EOC have been identified, although none has been
helpful as yet in aiding its prevention, except oral contraceptive use (Vessey et
al., 1987). To recapitulate, family history, early menarche, late menopause,
nulliparity, and infertility were amongst the most important risk factors. The only
preventable cancer at present is cancer of the cervix, by identification of pre¬
neoplastic lesions through the use of the Papanicolaou (Pap) smear test. Even
so, the proportion of individuals with cervical intra-epithelial neoplasia who
progress to frank malignancy is small, and prevention is incomplete. It is
estimated that 70-80% of cases are preventable given a 100% accurate
diagnostic test and 100% compliance rate. Part of the failure of this screening
programme is attributable to poor compliance; as many as nine in ten women
diagnosed have never had a smear test.
Elimination of tobacco use, estimated to be responsible for 30-40% of all
cancers, would bring greater net benefit to health than all our efforts to treat
cancer of all types. Most primary preventative health measures require drastic
alterations in our lifestyle, unfortunately there is no consensus yet, exemplified
by our inability to control the greatest identifiable cause. Cigarette smoking is
not an obvious risk factor for EOC. The inherent difficulties of imposition of a
"healthy" lifestyle on any population, means that we must turn our efforts to the





Britain has had a cervical screening programme in operation now for over 20
years, and has been embarking on the implementation of a national breast
screening programme following the recommendations of the Forrest Report
(DHSS, 1986). In contrast, ovarian cancer screening has received very little
attention until recently, and yet it kills twice as many women annually as cervical
cancer. Ovarian cancer has long been known as the "silent killer" because of
its insidious onset, but also because it rarely received publicity. This situation
has changed over the last two years as new reports of promising screening
tests have been published (Jacobs etai, 1988b, Campbell et ai, 1989, and
Bourne et a!., 1989). Previous attempts at early detection of ovarian cancer
using pelvic examination and cytology met with no success. New developments
in monoclonal antibody technology and imaging techniques have brought fresh
optimism to the hope of being able to diagnose ovarian cancer earlier when
chances of cure and remission are increased because treatment of localised
disease is more effective. Early diagnosis in general is believed to be a better
approach to the reduction in mortality than the development of specific
treatment.
Screening may be defined as "the presumptive identification of unrecognised
disease or defect by the application of tests, examinations, or otherprocedures
that can be applied rapidly" (Miller, 1985). Thus, a screening test is applied to
asymptomatic individuals and is not intended to be diagnostic, where
necessary this is confirmed by specialized secondary procedures. Conversion
of the simple tenet "early diagnosis leads to better prognosis" into an effective
large scale screening programme is a very complex organisational undertaking.
Design and ultimately implementation of a screening programme for cancer is
fraught with difficult and not entirely apolitical issues, ranging from ethical to
economical, when large populations are to be screened in which only a small
number of cases will be found. Many original problems encountered with
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screening programmes arose because the issue was considered to be clinical
rather than epidemiological, with attention focused on cases diagnosed at the
expense of the population under study. Consequently, there are many lessons
to be learned from those programmes already in existence. At the very least,
a screening programme should guarantee an overall benefit to the community
and minimal risk that it will be detrimental to certain individuals. At present,
screening for cervical and breast cancer are the only two sites backed up by
hard evidence as to the benefits at the population level in terms of overall
achieveable reduction in mortality rates (Mant and Fowler, 1990). Recently,
however, breast cancer screening has come under much dispute (Roberts,
1989), in particular the speed with which it has been introduced in relation to
establishment of back-up services (Baum, 1990).
3.4.2 Principles of screening
The principles of screening for disease were first formulated by Wilson and
Jungner in 1968 for WHO, comprising the following 10 criteria:-
1. The condition to be screened for should pose an important health problem.
2. The natural history of the disease should be well understood.
3. There should be a recognisable early stage.
4. Treatment of the disease at an early stage should be of more benefit than
treatment started at a later stage.
5. There should be a suitable test or examination.
6. The test or examination should be acceptible to the population.
7. There should be adequate available facilities for the diagnosis and treatment
of detected abnormalities.
8. For diseases of insidious onset, screening should be repeated at intervals
deemed by the natural history of the disease.
9. The chance of physical or psychological harm should be less than the
chance of benefit.
10. The cost of a screening programme should be balanced against the
benefits it provides.
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There are many important factors which may influence the outcome of
population screening, some of which are considered below, see sections 3.4.3
to 3.4.6. The degree to which EOC fulfils these criteria will be addressed in
section 3.5.
3.4.3 Evaluation of screening
Greenwald etal. (1985) have defined cancer control as "the reduction of cancer
incidence, morbidity and mortality through an orderly sequence from research
on interventions and their impact in defined populations to the broad
systematic application of the research results". Thus, the basis of any screening
programme must be quantification of the extent to which the above are
reduced. Ultimately, the impact on mortality rates, through the implementation
of randomised controlled trials, where the population is divided into a study
group offered screening and a control group that receives the currently
accepted programme of routine diagnosis and care, will be the only true
measure of the efficacy of screening. Three important phenomena, lead time
bias, length bias and selection bias, which may improve the apparent survival
in the screened population, are examined below.
3.4.4 Lead time bias
Survival is measured from the date of diagnosis to death, rather than from the
date of inception to death. The date of diagnosis may therefore vary
considerably, depending on the methods of detection used, without altering the
true length of survival from the date of inception. Lead time generated by
screening, or the period from detection while the woman is still asymptomatic
until the appearance of clinical symptoms which would permit conventional
diagnosis, may increase the apparent survival without in fact the individual
having benefitted from screening. In such circumstances the patient has to live
with the knowledge of her disease for longer.
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3.4.5 Length bias
A series of cases diagnosed at screening will be atypical of those arising
clinically, since it will contain a disproportionate number of women with slowly
developing tumours with probably a better prognosis. Women with rapidly
progressing tumours are more likely to present with symptoms before the
initiation of, or in the interval between, screening tests. This bias is more likely
to be manifest at the initiation of screening and is therefore especially important
in studies of short duration.
3.4.6 Selection bias
Selection bias results from entry of a cohort into a screening trial who have a
different probability of developing and dying from the disease than the
population at large. In self selected populations, it is common to find a higher
than normal proportion of women presenting for screening because of a
positive family history. These women are more motivated to present for
screening because they are more educated in this respect and are more likely
to benefit from it. This has been well demonstrated in breast and cervical
screening programmes.
3.4.7 Value of a diagnostic test
The validity of a screening test is measured by its sensitivity, specificity,
accuracy and predictive powers, see below. These may be expressed as a
fraction or a percentage.
Sensitivity is the index of the chance that someone with the disease will have
a positive test result, given by the formula:-
Sensitivity = TP / TP + FN (x 100%)
The false negative rate is given by 1 - sensitivity.
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Specificity is the index of the chance that someone without the disease will have
a negative test result, given by the formula:-
Specificity = TN / TN + FP (x 100%)
The false positive rate is given by 1 - specificity in this thesis, although may
be defined in three other ways (Galen, 1990).
Accuracy (or efficiency) is the index of the chance that a test result is correct,
given by the formula:-
Accuracy = TP + TN / TP + TN + FP + FN (x 100%)
The predictive value of a positive result (PVP), is the index of the chance that
a positive test result means disease is present, given by the formula:-
PVP = TP / TP + FP (x 100%)
The predictive value of a negative result (PVN), is the index of the chance that
a negative test result means disease is absent, given by the formula;-
PVN = TN / TN + FN (x 100%)
where TP = true positive, TN = true negative, FP = false positive, and FN =
false negative results.
Difficulties in quantifying sensitivity and specificity may be due to uncertainty as
to what constitutes an abnormality. This is where knowledge of the natural
history of the disease becomes important, often this may only be determined
after careful study of a screening programme's findings. Sensitivity is difficult
to determine initially as false negatives are not readily apparent, long-term
follow-up is required to determine the extent of these. Sensitivity was originally
thought to be more important than specificity as it was felt to be crucial to avoid
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missing individuals with disease. However, maximising sensitivity usually
disproportionately increases cost, and some of the lesions detected at
screening may never progress or may be picked up later in a curable state.
When deciding on a cut-off point for any test which is to discriminate between
a dichotomous outcome, ie. disease positive and disease negative, a trade-off
between sensitivity and specificity has to be made. These two are interrelated,
hence, if sensitivity is increased specificity decreases and vice versa. It is more
important to maximise specificity and thus minimise the number of individuals
who are misclassified as disease positive when dealing with the diagnosis of
a disease as serious as cancer. High numbers of false positives generates
more work for the back up services, not to mention the unnecessary anxiety
caused to the women who are falsely suspected of having cancer. It can be
mathematically proven that if false negatives and false positives are of equal
clinical concern, as prevalence tends to zero, specificity ascends over
sensitivity,
FP + FN = prevalence^ -sensitivity) + (1-prevalence) (1-specificity)
Therefore, if prevalence tends to zero, FP + FN = 1 -specificity,
therefore increasing specificity reduces false results (Roulston, 1990).
The best measure of the efficacy of a screening test is the PVP, because unlike
sensitivity and specificity it is dependent upon the disease prevalence in the
population being screened. Two tests, each for different types of cancer, may
have equal sensitivity and specificity for their respective diseases, but the test
applied to the population in which the disease prevalence is higher will have a
higher PVP, making it a more reliable assessment of the disease presence in
that particular population.
For example, consider screening two hypothetical populations for EOC with
CA125 serum assay, which has a sensitivity of 80% (or false negative rate of
20%) and specificity of 99% (or false positive rate of 1%). Population A consists
of postmenopausal women over 50 years old in whom the disease prevalence
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is of the order of 40/100,000, and population B consists of postmenopausal
women over 50 years old with a positive family history and relative risk of
approximately 3, and therefore a disease prevalence of 120/100,000. If 10,000
women from each population are screened, one would expect to find four
cases of ovarian cancer in population A and 12 cases in population B. Given
a false positive rate of 1 %, 100 women from each population would have falsely
elevated CA125 levels. The PVP of CA125 assay in population A would be 3.8%
[4/(4 + 100)], and 10.7% [12/(12 + 100)] in the high risk population B.
Therefore, using the same test in different populations yields a greater PVP in
the population with the higher disease prevalence.
3.4.8 Screening outcomes
Apart from attempting to control cancer, the role of screening is to provide
individuals with information regarding the likelihood that they may have or may
develop cancer. The four possible outcomes of a screening test each has
significant implications for the individual concerned, see figure 3.1.
Screening women with cancer





depends on stage at diagnosis
Outcome: treatment may be less
effective than if cancer was
detected at screening
Screening women without cancer
Positive (FP): further testing
to determine that cancer is not
present - if not may lead to
unnecessary treatment
Negative (TN): subject returned
to general population for next
round of screening - women is
appropriately deemed free of
cancer and is reassured
Figure 3.1 Screening outcomes (modified from Greenwald eta!., 1985)
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The psychological sequelae of a positive diagnosis is perhaps easier to discern
than that resulting from a negative result, or for that matter participation in
screening alone. A false result will not only cause undue anxiety but may
damage a woman's trust in the programme preventing her from further
participation. The success of any screening programme is very dependent
upon a high compliance rate from the target population.
3.5 SCREENING STUDIES
Ovarian tissue is not amenable to direct sampling in the way that breast and
cervical tissue are. Thus the anatomical site of the ovaries imposes a number
of restrictions as to the nature of a screening test. Screening must therefore
be performed by techniques which either demonstrate a change in ovarian
structure ie. size and morphology, or an alteration of ovarian function ie. re¬
flected by the release of metabolites into the peripheral circulation. Several
promising studies involving such techniques have come to light in recent years.
3.5.1 Ultrasound screening for EOC
Campbell and colleagues at King's College Hospital in London, have been
performing trials to assess the use of ultrasound for the early detection of
ovarian cancer for over 10 years. Initially, they found a good agreement
between sector real-time pelvic ultrasound assessment of ovarian size and
morphology with that obtained at laparotomy (Campbell et a/., 1982).
Subsequently, they reported results of a prospective study of 5540
asymptomatic self-referred women over 45 years old, who underwent annual
ultrasound for three years, to determine the prevalence of ovarian cancer in this
population and assess the predictive value of ultrasound. Eight malignancies
were detected of which five were stage 1 a and three were metastatic. No false
negative results were found, therefore, sensitivity was 100%. The false positive
rate was 97.4% and PVP was 2.6%. When tumours of low malignant potential
were included among the true positives, PVP rose to 19.3%, indicating a one
in five chance of malignancy or potential malignancy with a positive result (Bhan
72
et al., 1987). This study highlights the difficulties in defining a positive result; as
it is unknown what proportion of benign tumours will become frankly malignant
(Fox, 1990).
Later, Campbell et al. (1989,1990) report detection of an additional metastatic
cancer. Screen detected cancers declined in incidence over three successive
screens from 1.7% at the first screen to 0.6% and 0.2% at the second and third
respectively. Two primary cancers were detected at the first screen and three
at the second screen, 16, 18 and 22 months after the first screen. The authors
have suggested these results show a need to screen every 12-18 months. A
gradual reduction in the false positive rate was noted as more criteria were
included in the definition of abnormality. Thus, the false positive rate was lowest
when morphology, volume and change in volume were taken into account
(women with abnormal scans were rescanned three weeks later to exclude any
transient alterations, and if the second scan was abnormal laparotomy was
indicated), giving a sensitivity of 100%, specificity of 98.8% and PVP of 2.9%
(Campbell et al., 1990).
In addition, Campbell et al. (1989) and Bourne et al. (1989) have been
conducting a comparative study of transabdominal and transvaginal ultrasound
screening respectively. Transvaginal ultrasound imaging has two main
advantages; the woman does not need a full bladder hence it is less
uncomfortable, and the tip of the probe can be placed nearer to the ovary
allowing higher frequency ultrasound to give a better resolution of the ovaries.
The results of these studies indicate that transvaginal ultrasound is more
sensitive than transabdominal ultrasound (Bourne eta!., 1989). In addition, the
specificity of transvaginal ultrasound can be improved by assessing blood-flow
impedance in the ovarian vasculature using colour-flow imaging. Ovarian
cancers have a lower impedance to blood flow than benign ovarian tumours as
a result of neovascularisation.
Andolf etal. (1986) screened 805 women using transabdominal ultrasound, and
found one ovarian cancer, two borderline tumours and one caecum cancer.
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This study, however, was applied to symptomatic women attending a
gynaecology outpatient clinic and is therefore inconclusive with regards to
screening in its true sense. Abdominal ultrasound as a secondary procedure
to serum CA125 assay and vaginal examination has also been employed
(Jacobs et at., 1988b). If effective, utilization of CA125 as a primary screen and
ultrasound as a secondary screen, would reduce costs enormously as the
cheaper test is used first. The primary test in this incidence needs to have a
high specificity to maximise the number of cases detected without referring
excessive numbers of women for needless surgery. Inevitably there will be a
few followed up unnecessarily.
3.5.2 Screening for EOC with tumour markers
Since the rationale for screening comes from the much improved survival rates
in women with FIGO stages I and II disease, it is expedient to look at marker
levels in such women. Over a decade ago, Knauf and Urbach (1980) found
OCA to be elevated in 70% of women with stages I and II EOC, but also in 10%
of normal individuals. The high false positive rate precluded the use of OCA for
screening large populations, however, these early observations did suggest that
antigens shed from tumour cells could find their way into the peripheral
circulation at an early stage of tumour spread. Bast etal. (1990) postulated that
tumour markers may reach the peripheral circulation in early disease by
shedding from cells into lymphatics or blood vessels in the well vascularised
ovarian stroma, whilst antigen shed into the peritoneal cavity may reach the
thoracic duct and hence venous circulation via diaphragmatic lymphatics.
Several studies have assessed the sensitivity of pre-operative serum CA125 in
women subsequently diagnosed with EOC (for review see Jacobs and Bast,
1989). Jacobs and Bast (1989) in a review of 15 studies report a cumulative
elevation of CA125 (>35 Urnl"1) in 48/96 (50%) women with stage I EOC at
diagnosis. In the first large screening study, Zurawski et al. (1987), using a
cut-off value of 65 Uml"1, found a false positive CA125 rate of 0.6% in 915 post¬
menopausal Roman Catholic nuns. Given a disease prevalence of 20-40/100000
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in women over 50 years old, 15-30 false positive CA125 results would be
encountered with each case detected. Jacobs et al. (1990a) have estimated
that a screening test with 100% sensitivity would have to have a specificity of
99.6% in order to detect one case of ovarian cancer for every 10 operations
performed (see section 3.4.7, pp. 68-71). The authors have assumed that
clinicians would be unlikely to employ a test which would result in greater than
10 surgical procedures to detect one case (ie. PVP would have to be at least
10%).
Jacobs et al. (1988b) conducted a pilot screening study in 1010 asymptomatic,
self-referred postmenopausal women at the Royal London Hospital. If serum
CA125 was greater than 30 Urnl"1, or vaginal examination abnormal, the woman
underwent abdominal ultrasound. If this was abnormal they were referred for
surgery. Three women had laparotomies and one was found to have a stage
1b serous EOC, and a CA125 level of 32 Uml"1, within the accepted reference
range. Roulston et al. (1988) calculated the PVP of Jacobs' results to be 3%.
As mentioned in chapter 2 (section 2.3.3, p 38), a well defined high risk
population and a high prevalence (10%) are the reasons for the success of/3
HCG in screening for choriocarcinoma. Both Jacob's and Campbell's screening
tests fall far short of an acceptable PVP, because the prevalence of ovarian
cancer is low in their test populations. Therefore, a single CA125 assay
produces a prohibitively low PVP. No single test will be sufficiently sensitive or
specific enough to screen for ovarian cancer. Therefore, most investigators
favour a multimodal approach, however, the best is yet to be determined.
Zurawski et al. (1990) have recently reported the results of a study conducted
in Stockholm from 1985 to 1986, in which 1086 women over 40 years old were
screened with CA125. If CA125 levels were >35 Urnl"1, the assay was repeated
and women were also assessed by transabdominal ultrasound and pelvic
examination. The only patient with rising CA125 was found to have a stage II
ovarian cancer 20 months after initial CA125 elevation (Zurawski et al., 1990).
This study has recently been updated, Einhorn et al. (1990) report annual
CA125 screening of 5550 women from 1986 to 1988. CA125 was assayed every
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three months, and transabdominal ultrasound and pelvic examination
performed every six months, in 175 women with CA125 levels >30 Urnl"1. Six
post-menopausal women had ovarian cancer diagnosed during screening; four
of whom had early stage disease. However, three pre-menopausal women, who
had normal CA125 levels, also developed ovarian cancers which were missed
at screening (Einhorn et a/., 1990), illustrating the problem of length bias.
The need for randomised controlled trials to assess screening tests is well
recognized. In the meantime pilot studies are continuing to try to identify the
most feasible approach. The UKCCCR Subcommittee for coordination of
research into Gynaecological Cancers, recognising the growing interest in
screening for ovarian cancer, held a workshop in the Royal College of
Obstetricians and Gynaecologists in January 1989 to determine whether this
would be feasible on a population basis. This workshop has reported its
findings and recommendations on screening with reference to the WHO criteria
for implementation of a screening programme, see Appendix A.
3.6 DIFFERENTIAL DIAGNOSIS OF BENIGN AND MALIGNANTOVARIAN
TUMOURS
As the incidence is greater, more benign tumours will inevitably be detected at
screening than malignant. Unfortunately, the true incidence of benign disease
is unknown as many cases are recognized incidentally on histological
examination of hysterectomy specimens, which may have been performed for
other reasons. Initial exploratory laparotomy is most frequently performed by
a general gynaecologist. When malignancy is discovered, complete staging and
surgical cytoreduction often cannot be achieved. Consequently, the patient
must be referred for a second operation.
Several studies have shown that CA125 levels >65 Urnl"1 in patients with pelvic
masses are associated with malignancy in 80-90% of post-menopausal patients
(Einhorn et ai, 1986, Malkasian et al., 1988, Soper et al., 1990), although
Vasilev et al. (1988) found no improvement in the discriminatory capacity of
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CA125 using this cut-off value compared to 35 llml"1. Berchuck and Bast (1990)
report the PVP of CA125 to increase to 96% when a cut-off value of 95 Urnl"1
was employed. CA125 is less reliable when used to differentiate benign from
malignant ovarian tumours in pre-menopausal women; as CA125 is elevated in
a number of benign conditions (see chapter 2, section 2.4.1, p 43). As not all
women with EOC express CA125 the PVN is lower than PVP. A negative CA125
result, however, should not discourage a surgeon from performing exploratory
laparotomy on a post-menopausal woman with a pelvic mass who is otherwise
a candidate for cytoreduction.
Various strategies have been adopted to increase the specificity of detection
of malignant ovarian tumours using monoclonal antibodies. Wu eta/. (1988),
in attempt to increase specificity of diagnosis, found the ratio of CA125:CEA
useful in discriminating between serous and mucinous ovarian tumours. A ratio
of >1000 was associated with serous tumours, while a ratio of <10 was
associated with mucinous tumours. CA199 failed to help the discrimination in
their study (Wu et al., 1988).
It is more common in studies of differential diagnosis of benign and malignant
ovarian tumours to determine coordinate elevation of serum tumour markers.
No single tumour marker has 100% sensitivity and specificity for any tumour as
a result of tumour antigen heterogeneity. Different combinations of genetic
"lesions" resulting in malignant transformation give rise to many different tumour
cell phenotypes, each expressing a characteristic set of antigens (see chapter
2, section 2.2, pp. 32-36). Ovarian tumour antigen heterogeneity has been
amply demonstrated using immunohistochemical techniques and by serological
antigen profiles (Welch et al., 1990).
Other tumour markers, notably CA153 and CA724, not affected by the benign
conditions that cause CA125 elevation appear to be the best candidates for
panel testing. Finkler et al. (1988) found false positive CA125 levels in 50
patients with benign conditions, all of whom had CA125 levels >35 Urnl"1, while
42% had CA125 levels >65 Uml"1. CA153 and CA724, however, were only
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elevated in 2% and 6% of patients respectively, while NK/70K was raised in 62%
of patients. In those with EOC, either CA724 or CA153 was positive in 83%
while only 5% of patients with benign adnexal masses had elevated levels of
either marker (Finkler et al., 1988). Mogensen et al. (1990) have recently
advocated the use of TATI assay in addition to CA125 to discriminate benign
from malignant mucinous EOC. When multiple markers are used with CA125,
diagnostic sensitivity and specificity does not always improve, despite the fact
that several markers, including CEA, CA199 and CA724 detect mucinous
tumours more frequently than CA125 (Bast et al., 1990).
3.7 MONITORING EOC WITH TUMOUR MARKERS
After cytoreductive surgery, most patients with advanced disease have small
volume residual disease that is difficult to detect by physical examination or
radiographic procedures (see chapter 1). Although the majority of patients
respond to cisplatin based chemotherapy regimes, responses are often short¬
lived and most of these patients will relapse. Several months may elapse before
disease progression becomes clinically evident. CA125 has an established role
in monitoring patients with histologically proven EOC, as outlined in sections
3.7.1 to 3.7.5. These areas will be described in more detail in chapters 7, 8
and 9.
3.7.1 Correlation with tumour burden
All studies of serological tumour markers have found significantly higher levels
in patients with metastatic disease compared to those with either localised
malignant or benign tumours. Correlations with tumour burden are most
accurately determined using samples assayed immediately prior to laparotomy,
primary or secondary. As mentioned in chapter 1, section 1.9.2, p16, precise
measurement of tumour burden is difficult to obtain.
In a review of the literature, Jacobs and Bast (1989), reported serum CA125
elevation prior to second-look in 8/38 (21 %) patients with microscopic disease,
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14/45 (38%) patients with <1cm disease, 21/46 (46%) patients with <2cm
disease, 39/56 (70%) patients with >2cm disease and 39/39 (100%) patients
with disease >10cm in diameter. Different disease categories were used in
different studies. False negative CA125 results, however, are generally
associated with small volume disease, indicating a certain minimal tumour
volume necessary to cause elevation of serum CA125. Recall that radiological
scanning techniques are also insensitive for tumours of <1cm.
Ward and Cruickshank (1987b) assayed serum HMFG2 in 98 EOC patients two
to six weeks after primary surgery. Elevated levels were found in 1/9 (11%)
patients with no residual disease, 12/28 (43%) patients with <2cm residual
disease, and 37/61 (61%) patients with >2cm residual disease. The statistical
significance of these observations was not tested, moreover, the authors had
insufficient longitudinal data to determine if serum HMFG2 levels reflected
changes in tumour bulk in individual patients with time. Pre-operative HMFG2
levels have not been correlated with tumour burden, and the effect of surgery
on post-operative serum levels is unknown.
Scambia et al. (1988) correlated serum CA153 levels, measured three weeks
after primary surgery, with residual disease. Levels were >30Uml"1 in 5/10
(50%) patients with <2cm residual disease, while 10/14 (71%) patients with
resdiual disease >2cm had elevated levels. Later, Scambia et al. (1990)
assayed serum CA724, four to six weeks after primary laparotomy, and found
elevated levels in 1/4 (25%) patients with no residual disease, 0/3 with <0.5cm
disease, and 5/12 (42%) patients with >0.5cm residual disease. Serum CA199
levels were found elevated in 4/18 (22%) patients with <2cm residual disease,
5/13 (38%) patients with 2-10cm disease, and 7/23 (30%) patients with >10cm
residual disease. Halila et al. (1988) found elevated serum TATI levels in 2/22
(9%) patients with no evidence of disease, 3/8 (38%) patients with microscopic
disease, 1/6 (17%) patients with <1cm disease, 2/12 (17%) patients with >1cm
disease, and 3/18 (17%) patients with macroscopic disease at second-look.
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The statistical trends of these results are unknown due to the small numbers
of patients in each study, although fewer patients with disease <2cm in
diameter in general have elevated serum tumour marker levels. In addition,
none of these studies distinguishes between patients with different
histopathological types of EOC.
3.7.2 Correlation with disease course
There have been numerous studies investigating the correlation between serial
serum CA125 levels and the course of disease, and relatively few documenting
this information with regard to each of the other ovarian tumour markers
mentioned so far. Bast et al. (1983) originally found a correlation with serial
CA125 and the clinical course in 93% of cases. CA125 levels increased with
progressive disease in 17/17 cases and fell with response in 20/21 patients.
The authors considered halving or doubling of marker levels to be clinically
"significant".
Since this initial report, many studies have confirmed the value of CA125 in
determining response to chemotherapy. In a review of the literature, Kenemans
et al. (1988) reported an overall correlation with course of disease in 87% of
patients, ranging from 76% to 95% in different studies. CA125 levels fell with
regression in 108/109 (99%) patients, were unchanged in 29/40 (73%) patients
with stable disease, and increased in 111/137 (81%) patients with disease
progression. As shown in section 3.7.1, the majority of patients with tumour
volumes <2cm in diameter have negative CA125 levels. Hence, a negative
CA125 result does not preclude the presence of occult disease. Consequently,
all studies of CA125 have shown that rising levels are more indicative of
progression than falling or negative levels are of disease remission.
In cases where CA125 is elevated in pre-operative serum samples, levels
correlate with the clinical disease course in nearly 90% of patients. As
mentioned in chapter 2, section 2.4.1, p 44, approximately 85% of all EOC
patients express CA125; while fewer patients with mucinous than any other
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subtype have elevated serum levels. Complementary markers have therefore
been intensely sought which would allow a wider range of patients to be
serologically monitored. Studies of other putative ovarian tumour markers to
date have shown that although elevated in a high proportion of patients, none
is elevated in as many patients as CA125. The correlation between disease
course, or response to chemotherapy, and the other markers investigated in
this thesis is examined in detail in chapter 8.
3.7.3 Prediction of disease status prior to second-look surgery
A high proportion of patients with no clinically evaluable disease before second-
look surgery have false negative CA125 levels. Surgery may be avoided in
patients with positive marker results if cytoreduction is not planned. Although
several other tumour markers have been found elevated in EOC, none to date
has proved more useful than CA125. Even so, approximately 50% of patients
with either microscopic or small volume macroscopic residual or recurrent
disease at second-look laparotomy have false negative serum CA125 levels.
In one of the earliest reports, Niloff et al. (1985) found false negative CA125
levels prior to second-look laparotomy in 22/36 (61%) patients. Kenemans
(1990), in a review of the literature, reported a cumulative false negative rate of
48% for CA125 for disease at second-look. Reports of the values for other
ovarian tumour markers investigated to date indicate lower sensitivities than
CA125 for second-look outcome. These will be examined in detail in chapter 8.
3.7.4 Prediction of recurrence or relapse
Progressively rising CA125 has correlated with recurrence, and provided an
average clinical lead time of three months in up to 87% of patients (for review
see Kenemans, 1988). However, the value of CA125 lead times has not yet




There is conflicting evidence regarding the value of pre-operative CA125 assay.
Vergote et al. (1987) and Van der Burg et al. (1988) found an inverse
correlation between CA125 levels and second-look outcome and survival
respectively, while Sevelda et al. (1989) reported no significant association
between pre-operative CA125 levels and survival in a larger patient cohort.
Cruickshank et al. (1987) also found no prognostic value in pre-operative
CA125 measurement. Rustin et al. (1989) found the pre-treatment level of
CA125 of no value in predicting which patients would relapse, but found a
seven-fold fall from pre-treatment to after the first cycle of treatment to be of
prognostic value. 8/14 (58%) patients who had greater than a seven-fold fall at
this time compared to 3/36 (9%) who had less than a seven-fold fall in CA125
were disease free after two years of follow-up. Van der Burg et al. (1988) found
a half-life of 20 days to give significant discrimination between two prognostic
groups. The median time to progression in 16 patients with a CA125 half-life of
>20 days was 11 months compared to a median time to progression of 43
months in 21 patients with a CA125 half-life of <20 days. After two cycles of
primary chemotherapy, Sevelda et al. (1989) and Redman et al. (1990) found
CA125 to be the most significant predictor of survival. Rosen et al. (1989),
using the absolute pre-operative CA125 level and CA125 level after surgery,
constructed a simple prognostic index. CA125 levels of 0-64 Uml"1 were given
a score of 1 point, CA125 levels of 65-299 Urnl1 were given a score of 2 points
and CA125 levels >300 Urnl"1 were given a score of 3 points. Patients with a
combined score of 2 or 3 points had a significantly longer time to recurrence
than those with a score of 4, 5, or 6.
Many reports therefore exist concerning the prognostic value of early CA125
assay in predicting response to chemotherapy, second-look outcome,
progression free survival and overall survival. There are little data regarding the
prognostic value of any of the other marker evaluated in this thesis. Although
the prognostic significance of early CA125 assay has been reported by several
authors, there is no consensus as to the most useful measurement.
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3.8 AIMS OF THIS THESIS
This thesis investigates the use of several monoclonal antibodies in serological
monitoring of patients with histologically proven EOC. Its aims are threefold, as
follows:-
1. To help clarify the role of serum CA125 assay in the monitoring and
prognosis of EOC patients.
2. To evaluate several promising ovarian tumour markers, using monoclonal
antibodies directed against epitopes on PEM, in monitoring EOC.
3. To compare these markers to CA125, and determine if any has value in
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4.1 INTRODUCTION
The development of the hybridoma technique for the production of monoclonal
antibodies (MAbs) has revolutionised cancer diagnosis in vitro (Kupchik, 1988).
Countless monoclonal antibodies are available, from both commercial and "in-
house" sources. The development of MAbs has been more than adequately
covered by numerous texts, see Campbell (1987) for review. Several types of
immunoassays exist, each based on the fundamental reaction between
antibody and antigen, employing a variety of detection systems, see Tjissen
(1987) for review.
Three types of immunoassay were used in this study; immunoradiometric assay
(IRMA), radioimmunoassay (RIA), and enzyme-linked immunosorbant assay
(ELISA) to determine serum CA125, CA153, CA199, CA724, TATI, HMFG2, and
c-neu p185 (described in chapter 2, sections 2.4.1 to 2.4.7, pp. 43-55).
Measurement of CA125, CA199, and HMFG2 each employed a single MAb in
homologous double-determinant (HoDD) sandwich assays, in which the same
antibody was used as both a catcher and tracer molecule. This type of assay
is possible where multiple sterically distinct identical epitopes are present on
the one antigenic molecule. Measurement of CA153, CA724 and c-neu p185
each employed two MAbs in heterologous double-determinant (HeDD)
sandwich assays, in which different antibodies were used as catcher and tracer
molecules. This type of assay exploits the ability of different antibodies to
recognise sterically distinct epitopes on the same antigenic molecule. TATI was
assayed by conventional competitive RIA. CA125, CA153, CA199, CA724, TATI,
and c-neu p185 assays were obtained from commercial sources, while HMFG2
was developed "in-house" in collaboration with Unilever Research, Colworth,
U.K.. Table 4.1 shows the tumour markers assayed in this study, the MAbs
used (the first MAb represents the catcher and the second MAb represents the
tracer in double-determinant assays), the types of assay, the source of each
assay (full addresses may be found in Appendix B), and the current retail cost
of each commercial kit. Each kit provides assay material sufficient for 96-100
tubes, the equivalent cost has been estimated for HMFG2 assay.
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Table 4.1 Tumour marker assays
Monoclonal Assay
Antigen Antibodies Type Source Cost/100 tubes
CA125 OC125 HoDD IRMA CIS, U.K. £418
CA153 115D8 and DF3 HeDD IRMA CIS, U.K. £495
CA199 NS199 HoDD IRMA CIS, U.K. £458
CA724 B72.3 and cc49 HeDD IRMA CIS, U.K. £433
TATI Anti-TATI RIA Farmos, Finland *
hmfg2 hmfg2 HoDD ELISA Unilever, U.K. £10
p185 NB3 and TA1 HeDD ELISA Dupont, U.S.A. *
* assayed free of charge
A novel combined ELISA was developed previously to measure placental-like
alkaline phosphatase (PLAP) using the MAb designated H17E2 (I.C.R.F.,
Lincoln's Inn Fields, London). Microtitre plates were coated with H17E2, and
PLAP activity and concentration, or immunoreactivity, measured sequentially on
the same plate (Fisken et al., 1989). The sensitivity and specificity of PLAP
activity assay were 66% and 53% respectively in patients with advanced
disease (stages III and IV), while the sensitivity and specificity of PU\P
immunoreactivity were 37% and 73% respectively in stages III and IV,
Therefore, PLAP was not included in the present analysis because this assay
gave high false positive and false negative rates and was shown to be of no
clinical value in addition to CA125 (Fisken et al., 1989a). This agrees with the
study by Haije et al. (1987) who also found poor sensitivity using PLAP
immunoreactivity assay and poor specificity using PLAP activity measurement
in EOC patients.
This chapter describes the principles of each assay, and details the methods
used. All commercially obtained assays were performed according to the
manufacturer's instructions which are outlined. In addition, the quality control
of each assay is described.
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4.2 CA125 ASSAY
The first commercial CA125 assay was developed by Klug et al. (1984). Since
1984 several commercial assay kits for CA125 have appeared on the market.
In an earlier study, the results obtained using three different assay systems
available at the time; an IRMA and an ELISA from Abbott Diagnostics, and an
IRMAfrom CIS, were compared (Fisken etal., 1989b). One hundred and thirty
two serum samples taken from 42 patients with established EOC were assayed
with each method, and the CIS IRMA was found to be the most sensitive and
specific assay for CA125. Consequently, this assay was adopted, and for the
past three years has been offered routinely in the Dept. Clinical Chemistry,
Royal Infirmary, Edinburgh. Currently, eight CA125 assays are available from
different commercial sources, each employing the same MAb OC125 but
different standard preparations (Milford-Ward,1991). Serial monitoring should
therefore be performed using kits from a single source.
4.2.1 CA125 assay principle
The CIS CA125 assay is a simultaneous solid phase IRMA, see figure 4.1
overleaf.
4.2.2 CA125 assay protocol
Each CA125 assay kit provides reagents and materials sufficient for 100 wells,
including; 100 OC125 MAb coated beads, one vial of 125l-OC125 tracer MAb,
one vial of each CA125 standard (6.5, 30, 80, 200, and 500 Umr1), one vial of
control serum (120 Umr1), diluent buffer, 6 x 20 well reaction trays, 12 cover
seals, and six x 20-place cardboard racks containing plastic counting tubes. All
reagents are brought to room temperature (20-25°c) before assaying. Samples
and controls are assayed in duplicate and standards are assayed in triplicate.
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1. Add 100 pi standards, control, and samples to their respective wells.
2. Add 100 pi 125l-OC125 tracer MAb to each well.
3. Add one OC125 MAb coated bead to each well.
4. Gently tap each tray to release any trapped air bubbles, mix the reagents,
and ensure that the beads are completely immersed.
5. Place a cover seal over each tray to prevent evaporation, and incubate
overnight (18-22h) at room temperature.
6. Remove cover, aspirate and wash three times with distilled H20 taking care
to avoid overflow from the reaction wells.
7. Transfer the beads from the reaction wells to appropriately labelled
counting tubes.




















Figure 4.1 Simultaneous IRMA. Polystyrene beads coated with OC125 MAb
are incubated simultaneously with the samples and tracer 125l-OC125 MAb.
These bind to the immobilised OC125 MAb forming a sandwich complex.
Unbound material is removed by washing, and the amount of radioactivity
counted is proportional to the concentration of CA125 antigen in the sample.
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4.2.3 CA125 standard curve
Sample concentrations were determined by interpolation from a dose-response
curve constructed with the standards provided. Samples with CA125 levels
>500 Uml"1 were diluted one in 10 and re-assayed. Table 4.2 shows the mean
counts per minute (cpm), standard deviation (SD), standard error (SE) and
coefficients of variation (CV) for each standard value (n=5), see figure 4.2.
Table 4.2 CA125 standard values
CA125 (Umr1) Mean cpm SD SE CV (%)
6.5 215 32 15.6 14.9
30 483 45 20.1 9.3
80 1182 51 22.8 4.3
200 3119 129 57.7 4.2
500 9049 500 223.6 5.5
4.2.4 CA125 assay precision
The between assay CV of three "in-house" plasma pools, and within assay CV
using the diluent and control provided with the CIS kit are shown in table 4.3
(kindly obtained from Dr.C.Sturgeon at the last immunoassay lab review).
Table 4.3 CA125 assay variation
Variation pool n Mean (Urnl1) Target (Urnl"1) CV (%)
Inter-assay 1 9 46.3 49 5.1
2 9 143.2 151 9.7
3 9 237.4 230 8.0
Intra-assay 1 9 13.9 11 10.3
2 9 121 120 4.6
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Figure 4.2 CA125 standard curve and precision profile
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4.3 CA153 ASSAY
The CA153 assay was originally developed by Tobias et at. (1985), and was
assayed using the ELSA-CA 153 IRMA in this study.
4.3.1 CA153 assay principle


















Incubate Add ^f>l-DF3 MAb
\s[y
Figure 4.3 Sequential two-site IRMA. Solid phase (plastic fins or ELSAs)
coated with 115D8 MAb are first incubated with sample. After washing, I-DF3
MAb is added and CA153 Ag present in the sample is sandwiched between the
two antibodies. After formation of the bound complex, unbound tracer is
removed by washing and the amount of radioactivity counted is proportional
to the concentration of CA153 antigen in the sample.
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4.3.2 CA153 assay protocol
Each CA153 assay kit contains reagents and materials sufficient for 96 tubes,
including; four x 24 tube-packages with 115 D8 MAb bound in excess to the
plastic fin (ELSA) jammed into the bottom of the tube, one vial of 125I-DF3 tracer
MAb, one vial of each standard (0, 12.5, 25, 50, 100, and 150 Urnl"1), one vial
of control serum (30 Urnl"1), and two vials of diluent buffer. All reagents are
brought to room temperature (20-25°c) before assaying. Samples and control
serum are assayed in duplicate and standards are assayed in triplicate.
1. Predilute samples and control serum by dispensing 20 jil of each sample
or control into appropriately labelled polystyrene tubes. Add 1 ml of diluent
buffer into each tube and mix by gently vortexing.
2. Dispense 300 jxl of each standard and prediluted sample and control into
appropriately labelled 115D8 MAb coated ELSA tubes, and mix by gently
vortexing.
3. Incubate for 1h ± 5min at room temperature (18-25°C) while shaking.
4. Aspirate the tubes, and wash three times with 3ml of distilled H20.
5. Add 300 ^l of 125I-DF3 MAb to each tube and mix by gently vortexing.
6. Incubate for 1 h ± 5min at room temperature (18-25°c) while shaking.
7. Aspirate and wash three times as before.
8. Measure radioactivity bound to the ELSA for 60s in a gamma scintillation
counter.
4.3.3 CA153 standard curve
The sample concentrations were determined by interpolation using the RiaCalc
programme from a dose-response curve constructed with the standards
provided. Samples with CA153 levels > 150 Urnl"1 were diluted one in 10 and
re-assayed. Table 4.4 shows the mean cpm, SD, SE, and CV for each standard
(n=3).
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Table 4.4 CA153 standard values
CA153 (Umr1) Mean cpm SD SE CV (%)
0 483 369 213 76.3
12.5 13157 1947 1124 14.8
25.0 18805 300 173 1.6
50.0 21238 178 72 0.9
100.0 23526 96 55 0.4
150.0 24138 1712 988 7.1
Figure 4.4 shows the standard curve for CA153 plotted using the values in table
4.4, together with standard errors and precision profile.
4.3.4 CA153 assay precision
One control (30 Urnl"1), supplied by the manufacturer, was included in each
assay run (n=5). The inter-assay CV was 15.12%, and the intra-assay CV was
4.89% (mean value 30.16 Urnl"1).
4.4 CA199 ASSAY
The CA199 assay was originally developed by Del Villano etal. (1983), and was
measured using the ELSA-CA 19-9 CIS IRMA in this study.
4.4.1 CA199 assay principle
The CIS ELSA-CA 19-9 assay is a solid phase sequential IRMA, similar to
CA153 assay, see figure 4.3, except that one MAb is employed as both catcher
and tracer MAb. ELSA coated with NS199 MAb are incubated with sample,
standard or control. After incubation unbound material is removed by washing
and NS199 MAb labelled with 125l is added. After formation of the bound
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Figure 4.4 CA153 standard curve and precision profile
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sandwich complex, unbound tracer is removed by washing. The amount of
radioactivity counted is proportional to the concentration of CA199 antigen
present in the sample.
4.4.2 CA199 assay protocol
Each CA199 assay kit contains reagents and materials sufficient for 96 tubes,
including; 12x8 tube-packages with excess NS199 MAb bound to the ELSA
jammed into the bottom of the tube, one vial of NS199-125! tracer MAb, one vial
of each standard (5, 15, 30, 60, and 120 Urnf1), one vial of control serum (40
Uml"1), and diluent buffer. All reagents are brought to room temperature (20-
25°c) before assay. Samples and control serum are assayed in duplicate and
standards are assayed in triplicate.
1. Add 100 \i\ of each standard, sample and control to an appropriately
labelled NS199 MAb coated ELSA tube.
2. Add 200 ^l of diluent buffer to each tube.
3. Gently mix using a vortex mixer, cover with parafilm to prevent evaporation
and incubate for 3h ± 10 min at 37 ± 1°c.
4. Aspirate the tubes and wash three times with 3 ml distilled H20.
5. Add 300 \i\ 125I-NS199 tracer MAb to each tube and incubate for 3h
10 min at room temperature (20-25°c).
6. Aspirate, and wash three times as before.
7. Measure radioactivity bound to the ELSA for 60s in a gamma scintillation
counter.
4.4.3 CA199 standard curve
The sample concentrations were determined by interpolation using the RiaCalc
programme from a dose-response curve constructed with the standards
provided. Samples with CA199 levels > 120 Uml"1 were diluted one in 10 and
re-assayed. Table 4.5 shows the mean cpm, SD, SE, and CV for each standard
(n=3).
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Table 4.5 CA199 standard values
CA199 (Uml'1) Mean cpm SD SE CV (%)
6.0 859 81 46 9.5
15.0 2041 96 55 4.7
30.0 4306 69 39 1.6
60.0 8271 889 513 10.8
120.0 15387 2193 1266 14.3
Figure 4.5 overleaf shows the standard curve for CA199 plotted using the
values in table 4.5, together with standard errors and precision profile.
4.4.4 CA199 assay precision
One control (40 Urnl1), supplied by the manufacturer, was included in each
assay run (n=5). Intra-assay CV was 5.7%, and the inter-assay CV was 10.7%
(mean value 40.85 Umr1).
4.5 CA724 ASSAY
The CIS CA724 RIA, an assay originally developed by Colcher et at. (1985),
was used to measure serum CA724.
4.5.1 CA724 assay principle
The CIS CA724 assay is based on a solid phase two-site sequential IRMA. It is
similar to CA153 assay, see figure 4.3, except that beads are used as the solid
phase and not plastic fins. Polystyrene beads coated with cc49 MAb are
incubated with samples. Unbound material is removed by washing and tracer
MAb B72.3 is added resulting in formation of a sandwich complex. Unbound
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labelled antibody is removed by washing the beads, and the radioactivity
counted is proportional to the concentration of CA724 antigen in the sample.
4.5.2 CA724 assay protocol
Each kit contains reagents and materials sufficient for 100 wells, including; six
x 20 well reaction trays, cover seals, cardboard racks containing counting
tubes, 100 cc49 MAb coated beads, two vials of 125I-B72.3 MAb, one vial of
each standard (3, 10, 20, 35, 50, 75, and 100 Urnl"1), one vial of each control
serum (9.7 Uml"1 and 75 Urnl"1) and diluent buffer. All reagents are brought to
room temperature (20-25°c) before assaying. Samples and controls are
assayed in duplicate and standards are assayed in triplicate.
1. Add 100 til sample, standard, or control to appropriately labelled wells.
2. Add 100 nl diluent buffer to each well.
3. Add one cc49 MAb coated bead to each well, apply cover seal and gently
tap the tray to ensure reagents are mixed and that the beads are
immersed.
4. Incubate for 4h ± 5min at 37°c.
5. Aspirate, and wash three times with distilled H20.
6. Add 200 ^l 125I-B72.3 tracer MAb and gently tap trays to mix.
7. Incubate for 18h ± 2h at 2°c - 8°c.
8. Aspirate, and wash three times as before.
9. Transfer beads to appropriately labelled counting tubes.
10. Count radioactivity for 60s in a gamma scintillation counter.
4.5.3 CA724 standard curve
The sample concentrations were determined by interpolation using the RiaCalc
programme from a dose-response curve constructed using the standards
supplied. Table 4.6 shows the mean cpm, SD, SE, and CV (%) for each
standard (n=2).
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Table 4.6 CA724 standard values
CA724 (Umr1) Mean cpm SD SE CV (%)
3.0 358 34 24 9.4
10.0 1277 14 10 1.1
20.0 2098 166 117 7.9
35.0 3578 62 44 1.7
50.0 4957 96 68 1.9
75.0 7630 122 86 1.6
100.0 9585 869 614 9.1
Figure 4.6 shows the standard curve for CA724 plotted using the values in table
4.6, together with standard errors and precision profile.
4.5.4 CA724 assay precision
CVs were calculated using two controls from each of the two assay runs; one
low concentration (9.7 Urnl"1) and one high concentration (75 Uml"1) supplied
by the manufacturer. The intra-assay CVs for low and high concentrations were
7.46% and 6.22% respectively. The inter-assay CVs for low and high
concentrations were 17.39% and 2.95% respectively. Mean values for the low
and high assay controls were 7.36 Urnl"1 and 73.94 Uml"1 respectively.
4.6 TATI ASSAY
The Farmos Spectria TATI RIA, an assay originally developed by Stenman et
al. (1982), was used to assay serum TATI.
4.6.1 TATI assay principle
The Farmos TATI RIA is based on the widely used radioimmunoassay
technique, see figure 4.7, p 102.
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Figure 4.7 Competitive RIA. Sample containing an unknown amount of TATI
is incubated with a standard amount of 125l labelled TATI, which competes for
binding to a limited number of high affinity binding sites of the solid phase
antibody. After washing to remove unbound labelled antigen the radioactivity
counted is inversely proportional to the amount of TATI antigen in the sample.
4.6.2 TATI assay protocol
Each TATI kit provides reagents and materials sufficient for 100 tubes,
including; two x 50 tubes coated with anti-TATI MAb, two vials of 125I-TATI, one
vial of each TATI standard (0.5, 5, 15, 45, 150, and 450pgl~1), one vial of each
control serum (12-23pgl"1 and 136-206p.gr1), diluent buffer, and washing
solution. All reagents are brought to room temperature (20-25°) before
assaying. Samples and controls are assayed in duplicate and standards are
assayed in triplicate.
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1. Add 25 nl of sample, standard or control to appropriately labelled
anti-TATI MAb coated tubes. Leave two tubes blank for background.
2. Add 200 nl 125I-TATI to all tubes, including two for determination
of non-specific binding and two for determination of total count.
3. Add 200 |il TATI antiserum to all tubes except those for determination of
non-specific binding and total count. Add 200 ^l H20 to the non-specific
binding tubes.
4. Shake gently and incubate overnight (18h) at room temperature.
5. Decant tubes and tap out any remaining liquid onto absorbent paper.
6. Wash with 1.0 ml wash solution and tap out any remaining liquid.
7. Count radioactivity for 60s in a gamma scintillation counter.
4.6.3 TATI standard curve
The sample concentrations were determined by interpolation using the RiaCalc
programme from a dose-response curve constructed with the standards
supplied. Samples with TATI levels > 450 p,gr1 were diluted one in 10 and re-
assayed. Table 4.7 shows the mean cpm, SD, SE, and CV (%) for each
standard (n=9).
Table 4.7 TATI standard values
TATI (ugl"1) Mean cpm SD SE CV (%)
5.0 13726 438 146 3.2
15.0 9788 547 182 5.6
45.0 6237 599 200 9.6
150.0 3267 306 102 9.4
450.0 1789 354 118 19.8
Figure 4.8 shows the standard curve for TATI plotted using the values in table
4.7, together with standard errors and precision profile.
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4.6.4 TATI assay precision
CVs were calculated using two controls from each assay run (n=9); one of low
concentration (12-23 p.gl"1), the other of high concentration (136-206 ^gl"1)
supplied by the manufacturer. The intra-assay CVs for low and high concen¬
trations were 13.3% and 8.6% respectively, while the inter-assay CVs for low
and high concentrations were 6.3% and 14.1 % respectively. Mean values for the
low and high controls were 14.75 p.gr1 and 188.9 ugl"1 respectively.
4.7 HMFG2 ASSAY
Several monoclonal antibodies have been developed which recognize different
epitopes on the polymorphic epithelial mucin (PEM) found in the human milk
fat globule membrane, see section 2.4.3, chapter 2. The antibody used in this
study was raised by Taylor-Papadimitriou et al. (1981), and is obtainable
commercially from Unipath. HMFG2 standards and horseradish peroxidase anti-
HMFG2 Ab conjugate were kindly prepared by I.Jonrup at Unilever.
4.7.1 HMFG2 assay principle
Several different types of immunoassay have been developed for HMFG2,
including RIAs (Burchell et al., 1984, Ward and Cruickshank, 1987b), ELISAs
(Dhokia et al., 1986, Ashorn et al., 1989) and a chemiluminescent ELISA
employing a camera to detect and quantitate HMFG2 (Badley.A., personal
communication). Poor sensitivity was experienced in this study using a double
determinant sandwich RIA.
The poor sensitivity experienced in attempts to develop a RIA in this study was
possibly due to a detection system which employed a 125l labelled polyclonal
Ab (SAPU, UK). The homologous double-determinant assay principle used in
the finally adopted ELISA was applied. 125l-anti-mouse IgG was used as a tracer
after formation of the HMFG2 MAb - HMFG - HMFG2 MAb complex. The assays
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developed by Burchell et al. (1984) and Ward and Cruickshank (1987b)
employed directly iodinated HMFG2 MAb as tracer.
At this time, an HMFG2 MAb-HRP conjugate became available from Unilever,
and this was used to develop a simple, rapid, sensitive ELISA. The ELISA deve¬
loped by Dhokia et al. (1986), where samples were treated with a low pH (pH
2.0) to expose the epitope, in an attempt to improve assay sensitivity, was
found in this study to be unreproducible. Optimal conditions were arrived at
after systematic variation of reagents and their concentrations, incubation
periods, incubation temperatures. Harsh treatments, such as use of strong
acidic conditions to disrupt serum complexes that may mask specific epitopes,
were unnecessary.
4.7.2 Preparation of HMFG2-horseradish peroxidase conjugate
Horseradish peroxidase (HRP) enzyme was conjugated to HMFG2 IgG in a 1:1
ratio. 5 mg HRP (Sigma Type VI) was dissolved in 1 ml distilled H20, and
oxidised by the addition of 0.4 ml freshly prepared 0.1 M sodium metaperiodate
for 20 min at room temperature in the dark, while gently stirring occasionally.
Oxidised HRP was then dialysed overnight at 4°c with 1L 1 mM acetate buffer
pH 4.4, stirring continuously. The pH was brought to pH 9.0 with 0.2 M
carbonate buffer pH 9.5. 5 mg HMFG2 MAb in 1 ml carbonate buffer pH 9.5
was added and stirred gently for 2h at room temperature in the dark. 0.1 ml of
freshly prepared sodium borohydride (5 mgml"1 in distilled H20) was added and
incubated at 4°c for 2h. The conjugate was finally dialysed with phosphate
buffered saline (PBS) pH 7.4 containing 0.01 % w/v Thimerosal, and was stored
in this buffer at 4°c in the dark.
4.7.3 Purification of the milk mucin
Human breast milk was centrifuged at 10000g for 30min to isolate the skimmed
milk fraction. HMFG was prepared from human skimmed milk by affinity
chromatography on an HMFG, sepharose column prepared by purification of
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tissue culture supernatant using a Protein A column and coupling of the purified
MAb to cyanogen bromide activated sepharose (Pharmacia) as described by
the manufacturer's instructions. Human skimmed milk was passed in batches
of 100 ml through the column followed by washing with PBS pH 7.4. Bound
antigen was eluted using 0.1 M glycine pH 2.5 and the fractions registering
absorbance at 280 nm were pooled and dialysed against 0.25M acetic acid and
freeze dried. Solutions made from this material were stored at - 20°c.
4.7.4 Deglycosylation of HMFG
Purified HMFG was partially deglycosylated by hydrolysis with anhydrous
hydrogen fluoride for 1h at 4°c, as described by Mort and Lamport (1977).
Longer incubation results in complete deglycosylation of HMFG which does not
react as strongly with HMFG2 antibody.
4.7.5 Preparation of HMFG2 standards
HMFG2 standards were prepared by the method of Burchell etal. (1987) using
the preparatory steps described in 4.7.3 and 4.7.4. Standards were prepared
in PBS pH 7.4, containing 7% bovine serum albumin (BSA) and 0.01% w/v
Thimerosal as preservative, to avoid interference from HMFG normally present
at varying levels in normal human sera. HMFG concentrations were set by refer¬
ence to an original preparation isolated by Dr. S. Mather (St. Bartholomew's
Hospital, London). 1 mg of the freeze dried powder was arbitrarily equal to 106
units. Deglycosylated HMFG was calibrated against a preparation obtained
from Dr. J. Taylor-Papadimitriou (I.C.R.F., Lincoln's Inn Fields, London) in a
similar way. Aliquoted standards were stable for at least 2 weeks at 4°c, whilst
deglycosylated HMFG kept for only 1 week at 4°c.
4.7.6 HMFG2 assay protocol
All samples were assayed in duplicate. Microtitre plates (M129B, Dynatech,
Billingshurst, Kent, U.K.) were coated overnight at 4°c with 50 ^l 5.0 ^gml"1
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HMFG2 MAb in 0.05M carbonate buffer pH 9.6. The plates were washed three
times with 100 jxl 0.15M PBS pH 7.4 containing 0.05% polyoxyethylene sorbitan
monolaurate (Tween 20) (PBS/Tween 20). 25 pi neat serum, standard, or
control were incubated with 25 pi PBS/Tween 20 for 30min at 37°c in a shaking
incubator (Dynatech). The plates were washed three times with PBS/Tween 20,
and 50 pi HMFG2 MAb-HRP conjugate (see 4.7.3) at 1:1000 in PBS/Tween 20
incubated for 30min at 37°c. After three final washes, 100 pi peroxidase
substrate: 0.04% w/v 0-phenylenediamine and 0.02% v/v H202 in 0.15M citrate
phosphate buffer pH 5.0 was added. The reaction was stopped after 30min
incubation at 37°c with the addition of 50 pi 2.5M H2S04, and optical density

























Figure 4.9 Sandwich ELISA with HRP detection system. Microtitre wells are
coated by overnight incubation with HMFG2 MAb. After washing to remove
unbound MAb, samples are incubated. After a further wash, HMFG2 MAb-HRP
conjugate is added and HMFG2 antigen present in the sample is sandwiched
between the two antibodies forming a complex bound to the solid phase. A
final wash removes unbound conjugate and substrate is added to develop the
colour. The reaction is stopped by the addition of acid, and the optical density
measured is proportional to the concentration of HMFG2 antigen in the sample.
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Control and unknown sample concentrations were interpolated manually from
dose-response curves constructed using standard preparations at the following
concentrations: 0, 50, 100, 200, 350, and 500 Urnl"1. One standard curve was
included for every two ELISA plates assayed. Table 4.8 shows the mean optical
densities (o.d.), SD, SE, and CV (%) for each standard (n=22).
Table 4.8 HMFG2 standard values
HMFG2 (Umr1) Mean o.d. SD SE CV (%)
0.0 0.215 0.068 0.014 31.6
50.0 0.394 0.073 0.016 18.5
100.0 0.586 0.102 0.022 17.4
200.0 0.943 0.155 0.033 16.4
350.0 1.337 0.184 0.042 13.8
500.0 1.656 0.317 0.073 19.1
Figure 4.10 shows the standard curve for HMFG2 plotted using the values in
table 4.8, together with standard errors and precision profile.
4.7.8 HMFG2 assay precision
CVs were calculated using two controls included in each assay run (n=22); one
of low concentration (50 Urnl"1) and one of high concentration (150 Uml"1). The
intra-assay CVs for low and high concentrations were 6.8% and 4.93% respec¬
tively, while the inter-assay CVs for low and high concentrations were 14.9%
and 6.56% respectively. Mean values for the low and high controls were 43.5
Urnl"1 and 149.8 Uml"1 respectively.
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HMFG2 (U/ml)
Figure 4.10 HMFG2 standard curve and precision profile
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4.8 P185 ASSAY
An assay for the neu (c-erbB 2/HER-2) oncogene product, c-neu p185, has
recently been developed, and is available from Dupont/NEN Research
Products, U.S.A.. The first study of c-neu p185 in breast cancer serum found
15% and 23% of patients with primary and metastatic breast cancer
respectively to have elevated serum c-neu p185 (Hayes et al., 1989).
4.8.1 P185 assay principle
Several monoclonal antibodies have been raised against c-neu p185. Two
MAbs, NB3 and TA1, recognise distinct epitopes on the extracellular domain of
the human neu oncogene product but do not cross react with the rat neu
product (McKenzie et al., 1989). These have been used to develop a
heterologous double-determinant sandwich ELISA using biotinylated TA1 tracer
MAb and streptavidin-HRP as the detection system, see figure 4.11 overleaf.
This assay is similar to HMFG2 assay, except that different Abs are used as
catcher and tracer molecules, and the detection system involves the additional
biotin/avidin step to improve assay sensitivity.
4.8.2 P185 assay protocol
Samples were kindly assayed for c-neu p185 by Dr.D.F.Hayes and colleagues
at the Dana Farber Cancer Institute in Boston, U.S.A. All incubations were
performed at room temperature (18-25°c). Samples and control were assayed
in duplicate and standards were assayed in triplicate.
1. Serum samples were diluted 1:50 in assay buffer (0.01 M PBS pH 7.4 with
1% BSA, 0.1% Tween 20, and 0.1% sodium azide).
2. 100 p.l sample, standard, and control were incubated for 18h in microtitre
plates coated with NB3 MAb.
3. The plates were washed three times and incubated with 100 \i\ biotinylated-
TA1 MAb in PBS for 30min.
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4. The plates were washed three times.
5. 100 til streptavidin-HRP (diluted in PBS with 1% BSA and 0.01%
chloracetamide) was incubated for 15min.
6. Colour was developed by the addition of 100 pi o-phenylenediamine in
0.1 M citrate buffer pH 5.0 with 0.01% H202.
7. The reaction was stopped after 60min with 100 p.l 2M H2S04, and
absorbance determined at 490nm.
Serum c-neu p185 was quantitated by interpolation from a dose-response
curve constructed with serial dilutions of cellular extract from c-neu transfected






























Figure 4.11 Sandwich ELISA with avidin/biotin detection system.
Samples are incubated with NB3 MAb coated microtitre plates. After washing
to remove unbound sample, biotinylated-TA1 MAb is added. C-neu p185
present is sandwiched between the two MAbs, and after washing streptavidin-
HRP is incubated. After a final wash, the colour is developed with the addition
of o-phenylenediamine and the absorbance measured is proportional to the
concentration of c-neu p185 in the sample.
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4.9 ESTABLISHMENT OF ASSAY CUT-OFF VALUES
Cut-off values may be established in different ways depending on the purpose
of the assay. For a review of methods of evaluating and influencing the
discriminatory capacity of tumour markers see Makuch and Muenz (1987). It is
most common to use the mean value plus two standard deviations of a normal
reference population. This is suitable when a differential diagnosis between
normal subjects, patients with benign disorders, and patients with malignancy
is desirable, i.e. in the context of screening. For the purposes of monitoring
patients with established malignancy it is more appropriate to use the disease
free patient population as a reference population. This may be done using
receiver operating characteristic (ROC) curves which plot the percentage of
false positive (FP) results (or 1 - specificity) on the x-axis versus the percentage
of true positive (TP) results (or sensitivity) on the y-axis. Choosing a cut-off
where the curve begins to plateau gives the best trade-off between sensitivity
and specificity. See chapter 3, section 3.4.7, pp. 68-71, for the definition and
relative importance of these parameters.
The price of each commercial kit precluded their use to determine our own
reference ranges. Therefore, in this study, the cut-off values commonly used
were those established by the original investigator and/or recommended by the
manufacturer. Table 4.9 shows the cut-off values used for each assay and how
each was established. The following values were used throughout all tumour
marker analysis.
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Table 4.9 Assay cut-off values
Tumour Cut-off Method of









t in 1 % of 888 normal $
t in 1% of 1051 normals
t in 0.6% of 1020 normals
x + 2sd of 66 normals
x + 2sd of * normals
f in 5% of 132 normals
x + 2sd of 42 normal ?
Bast et at. (1981)
Tobias et at. (1985)
Del Villano et al. (1983)
Scambia et al. (1990)
Stenman et al. (1982)
Fisken et al. (1991)
Hayes et al. (1989)
In summary, this chapter has described the variety of immunological methods
used to measure putative EOC tumour markers, and outlined the reasons for




EOC Population Characteristics and Management
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5.1 INTRODUCTION
Blood samples were collected from patients with established EOC in the post¬
operative follow-up period for over more than five years, from April 1984 to July
1989. The serum was separated by centrifugation at 1500g for 10 minutes and
stored at -20°c until use. The patients all came from Lothian Region, and were
eventually treated for their disease at the Western General Hospital and Royal
Infirmary in Edinburgh.
After careful and independent retrospective clinical documentation, a total of
1237 samples from 250 patients were included in the final analysis. The length
of clinical follow-up in the population was longer than the blood sampling
period, in some instances up to a year after the last serum assays were
performed. During this time a database combining patients' case histories and
serial serum tumour marker levels was being developed to perform statistical
analyses. This will be described in chapter 6. Initially, the database was used
to collate information on the demographics of the patient population and their
management, presented in this chapter.
This chapter is divided into three sections: the first documents the patients'
disease characteristics found at diagnosis; the second documents aspects of
the patients' management and outcomes of primary therapy; and the third
documents the number of tumour marker assays performed. The aim of this
chapter is twofold; firstly to show that the population under study is
representative of any EOC patient population encountered in a major treatment
centre, and secondly to provide a base from which the tumour markers can be
evaluated in different clinical settings incurred in this disease.
5.2 PRIMARY DISEASE CHARCTERISTICS OF EOC POPULATION
Table 5.1 shows the findings at primary surgery in all 250 patients. Factors of
major prognostic importance were noted, including stage, histological tumour
type, tumour grade, presence of adhesions and ascites (and cytology).
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*ECOG performance status was also noted prior to initiation of primary
chemotherapy.
Table 5.1 Findings at primary surgery












Tumour grade Well differentiated (WD) 31
Moderately differentiated (MD) 55


















*ECOG - European Committee for Obstetrics and Gynaecology
73/250 (29.2%) patients presented with early stage disease, and 177/250
(70.8%) patients presented with advanced disease at initial diagnosis. 17
patients were "upstaged" from early to advanced disease during follow-up.
Overall, the mean clinical follow-up was 26.8 months (median 20.3 months and
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range 0.5-173.7 months). One patient who had completely resected stage I
disease had recurrent stage IV disease 12 years later. Patients who presented
with early stage disease had a mean clinical follow-up of 36.7 months (median
31.7 months and range 5.1-173.7 months), while patients who presented with
advanced disease had a mean clinical follow-up of 22.7 months (median 17.2
months, and range 0.5-117.6 months). Overall, the mean age at diagnosis was
58.2 years (median 58 years and range 23-81 years). Patients presenting with
early disease had a mean age at diagnosis of 55.6 years (median 55 years and
range 29-79 years), while patients with advanced disease at diagnosis had a
mean age of 59.2 years (median 59 years and range 23-81 years).
Table 5.2 shows the frequency of each tumour type within each stage. The
predominance of stage III serous tumours can be clearly seen, accounting for
93/250 (37.2%) of the total.
Table 5.2 Frequency of histological type in each stage
FIGO stage
Histological type I II III IV Total
Serous 17 15 93 22 147
Endometrioid 12 6 19 4 41
Mucinous 11 3 4 4 22
Adenocarcinoma - 1 13 4 18
Clear cell 5 2 7 3 17
Mixed 1 - 2 - 3
Unknown - - 1 1 2
Total 46 27 139 38 250
Serous papillary cystadenocarcinomas and adenocarcinomas tend to present
at a later stage than endometrioid and clear cell tumours, while the majority of
mucinous tumours present in the earlier stages. Table 5.3 shows the frequency
of each tumour grade within each stage.
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The proportions of well and moderately differentiated tumours decrease with
progressive disease, while the proportion of poorly differentiated tumours rises
with advancing disease. The unknown grade category includes tumours of
variable differentiation, in which the composition of different grades is unknown.
Table 5.3 Frequency of histological grade in each stage
Histological grade I
FIGO stage
II III IV Total
WD 9 4 15 3 31
MD 16 8 30 1 55
PD 7 12 79 28 126
Unknown 14 3 15 6 38
Total 46 27 139 38 250
Table 5.4 shows the frequency of each tumour grade within each tumour type.
Adenocarcinomas, serous papillary cystadenocarcinomas and endometrioid
tumours contain the highest proportion of poorly differentiated cells, while
mucinous tumours contain the highest proportion of well differentiated cells.
Table 5.4 Frequency of histological grade in each type
Histological grade
Histological type WD MD PD Unknown Total
Serous 18 35 81 13 147
Endometrioid 2 8 24 7 41
Mucinous 8 3 2 9 22
Adenocarcinoma - 3 15 - 18
Clear cell 3 4 3 7 17
Mixed - 1 1 1 3
Unknown - 1 - 1 2
Total 31 55 126 38 250
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5.3 PATIENT MANAGEMENT AND TREATMENT OUTCOMES
The methods used to treat the patients and determine their responses to
primary therapy will be described. Chemotherapy regimes are given in
Appendix C. Endpoints include: the percentage of patients responding to first-
line chemotherapy; the findings at second-look surgery; progression-free
survival; and overall survival.
5.3.1 Primary surgery
A minority of the patients were initially operated on in peripheral hospitals
before coming to the Western General and Royal Infirmary in Edinburgh for
chemotherapy. The primary operative procedures are shown in table 5.5. TAH,
BSO, and omentectomy were performed in 18/46 (39%) of stage I patients,
13/27 (48%) of stage II patients, 38/139 (27.3%) of stage III patients, and 9/38
(23.7%) of stage IV patients.
Table 5.5 Primary operative procedures
FIGO stage
Procedure I II III IV Total
TAH 42 22 53 14 131
SubTAH 1 1 10 5 17
BSO 41 24 85 24 174
Unilateral SO 2 1 6 2 11
Ovariotomy 3 1 3 2 9
Ovarectomy - - 5 2 7
Omentectomy 21 14 63 18 116
Partial omentectomy 1 1 8 5 15
Biopsy only - 1 40 9 50
Other (palliatve) - - 20 2 22
The extent of residual disease after primary surgery was divided into five
categories: no residual disease (complete debulk); <2cm residual disease; 2-
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5cm residual disease (partial debulk); >5cm residual disease; gross residual
disease (no debulk, tumour biopsy only). Optimal debulking was defined as
either complete resection or resection to less than 2cm residual disease. The
frequency and extent of debulking achieved in each stage is shown in table 5.6.
Table 5.6 Frequency and extent of debulking in each stage
FIGO stage None <2cm
Residual disease
2-5cm >5cm Gross Total
I 39 7 4
II 4 19 2 1 1 27
III - 52 34 19 34 139
IV - 8 13 10 7 38
Total 43 86 49 30 42 250
Optimal debulking was achieved overall in 129/250 (51.6%) of patients. 46/46
(100%) of stage I patients, 23/27 (85.2%) of stage II patients, 52/139 (37.4%) of
stage III patients, and 8/38 (21.1%) of stage IV patients were optimally
debulked.
Table 5.7 shows the frequency and extent of debulking for each tumour type.
Optimal debulking was achieved in 66/147 (44.9%) of patients with serous,
29/41 (70.7%) with endometrioid, 15/22 (68.2%) with mucinous, 7/18 (38.9%)
with adenocarcinoma, 11/17 (64.7%) with clear cell, and 1/3 (33.3%) with mixed
tumours.
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Table 5.7 Frequency and extent of debulking in each tumour type
Tumour type None <2cm
Residual disease
2-5cm >5cm Gross Total
Serous 17 49 27 22 32 147
Endometrioid 10 19 9 3 - 41
Mucinous 10 5 4 1 2 22
Adenocarcinoma - 7 3 3 5 18
Clear cell 5 6 5 - 1 17
Mixed 1 - 1 1 - 3
Unknown - - - - 2 2
Total 43 86 49 30 42 250
Table 5.8 shows the frequency and extent of debulking for each tumour grade.
Optimal debulking was achieved in 23/31 (74.2%) of patients with well
differentiated tumours, 23/55 (60%) with moderately differentiated tumours, and
49/126 (38.9%) with poorly differentiated tumours.
Table 5.8 Frequency and extent of debulking for each tumour grade
Residual disease
Tumour grade None <2cm 2-5cm >5cm Gross Total
WD 9 14 5 2 1 31
MD 14 19 7 5 10 55
PD 6 43 27 21 29 126
UNK 14 10 10 2 2 38
Total 43 86 49 30 42 250
Thus, the feasibility of optimal debulking decreased with increasing stage and
progressive tumour dedifferentiation. Optimal debulking was more often
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achieved in patients with tumours of endometrioid, mucinous and clear cell
types, which tend to present earlier (table 5.2) and have a higher proportion,
except for endometrioid, of well differentiated cells than serous papillary cyst-
adenocarcinomas and adenocarcinomas (table 5.4).
5.3.2 Chemotherapy and responses
The majority of patients in this study were entered into ICRF clinical trials.
Responses to first-line chemotherapy, usually started one month after primary
surgery, were determined using UICC response criteria (chapter 1, table 1.4,
p 27). The methods used to determine responses to therapy in patients with
advanced disease are summarized, and the number of second-look operations
performed and their outcomes are described for each stage. No account of
independent prognostic factors, other than stage, in determining response to
therapy has been made. A more detailed breakdown of prognostic groups will
be given when the markers are analysed in detail (chapter 9, sections 9.2 and
9.3, pp. 220-233). Treatment of patients is presented according to stage, and
outcomes determined at the last case note review (August 1989).
5.3.3 Stage I patients
46 patients presented with stage I disease (3, 24, 10 and 9 had stages I, la, lb
and Ic disease respectively). 24 patients received no post-operative therapy,
three had whole abdominal radiotherapy, and 19 had chemotherapy (18
adjuvant and one therapeutic). 11 patients have died, and 35 remain alive, two
with progressive disease and 33 with no evidence of disease.
Stage I: 2/3 patients had no post-operative therapy and remain disease free,
while the other patient had radiotherapy and died from recurrent stage IV
disease 13 years later.
Stage la: 16/24 patients received no post-operative therapy, none had radio¬
therapy and six had complete courses of adjuvant chlorambucil. Six patients,
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three of whom received chlorambucil, relapsed with stage III (five patients) and
stage IV (one patient) disease, have died and 18 remain alive and disease free.
Stage lb: 4/10 patients received no post-operative therapy, none had radio¬
therapy, and six had adjuvant chemotherapy. Three patients had complete
courses of chlorambucil, one relapsed with stage III disease and died and the
other two remain disease free. 1/2 patients completed a course of cisplatin/a-
interferon, and one patient had an incomplete course of cisplatin. Both had to
stop due to toxicity. All three patients remain disease free. In this group, one
patient has died and nine remain alive, one with progressive disease and eight
with no evidence of disease.
Stage Ic: 2/9 patients received no post-operative therapy, none had radio¬
therapy, and seven had chemotherapy. 4/4 completed courses of adjuvant
chlorambucil, one relapsed with stage III disease and died, one has progressive
disease, and two remain disease free. Two patients had incomplete courses of
adjuvant cisplatin and cisplatin/prednimustine due to toxicity and both remain
disease free. One patient stopped therapeutic 5-fluorouracil/cisplatin/
hexamethylmelamine/prednimustine (5FU/P/H/P) early due to toxicity and had
a partial response, but later relapsed with stage IV disease and died. In this
group three patients have died and six remain alive, one with progressive
disease and five with no evidence of disease.
The second-look procedures performed and their findings are shown in table
5.9. Outcomes were divided into three categories: negative, microscopic
disease present or macroscopic disease present. Overall, 21/46 (45.7%) of
stage I patients underwent second-look operation, 15/21 had laparotomy and
6/21 had laparoscopy. 10/21 (47.6%) of all second-look procedures were
negative, 5/21 (23.8%) patients had microscopic disease and 6/21 (28.6%)
patients had macroscopic disease. Four patients were "upstaged" at second-
look, three to stage III and one to stage IV, while one patient subsequently
relapsed with stage III disease.
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Table 5.9 Findings at second-look in stage I patients
FIGO Stage
Second-look outcome I la lb Ic Total
No. patients 3 24 10 9 46
No. Laparotomies 6 7 2 15
Negative 1 4 - 5
Microscopic - 3 1 4
Macroscopic 4 - 1 5
No. restaged 2 - 1 3
No. Laparoscopy _ 5 . 16
Negative 4 - - 4
Microscopic - - 1 1
Macroscopic 1 - - 1
No. restaged 1 - - 1
5.3.4 Stage II patients
27 patients presented with stage II disease (9, 5, 2, and 11 had stage II, lla, lib,
and lie respectively). Three received no post-operative therapy, two had whole
abdominal radiotherapy, and 22 had chemotherapy (four adjuvant and 18
therapeutic). Eleven patients have died (one death was not due to EOC) and
10 remain alive, two with progressive disease and 13 with no evidence of
disease.
Stage II: 1/9 patients had no post-operative therapy, none had radio-therapy,
and eight received chemotherapy. Two patients received adjuvant therapy, one
had a complete course of chlorambucil, while the other patient refused to finish
a course of cisplatin, both remain disease free. Three patients had
chlorambucil, two had to stop due to disease progression, the other relapsed
later, and all three have died. Two patients had cisplatin/prednimustine, one
stopped due to toxicity but had a complete response and remains disease free,
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while the other progressed and died. One patient had a complete course of
cisplatin but subsequently relapsed and died. In this group, five patients have
died and four remain disease free.
Stage lla: 1/5 patients received no post-operative therapy, two had
radiotherapy and two had chemotherapy. One patient had adjuvant chloram¬
bucil and remains disease free, and one had therapeutic cisplatin and remains
disease free. Four patients are still alive, one with progressive disease and
three with no evidence of disease.
Stage lib: 1/2 patients had chlorambucil but the response was inevaluable due
to unmeasurable disease. One patient had an incomplete course of cisplatin
due to toxicity but had a pathological complete response documented at
second-look laparotomy. Both patients remain disease free.
Stage lie: 1/11 patients in this group had radiotherapy, one had adjuvant
prednimustine, and nine had therapeutic regimes. Two patients had complete
courses of chlorambucil, both achieved a complete response, one
subsequently had recurrent stage IV disease and died, while the other remains
disease free. Five patients had cisplatin/prednimustine; three completed the
regime, one stopped due to toxicity and all four had a complete response,
while the other patient stopped due to disease progression. Two have died and
three remain disease free. Two patients had cisplatin, one had a complete
response and remains disease free, the other stopped due to toxicity, had a
subsequent complete response to iproplatin but later had recurrent stage IV
disease and died.
The second-look procedures performed and their findings are summarized in
table 5.10. Overall, 14/27 (51.8%) of stage II patients underwent second-look
operation, 8/14 had laparotomy and 6/14 had laparoscopy.
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Table 5.10 Findings at second-look in stage II patients
FIGO Stage
Second-look outcome II lla lib lie Total
No. patients 9 5 2 11 27
No.Laparotomy 2 2 - 4 8
Negative - 1 - 3 4
Microscopic - - - - -
Macroscopic 2 - - 1 3
No.upstaged 1 - - - 1
No.Laparoscopy 2 - 1 3 6
Negative 2 - 1 3 6
Microscopic - - - - -
Macroscopic - - - - -
No. upstaged - - - - -
10/14 (71.4%) of all second-look procedures were negative, none had micro¬
scopic disease, 3/14 had macroscopic disease, and the outcome of one was
unknown. One patient was "upstaged" to stage IV at second-look, three
patients who had a negative second-look subsequently relapsed with stage IV
disease.
5.3.5 Stage III patients
4/139 patients received no post-operative therapy due to frailty, two had whole
abdominal radiotherapy, the treatment of one patient is unknown as case notes
could not be found at the time of assessment, and the remaining 132 patients
had chemotherapy. 97/139 patients have died and 42 are still alive; six with
progressive disease, three with suspected progressive disease due to rising
CA125 levels, eight with stable disease, 17 in complete remission, five with
inevaluable disease, and three whose disease status is unknown.
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The responses to first line therapy could not be determined in 15 patients; four
who had no therapy, two who had radiotherapy, four who had adjuvant
chemotherapy, and five whose case notes could not be found at the time of
assessment. A further nine patients were inevaluable. 65/115 (56.5%) of patients
with evaluable disease responded to first line therapy. 39/65 (60%) of these
were complete responses and 26/65 (40%) were partial responses. 25/39 (64%)
of those who achieved a complete response, 7/26 (26.9%) of those who
achieved a partial response, 2/21 (9.5%) of those who remained stable, and
0/29 patients who progressed on therapy remain alive.
66/115 (57.4%) of patients completed their chemotherapy regimes, while 49/115
(42.6%) had incomplete regimes. The reasons for stopping are shown in table
5.11.
Table 5.11 Reasons for stopping chemotherapy in patients with stage III
Response
Reason for stopping CR PR SD PD Total
Regime complete 30 21 11 4 66
Toxicity 9 5 2 1 17
Progressive disease - - 8 24 32
Patient refused - - - - -
Total 39 26 21 29 115
Responses to individual regimes are shown in table 5.12, with the number of
pathologically documented responses shown in brackets. Thus, 29/39 (74%)
of complete reponses and 13/26 (50%) partial responses were documented
pathologically.
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Table 5.12 Responses to individual regimes in patients with stage III
Chemotherapy regime CR PR
Response
SD PD Total
Cisplatin/pred. 19 (17) 8(3) 2 10 39
5-FU/P/H/P 6 (5) 5(4) 6 1 18
Chlorambucil 3 3 8 16 30
Cisplatin 4 (2) 6(6) 3 1 14
Prednimustine 3 (2) 2 2 1 8
Cisplatin/a-interferon 2 (2) - - - 2
Carboplatin 1 - - - 1
Cisplatin/adriamycin 1 - - 1
Cisplatin/CMF 1 (1) - - - 1
CHIP 1 - - 1
Total 39 (29) 26 (13) 21 29 115
The methods used to assess response to first line therapy are summarized in
table 5.13. 49/115 (42.6%) of all responses were assessed by second-look
operation, 39/115 (33.9%) were assessed clinically, 26/115 (22.6%) were
assessed radiologically, and 1/115 (0.8%) were determined by CA125 assay.
The patient assessed by CA125 had rising levels with progressive disease.
Table 5.13 Method of assessing response in patients with stage III
Response
Method of assessment CR PR SD PD Total
Laparotomy 18 15 3 36
Laparoscopy 11 1 1 - 13
CT scan 2 2 2 7 13
US scan 1 4 2 4 11
X-Ray - - 1 1 2
Clinical 7 4 12 16 39
CA125 - - - 1 1
Total 39 26 21 29 115
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5.3.6 Stage IV patients
All but one patient with stage IV disease, who was moribund after surgery, had
post-operative chemotherapy. Eight patients in this group remain alive, two with
progressive disease, four with stable disease, and two with inevaluable disease.
18/34 (52.9%) of stage IV patients with evaluable disease responded to first-line
therapy. 4/18 (22.2%) of these were complete responses and 14/18 (77.7%)
were partial responses. There was a higher proportion of complete responders
in stage III than stage IV patients. 1/4 (25%) of those stage IV patients who
achieved a complete response, 5/14 (35.7%) of those who achieved a partial
response, 1/4 (25%) of those who remained stable, and 1/12 (8.3%) of those
who progressed on first line therapy remain alive.
The reasons for stopping chemotherapy are shown in table 5.14. The majority
20/34 (58.8%) completed their regime, while 14/34 (41.2%) had incomplete
regimes.
Table 5.14 Reasons for stopping therapy in patients with stage IV
Reason for stopping CR PR
Response
SD PD Total
Regime complete 4 13 3 20
Toxicity - 1 - 1 2
Progressive disease - - 1 11 12
Patient refused - - - - -
Total 4 14 4 12 34
Responses to individual regimes are shown in table 5.15, with the number of
pathologically documented responses shown in brackets. 3/4 (75%) of
complete responses and 4/14 (28.6%) of partial responses were documented
pathologically.
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Table 5.15 Responses to different regimes in patients with stage IV
Response
Chemotherapy regime CR PR SD PD Total
Cisplatin/prednimustine4 (3) 9(2) 3 4 20
Chlorambucil 1 1 6 8
Cisplatin 1 - 1 2
Prednimustine 3(2) - - 3
Carboplatin - 1 1
Total 4 (3) 14(4) 4 12 34
The methods used to assess response to first line therapy are summarized in
table 5.16. 7/34 (20.5%) of the total were assessed by second-look surgery,
13/34 (38.2%) by clinical examination, and 14/34 (41.2%) by radiological
scanning.
Table 5.16 Method of assessing response in patients with stage IV
Response
Method of assessment CR PR SD PD Total
Laparotomy 3 2 5
Laparoscopy 2 - - 2
CT scan 1 6 2 1 10
US scan 1 1 2 4
X-ray - - - -
Clinical 3 1 9 13
CA125 - - - -
Total 4 14 4 12 34
The findings at second-look surgery were summarized in tables 5.9 and 5.10
for patients with stages I and III disease respectively. Table 5.17 summarizes the
findings in patients with stages III and IV disease. While second-look surgery
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was performed in 21/46 (45.7%) of stage I patients and 14/27 (51.8%) of stage
II patients, 65/139 (46.8%) of stage III and 7/38 (18.4%) of stage IV patients had
second-look surgery. 31/65 (47.7%) of stage III and 3/7 (42.9%) of stage IV
patients had a negative second-look operation. 8/65 (12.3%) of stage III and 2/7
(28.5%) of stage IV patients had microscopic disease at second-look operation.
15/65 (23%) of stage III and 1/7 (14.3%) of stage IV patients had macroscopic
disease at second-look operation. 10/65 (15.4%) of stage III and 1/7 (14.3%) of
stage IV patients had bulky disease at second-look operation.
Table 5.17 Findings at second-look in patients with stages III and IV
Second-look outcome Stage III Stage IV Total
No.patients 139 38 177
No. Laparotomy 51 5 56
Negative 20 3 23
Microscopic disease 7 1 8
Macroscopic disease 13 - 13
Bulky disease 10 1 11
Unknown 1 - 1
Debulked 5 1 6
No. Laparoscopy 14 2 16
Negative 11 - 11
Microscopic disease 1 1 2
Macroscopic disease 2 1 3
Bulky disease - - -
Unknown - - -
The most common reason for performing a second-look procedure was to
determine response to therapy in patients clinically free of disease. Although 42
patients had inoperable disease at primary surgery, only six patients were
subsequently rendered operable and had interval debulking at second-look
after several courses of chemotherapy.
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5.3.7 Progression-free survival
Progression free survival was calculated for those patients where it was
possible to give a date of progression. This date inevitably will be later than the
"true" date of progression, depending on how it was assessed and how closely
the patient was being monitored at the time. Time to progression, shown in
table 5.18, was calculated by subtracting the date of primary diagnosis from the
date of progression.
Table 5.18 Progression-free survival in each stage
No. patients Progression-free survival (months)
Stage alive (%) Mean Median Range
I 7/ 17(41) 24.4 16.3 3.2- 155.6
II 3/ 12(25) 20.0 14.4 4.3- 42.6
III 11 /94(12) 14.4 9.9 1.6- 57.1
IV 5/31(16) 10.6 8.4 1.4- 38.3
5.3.8 Survival
The percentage survival, expressed as the possible number of patients alive
(including the number of patients who had died and the number alive followed
up for a length of time) over the total number alive is shown in table 5.19. The
two year survival for stages I, II, III, and IV was 97%, 80%, 40.8%, and 21.1%
respectively, and the five year survival rate was 50%, 16.7%, 8.6%, and 0%
respectively. Five year survival rates are lower than often presented in the
literature, possibly due to the small numbers followed up for this length of time.
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1 year 42/43(97.7%) 24/27(88.9%) 95/137(69.3%)
2 years 32/33 (97.0%) 20/25 (80.0%) 49/120 (40.8%)
3 years 18/26(69.0%) 15/21(71.4%) 26/112(23.2%)
4 years 13/21(62.0%) 7/16(43.3%) 17/108(15.7%)






5.4 TUMOUR MARKER "FOLLOW-UP"
The main purpose of this chapter is to lay the foundations of the clinical
settings in which the tumour markers in this study were measured. Whether
tumour markers have anything useful to add to the total clinical picture of EOC
will be addressed in chapters 7, 8 and 9.
The number of assays performed for each marker, the length of "marker" follow-
up as opposed to "clinical" follow-up (see section 5.2, pp. 117-118) will be
described. CA125 was assayed in all 1237 samples from the total population
of 250 patients, while the other markers were assayed in smaller numbers of
patients samples. "In-house" assays, HMFG2 and p185, were assayed in
greater numbers than the commercial assays, the major restriction being the
expense of the commercially available assay kits. The time the assays were
performed and the number of serum aliquots remaining were also important
factors in the choice of samples assayed.
Table 5.20 shows the numbers of each tumour marker assay performed in the
total population. In addition to this, the mean, median and range is shown for
the number of samples assayed per patient.
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Table 5.20 Number of tumour marker assays
Tumour No. No. No. samples per patient
marker patients samples Mean Median Range
CA125 250 1237 4.8 4.0 1-17
HMFG2 215 880 3.9 3.0 1-13
p185 173 601 3.4 3.0 1-10
TATI 117 346 2.9 2.0 1-8
CA153 42 192 4.3 4.0 1-13
CA199 42 193 4.3 4.0 1-13
CA724 20 70 3.3 3.0 1-6
Tables 5.21 and 5.22 show the number of assays performed in patients with
early and advanced disease respectively. The numbers of samples in tables
5.21 and 5.22 add up to give the total numbers found in table 5.20, however,
there is a discrepancy in the numbers of patients. This is because seven
patients who were "upstaged" from early to advanced stage during follow-up
had samples taken during both phases of their disease, and not all patients
had samples assayed for each marker.
Table 5.21 Number of tumour marker assays in early stage disease
Tumour No. No. No. samples per patient
marker patients samples Mean Median Range
CA125 63 286 4.5 3.0 1-16
hmfg2 62 236 3.8 3.0 1-13
p185 52 158 3.0 3.0 1-9
TATI 39 111 2.8 3.0 1-8
CA153 18 86 4.8 4.5 1-13
CA199 18 86 4.8 4.5 1-13
CA724 8 32 4.0 4.5 1-6
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Table 5.22 Number of tumour marker assays in advanced stage disease
Tumour No. No. No. samples per patient
marker patients samples Mean Median Range
CA125 194 951 4.9 4.0 1-17
hmfg2 159 644 4.1 3.0 1-13
p185 125 443 3.6 3.0 1-10
TATI 80 235 2.9 2.0 1-8
CA153 27 106 3.9 4.0 1-11
CA199 27 107 3.9 4.0 1-11
CA724 13 38 2.9 3.0 1-6
The length of "marker" follow-up was calculated in months by subtracting the
first sample date from the last. Overall, the mean CA125 "follow-up" time was
11.5 months (median 7.6 months and range 0-54.4 months). Patients with early
stage disease had a mean CA125 "follow-up" of 14.5 months (median 11.8
months and range 0-50.7 months). Patients with advanced disease had a mean
CA125 "follow-up" of 10.3 months (median 6.6 months and range 54.4 months).
Each marker result was scored true positive, true negative, false positive or
false negative, see Appendix D for scoring system. The clinical settings,
outlined in the first two sections in this chapter, in which the markers were
evaluated, numbers permitting, will be described in the chapters 7, 8 and 9.
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CHAPTER 6
Establishment of an EOC Patient Database
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6.1 INTRODUCTION
A database comprising the epithelial ovarian cancer patients' case histories
together with their serum tumour marker levels was developed in collaboration
with Unilever Research at the Colworth Laboratory, Sharnbrook, U.K.. The
database was constructed using a VT 220 IBM terminal on the URL Colworth
MARS - VAXA/MS mainframe computer system, and statistical analyses per¬
formed using the SAS (Statistical Analysis System) software package. A similar,
but less comprehensive system had previously been used for analysis of breast
tumour markers (Robertson, 1989), also in collaboration with Unilever Research.
Robertson's study set out to determine if there was a correlation between
tumour marker levels and UICC response to therapy 2, 4, and 6 months after
its initiation, and to construct a clinically useful prognostic index with the
appropriate markers.
6.2 NECESSITY OF THE DATABASE FOR CLINICAL ANALYSIS
Epithelial ovarian cancer is a multifarious disease; patients fall into several
different prognostic groups, each requiring a different treat-ment strategy. From
the outset of this study blood sampling was to be performed on a regular
monthly basis, particularly during chemotherapy, and subsequently during
regular clinic visits. In practice, however, the timing and number of blood
samples obtained from each patient varied greatly. A number of factors had an
influence on the range of samples obtained from the patient population. The list
below is by no means exhaustive, but illustrates several such factors inherent
in this and any clinical study of a similar nature.
Factors influencing the range of samples obtained:-
1. The time between April 1984 and July 1989 that each patient was entered
into the study; this determined the length of follow-up each patient had and
ultimately affected analyses of progression and survival.
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2. The period in the course of disease and treatment during which the patient
was entered into the study; this affected the number of samples obtained
at specific times. For example, patients already receiving second-line
chemotherapy could obviously not be included in a multivariate analysis of
markers as early prognostic factors.
3. Several clinical trials were conducted concurrently. Thus, where possible
the treatment the patient received had to be taken into account in order to
eliminate the effects of different treatments on marker levels.
4. Clinicians remembering to take samples at appropriate times during treat¬
ment. For example, the number of samples obtained immediately prior to
second-look was poor. If surgery was deferred for some reason in a
patient awaiting second-look, then such a patient often did not have a
repeat sample sent for marker assay at the appropriate time. This was
frequently the case and greatly reduced the possible number of samples
with which to correlate marker levels with second-look outcome.
5. Samples reaching the laboratory for separation of serum within an appro¬
priate time. Blood samples were discarded if they reached the laboratory
from the wards and clinics greater than two days after being taken if they
had been left at room temperature. Unfortunately this was relatively
common, up to 10% of samples arrived too late.
6. When and how many of the assays were performed for each marker (as
described in chapter 5, section 5.4, pp. 134-136). The commercial assays
were not performed on a routine basis, except for CA125, therefore the
range of samples assayed depended on which samples were available at
the time of receiving the marker assay kits.
The complexities described above contributed to the necessity of developing
this database to answer clinical questions retrospectively. Upon it's completion,
the availability of sufficient numbers of "appropriate" tumour marker data to
139
analyse became clear immediately and clinical and statistical analyses were
greatly facilitated.
6.3 CONSTRUCTION OF THE DATABASE
With hindsight, construction of two separate databases; one containing the
case histories and the other containing the serial tumour marker levels would
have been more straightforward. However, one database was developed
containing patients case histories and serial tumour marker data. Consequently,
information was entered on a sample basis rather than on a patient basis. This
meant that for each blood sample taken from a patient, all diagnostic and other
clinical details had to be entered, with the sample date as the "fixed" entry,
resulting in much unavoidable duplication of clinical information in the database.
For each blood sample, the maximum number of variables or "fields" was 59.
The total number of samples included in the final analysis was 1237 resulting
in a maximum of 72,983 data entries, which occupied 413696 bytes (1/2 Mbyte)
of computer memory. The fields were visualised within 3 computer screens.
Screens 1 and 2 displayed all the clinical details pertaining to that sample date,
while the remainder displayed the tumour marker levels at that date.
The fields were ordered in a logical sequence to ensure ease of data entry and
ease of selection of samples or patient groups of interest to facilitate
programming. Some of the entry options are self-explanatory, however the
majority consist of several codes. Short codes were constructed for clinical
information to reduce the amount of computer memory required. Whilst some
of these are generally accepted abbreviations, others were constructed purely
for the purpose of this database and are decoded later. The list overleaf shows
the fields in order together with their respective entry options.
140
6.3.1 Order of database fields and entries
Screen 1
Field Data entry option
1. Sample number 0001 - 2000
2. Patient name e.g. SMITH-MARY
3. Date of birth e.g. 01/01/33
4. Sample date e.g. 01/01/88
5. Patient age e.g. 55
6. Cancer stage FIGO I - IV
7. Histopathological grade 0-4
8. Cancer subtype SPC, MUC, etc...
9. Smoker Y/N/U




14. Date diagnosis/surgery 1 e.g. 01/12/87
15. Operative procedure 1 0 - 9
16. Debulk C/Y/P/N/B
17. Date second-look surgery e.g. 01/07/88
18. Operative procedure 2 0 - 9
19. Second-look outcome NEG/MIC/MAC/BUL
20. Drug therapy Y/N
21. Current therapy CIS/PRED/etc...
Screen 2
Field Data entry option
22. Type of therapy T/A/P
23. Date first given e.g. 01/01/88
24. Regime number 0-6
25. Number of cycles 0-20
26. % Completion of regime 0 - 100
27. Reason for stopping regime PC/TOX/etc...
28. Clinical disease Y/N
29 Evaluable disease ED/NED
30. Response to therapy NA/NE/CR/PR/SD/PD
31. Date response assessed e.g. 01/07/88
32. Method response assessed LRT/LSC/etc...
33. Date of progression e.g. 01/01/89
34. Method progression assessed LRT/LSC/etc...
35. Date last seen (if alive) e.g. 01/07/89
36. Current status (if alive) NE/CR/PR/SD/PD
37. Date of death e.g. 01/08/89
38. Survival (months) 0 - 100
39. CA125 censored < or >
40. CA125 result 0 - 500
41. CA125 qualifier TP/TN/FP/FN
42. HMFG2 censored < or >
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Screen 3
Field Data entry option
43. HMFG2 result 0 - 500
44. HMFG2 qualifier TP/TN/FP/FN
45. CA153 censored < or >
46. CA153 result 0 - 500
47. CA153 qualifier TP/TN/FP/FN
48. CA199 censored < or >
49. CA199 result 0 - 500
50. CA199 qualifier TP/TN/FP/FN
51. CA724 censored < or >
52. CA724 result 0 - 500
53. CA724 qualifier TP/TN/FP/FN
54. TATI censored < or >
55. TATI result 0-500
56. TATI qualifier TP/TN/FP/FN
57. NEU censored < or >
58. NEU result 0 - 10000
59. NEU qualifier TP/TN/FP/FN
6.3.2 Information entry
Entry of marker data, unlike clinical information, presented no problems. These
data wife "censored", for example if a marker was undetectable it was given a
value of less than the limit of detection of the assay, i.e. <5 Urnl"1 for CA125,
instead of the value zero. This resulted in data enhancement for SAS package
handling.
Some of the initial diagnostic information e.g. operative procedure and histology
remained constant throughout the blood sampling period. However, the
majority of clinical information e.g. therapy regimes and responses changed
with time, as did the marker levels. Therefore the resulting database consisted
of longitudinal or continual clinical information and discrete marker data.
Thus, certain "rules" regarding entry of clinical information had to be developed
in order to maximise the use of information gained from the case notes relating
to the blood sampling time. This will become clearer when the rules are
examined. For example, a blood sample was taken from a patient three months
after completing a course of cisplatin and a routine CT scan taken two months
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previously showed the patient to have a complete response. The "response"
recorded with that sample date was CR if it was later confirmed after reviewing
retrospectively all available clinical information.
Responses to therapy are conventionally documented upon completion of
therapy using UICC response criteria (see chapter 1, table 1.2, p 27). Blood
samples were very rarely taken precisely at this time, therefore to maximise the
use of the marker data obtained throughout the disease course a special
system for documenting "response" or disease status at all times was
implemented, as described in the example above. It must be stressed that this
was purely for research purposes. It was vital to have a consistent clinical base
from which the markers could be evaluated. Field number 28 was also created
to aid this purpose. Using all the information available the presence or absence
or disease was judged in retrospect to enable a marker scoring system to be
used to evaluate their sensitivity, specificity, accuracy and predictive powers.
Data printouts were painstakingly checked and double-checked for mistakes.
One or two mistakes in entering marker data became apparent when simple
programmes were run. For example, typing in a value of 165 Urnl"1 for CA724
instead of 16.5 Urnl"1 would have resulted in a gross over-estimate of mean
levels. Clinical information on the other hand was less reliable and less
amenable to error testing; many discrepancies in details arose from different
sources. Where possible information was obtained from the case notes, which
were less contradictory, rather than the sample forms which tended to be less
reliable. Great care was taken to ensure consistency in clinical documentation.
6.3.3 Field information entry and applications
The list overleaf shows the decoding of the field options. Data that may change
with time are marked with an asterisk. Brief rules for entry of information are
given where appropriate.' Finally, some general applications are indicated:
selection (S), correlation (C), prognosis (P), and various (V) including
combinations of the first three analyses.
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Field Entry Decode Use Rules for data entry
* 1. 1000 _ _ _
2. NAME . s -
3. DOB - p -
4. DATE - V -
* 5. AGE - p Age at sampling
* 6. I - IV FIGO stage p Stage at sampling
* 7. 0 Unknown - -
1 Well cliff. V -
2 Moderate diff. V -
3 Poorly diff. V -
4 Variable diff. V Enter if mixture of grades is
unknown
8. SPC Serous V -
MUC Mucinous V -
ENDO Endometrioid V -
CC Clear cell V -
ADENO Adenocarcinoma V -
MIX Mixed V -
UNK Unknown - -
* 9. Y/N Yes/No c -
10. 0 - 4 ECOG perfor¬ p Initial pre-therapy
mance status value only
11. Y/N/U Yes/No/Unknown p -
12. NEG/POS Negative/Positive P -
UNK/ND Unknown/Not done - -
13. Y/N/U Yes/No/Unknown p -
14. DATE - V -
15. 0 Biopsy only V -
1 TAH V -
2 BSO V -
3 Omentectomy V -
4 Partial oment. V -
5 Infracolic oment. V -
6 Oophorectomy V Left or right
7 Ovariotomy V Bilateral or one
8 Ovarectomy V Bilateral or one
9 OtherVeg. - Palliative procedures
16. C Complete V No residual disease
Y Yes V < 2cm
P Partial V 2 - 5 cm
N No V > 5cm
B Biopsy only V Gross disease left
* 17. DATE - V -
* 18. As 16.
* 19. NEG Negative V -
MIC Microscopic V -
MAC Macroscopic V -
BUL Bulky disease V -
* 20. Y/N Yes/No s Y - if patient is on Rx, or has had it in the
past, N - if patient has never had Rx
* 21. NIL Not on Rx s Patient may be pre or post regime
CIS Cisplatin V -
CARBO Carboplatin V -
PRED Prednimustine V -
CHLOR Chlorambucil V -
AIFN a-lnterferon V -
MEL Melphalan V -
MITOX Mitoxantrone V -
MITOZ Mitozolamide V -
IFOS Ifosfamide V -
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Field Entry Decode Use Rules for data entry
* 21. BLEO Bleomycin V _
ADRIA Adriamycin V -
MC Mitomycin C V -
CYCLO Cyclophosphamide V -
BIANT Biantrazole V -




* 22. T Therapeutic s -
A Adjuvant s -
P Palliative s -
* 23. DATE - V Date of first cycle of most recent regime
* 24. 0-6 - V Number of regimes patient has had
including the current
* 25. 0-20 - p Number of cycles of current Rx given by
that sample date
* 26. 0 - 100 - V .
* 27. PC Protocol complete s -
TOX Toxicity s -
PD Progression s -
REF Patient refusal s -
* 28. Y/N Yes/No V Disease presence or absence judged in
retrospect using all available information
* 29. ED/NED Evaluable/ V Clinically, radiologically, or surgically
non-evaluable disease
* 30. NA Not applicable V Patients on adjuvant Rx
NE Not evaluable V No measurable disease
CR Complete response V -
PR Partial response V -
SD Stable disease V -
PD Progression V -
* 31. DATE - V Date of most recent assessment, + or - one
month
* 32. CLIN Clinical V .
LRT Laparotomy V -
LSC Laparoscopy V -
XRAY X-Ray V -
US Ultrasound scan V -
CT Computed V -
tomography
BIOC Biochemical V -
CA125 CA125 assay V -
* 33. DATE - V Date of most recent assessment
* 34. As 32. - p -
35. DATE - p _
36. AS 30. - p _
37. DATE - p .




The database was used initially to collate the information on the patient
populations demographics, their management, and the results of treatment,
presented in chapter 5. Once the database was established, the ability to
answer retrospectively certain clinical questions was greatly facilitated.
Longitudinal plots of serial marker levels were constructed for all patients to
help identify which patients would provide information regarding various clinical
correlations. In addition, they helped to define exclusion criteria necessary to
develop or modify existing programmes.
Programmes were written using the SAS software package to perform the
appropriate statistical analysis. As marker data show a positively skewed and
not a Gaussian distribution, non-parametric statistical tests were commonly
employed. Tumour marker data were first standardised by logarithmic
conversion (Iog10) before performing many of the following statistical tests.
The F test (one way analysis of variance) was used to determine the correlation
between post-operative residual disease and marker levels in samples assayed
1-4 weeks after primary surgery (chapter 8, section 8.2, pp. 181-184). The
Kruskal Wallis test was used to determine the correlation with overall response
to chemotherapy (chapter 8, section 8.3, pp. 185-197). The difference between
marker response in complete and partial responders was determined by the
Mann Whitney test (chapter 8, section 8.3, pp. 185-197). The difference
between pre-treatment and post-treatment marker levels in patients who
received first-line chemotherapy was determined by theWilcoxon Signed Rank
test (chapter 8, section 8.3, pp. 185-197). The sensitivity, specificity, accuracy
and predictive values for pre-second-look marker data (chapter 8, section 8.4,
pp. 198-206) were calculated using the formulae given in chapter 3, section
3.4.7, pp. 68-71.
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The SAS Lifetest procedure (SAS/STAT Users Guide, 1989) using the chi-
squared statistic for the Wilcoxon test was used to perform both univariate and
multivariate analyses of prognostic factors (chapter 9, section 9.2, pp. 220-225).
Cox's proportional hazard model was not available on SAS. Kaplan Meier
progression free survival and overall survival curves were constructed (chapter
9, section 9.3, pp. 225-233), and differences between progression free survival






EOC Tumour Marker Elevations
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7.1 INTRODUCTION
The ability of serum tumour markers to discriminate between the presence and
absence of viable malignant cells, far less determine the tumour volume,
depends not only on the marker, the type of malignancy and the assay
conditions, but also on the method used to assign a cut-off value above which
marker levels are considered "abnormal". The choice of cut-off values for the
marker assays in this study were described in chapter 4, table 4.9, p 114.
All studies have found significantly elevated marker levels in patients with
advanced disease, irrespective of marker or tumour type. Kabawat et al.
(1983b) first described the association of CA125 with serous, endometrioid,
clear cell, mixed, and undifferentiated epithelial ovarian malignancies, but not
mucinous tumours, using immunohistochemistry. Subsequent studies found
elevated serum levels in patients with mucinous EOC, although levels were
generally lower and were raised in fewer patients than those with non-mucinous
tumours (for reviews see Kenemans et at., 1988, and Jacobs and Bast, 1989).
Each of the markers described in this thesis has been found raised in serum
from patients with all histological types of ovarian cancer, and each has been
advocated for a particular histological type(s) - commonly mucinous or non-
mucinous (see chapter 2). There are few studies in the literature describing the
association between levels of serum CA125, or other markers, and tumour
grade. This chapter therefore examines the distribution of elevated levels of
CA125, CA153, CA199, CA724, TATI, HMFG2, and p185 in patients with different
disease stages, histological types and tumour grades.
No single tumour marker has 100% sensitivity and specificity for any particular
stage or histological variety of EOC. This is due to the heterogeneity of antigen
expression in epithelial ovarian tumours, demonstrated in numerous immuno-
histochemical and serological studies (Bast etal., 1990, Esteban and Battifora,
1990, Welch et al., 1990). The performances of each tumour marker assay, in
terms of overall sensitivity and specificity for EOC, are compared using
Receiver Operating Characteristic (ROC) curves (Makuch and Muenz, 1987).
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ROC curves were also used to compare the general performance of each
marker in patients with different tumour types (Hanley and McNeil, 1982).
Tumour antigen heterogeneity presents problems not only in diagnosis and
monitoring, but also in imaging and therapy with monoclonal antibodies. The
ideal "panel" or combination of markers has not yet been identified for any of
the above applications although many have been evaluated (Einhorn et al.,
1989, Bast et al., 1990, Lahousen et al., 1990). The value of each marker
assayed in this thesis was therefore determined in addition to the universally
accepted best single serum marker, CA125.
7.2 EOC TUMOUR MARKER ELEVATIONS
Every sample collected was assayed for CA125, whereas fewer assays were
performed for the other markers for reasons given in chapter 5, section 5.4,
p134. The numbers and percentages of patients with each disease stage who
had at least one positive marker result are shown in table 7.1.
As stated earlier, the cut-off values employed for CA125, CA153, CA199,
CA724, TATI, HMFG2 and p185 were 35 Uml"1, 30 Urnl"1, 33 Umf1, 5 Urnl'1,
20 ugl"1, 40 Urnl"1 and 1900 Uml"1 respectively. Overall, in descending order;
CA125, HMFG2, CA153, TATI, CA724, CA199 and p185 were elevated in
211/261 (80.8%), 134/221 (60.6%), 21/46 (45.6%), 50/117 (42.7%), 9/22 (40.9%),
15/46 (32.6%) and 21/179 (11.7%) patients respectively (table 7.1). There is a
discrepancy in the number of patients; several patients were re-staged after
disease progression and had markers assayed during both stages of their
disease, these patients were counted twice. CA125 was elevated in a greater
proportion of patients with all FIGO stages than any of the other markers. Apart
from CA125, HMFG2 was elevated in a greater proportion of patients with all
disease stages than any of the other markers.
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Table 7.1 Proportion ofpatients with elevated marker levels in each stage
Tumour FIGO Stage
marker I II III IV Total
CA125 19/38 16/25 126/147 50/51 211 / 261
(50.0%) (64.0%) (85.7%) (98.0%) (80.8%)
CA153 2/9 3/9 11 / 18 5/10 21 / 46
(22.2%) (33.3%) (61.1%) (50.0%) (45.6%)
CA199 3/9 3/9 5/18 4/10 15/46
(33.3%) (33.3%) (27.8%) (40.0%) (32.6%)
CA724 1 / 4 2/4 2/8 4/6 9/22
(25.0%) (50.0%) (25.0%) (66.7%) (40.9%)
TATI 4/22 8/17 25/57 13/21 50/117
(18.2%) (47.0%) (43.8%) (61.9%) (42.7%)
hmfg2 18/38 13/24 71 /115 32/44 134/221
(47.0%) (54.2%) (61.7%) (72.7%) (60.6%)
p185 1 / 33 1 / 19 12/88 7/39 21 / 179
(3.3%) (5.3%) (13.6%) (17.9%) (11.7%)
Figures 7.1 to 7.7 show the distribution of marker levels in patients with each
disease stage. The numbers of patients with elevated levels correspond to
those given in table 7.1. As no pre-operative samples were available, figures 7.1
to 7.7 were constructed using the highest level of each marker from each series
of samples assayed per patient. The first, last, middle, highest, lowest or a
random value could have been used for this purpose. However, in the absence
of pre-operative samples, the highest value was chosen to represent the
number of patients with elevated levels (table 7.1); this measurement also gave

























































































































































































































































Figure 7.7 p185 levels; distribution according to FIGO stage
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The numbers and percentages of patients with each histological type who had
at least one elevated level of each marker are shown in table 7.2.












































































* Poorly differentiated adenocarcinoma
Ignoring those tumour types where only one patient had a particular marker
assay, CA125 was elevated in a higher proportion of patients with all
histological types than all the other markers, except for CA724 which was
elevated in a slightly greater percentage of patients with mucinous tumours,
although the number of patients was small (table 7.2). Apart from CA125,
HMFG2 was elevated in a greater proportion of patients with all histological
types than any of the other markers. In general, fewer patients with mucinous
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tumours had elevated markers than those with non-mucinous tumours, except
for CA724.
The numbers and percentages of patients with well differentiated, moderately
differentiated and poorly differentiated tumours who had elevated levels of at
least one marker are shown in table 7.3.




marker Well Moderate Poor
CA125 26/36 (72.2%) 43/60 (71.7%) 119/134 (88.8%)
CA153 1 / 7 (14.2%) 6/14 (42.8%) 12/18 (66.7%)
CA199 2/7 (28.6%) 5/14 (35.7%) 5/18 (27.8%)
CA724 2/4 (50.0%) 4/9 (44.4%) 3/8 (37.5%)
TATI 5/18 (27.8%) 13/30 (43.3%) 27/72 (37.5%)
hmfg2 16/32 (50.0%) 31 / 51 (60.8%) 77/112 (68.8%)
p185 2/26 (7.7%) 2/39 (5.1%) 18/87 (20.6%)
The percentages of patients with elevated marker levels with well, moderately
and poorly differentiated tumours shown in table 7.3 is displayed in figure 7.8.
The percentage of patients with serum marker elevations increased with tumour
grade for CA125 (although there was no difference between those with well and
moderately differentiated tumours), CA153 and HMFG2. The opposite trend was
observed for CA724. Serum expression of p185 was highest in patients with
poorly differentiated tumours, whereas serum expression of both CA199 and
TATI were highest in those with moderately differentiated tumours.
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CAT 2 5 CAT 53 CA199 CA724 TAT1
Elevated tumour marker
HMFG 2
Figure 7.8 Association of serum marker elevation with tumour grade. The
percentage of patients with elevated levels of each serum tumour
marker investigated in this thesis with well differentiated (h),
moderately differentiated(n) and poorly differentiated (■) tumours
is shown.
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7.3 MARKER SENSITIVITY, SPECIFICITY, ACCURACY AND PREDICTIVE
VALUES
The formulae given in chapter 3, section 3.4.7, pp. 68-69, can be used to
determine the sensitivity, specificity, accuracy, and predictive values of a
positive and negative marker result. These parameters are usually calculated
pre-operatively to determine if a particular marker can distinguish benign from
malignant disease or indicate the stage or extent of disease. A general
calculation of these parameters is clinically meaningless. They were however
determined using samples assayed for CA125, HMFG2 and TATI prior to
second-look operation to ascertain the value of each test in predicting disease
presence, see chapter 8, table 8.14, p 205.
7.4 RECEIVER OPERATING CHARACTERISTIC (ROC) CURVES
The relationship between test sensitivity and specificity, as the proportion of
false negative and false positive results vary inversely with cut-off value, can be
simply shown in a receiver operating characteristic (ROC) curve (Makuch and
Muenz, 1987). ROC curves are an excellent way of graphically illustrating the
performance of a test; sensitivity or true positive rate (y-axis), is plotted as a
function of 1-specificity or false positive rate (x-axis). As the cutoff value
increases, the closer the curve lies to the y-axis the better, i.e. the more
sensitive and specific, the test. Increasing the cut-off value to maximise
specificity reduces sensitivity and vice-versa. A cut-off value is usually chosen
to give the best trade off between the two, as described in section 3.4.7, p 70.
The choice of cut-off value depends on the stringency of test requirements; for
example, in the case of a disease as serious as cancer, where cure is often
unobtainable, it is desirable to maximise the specificity of a diagnostic test
(Galen and Gambino, 1975).
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7.4.1 ROC curve comparison of overall sensitivity and specificity of each
tumour marker assay
ROC curves were constructed for each tumour marker using all samples
scored retrospectively as true positive, true negative, false positive or false
negative (see Appendix D for scoring system). Figure 7.9 compares computer
(SAS) generated ROC curves for each marker. Figure 7.9 clearly shows that
CA125 is superior to all the other markers in the evaluation of EOC.
1 - Specifity
Figure 7.9 ROC curve comparison of markers. Computer generated ROC
curves for CA125 ( ), CA153 ( ), CA199 ( ),
CA724 ( ), TATI ( ), HMFG2 ( ), and p185
( - . - . - ) are compared.
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7.4.2 ROC curve comparisons of assay performance for different
histological tumour types
The most common quantitative index describing the ROC curve is the area
under it. Areas may be compared using the Wilcoxon rank test to determine if
there are any significant differences in sensitivity and specificity between
different tests (Hanley and McNeil, 1982). These comparisons were made
between different histological types for each marker. Differences were
designated significant only if p<0.05. CA125 was a significantly more sensitive
and specific marker for poorly differentiated adenocarcinomas (PDA) than either
serous or endometrioid tumours. There were no significant differences between
any other tumour types. CA153 was a significantly better marker for PDA than
serous, endometrioid and mucinous tumours. CA153 was also a significantly
better marker for either serous or endometrioid than mucinous tumours. No
other differences were observed. CA199 was a significantly better marker for
PDA than serous, endometrioid and mucinous tumours. CA199 was, however,
a significantly better marker for mucinous than either serous or endometrioid
tumours. CA724 was also a significantly better marker for mucinous than both
serous and endometrioid tumours. No other differences were observed. TATI
was a significantly better marker for PDA than serous, endometrioid and
mucinous tumours. TATI was significantly poorer marker for serous than either
endometrioid or clear cell tumours, and a significantly poorer marker for
mucinous than of clear cell tumours. There were no significant differences
between any histological types for HMFG2 or p185, although HMFG2 was least
sensitive and specific for mucinous tumours and most sensitive and specific for
PDA.
7.5 TUMOUR MARKER COMBINATIONS OR "PANELS"
The value of each marker in addition to CA125 was investigated in two ways.
A stepwise discriminant analysis was performed to determine whether any
marker could improve the ability of CA125 to discriminate simply between
disease activity and inactivity, ignoring pre-determined cut-off values. Secondly,
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assuming positive CA125 results to be correct, each of the remaining markers
was evaluated in a series of CA125-negative samples. These analyses were not
performed for p185 because it was elevated in only 11.7% of patients (table
7.1), the vast majority of whom had markedly raised CA125 levels.
7.5.1 Stepwise discriminant analysis
The number of samples that were assayed for CA125 and each of the
remaining markers differed. The number of positive samples, i.e. samples taken
from patients who either had evaluable disease or were judged retrospectively
to have active disease at the time of assay, out of the total number of samples
assayed for each marker were: 108/184 (58.7%) for CA153; 108/185 (58.4%)
for CA199; 47/69 (68.1%) for CA724; 199/357 (59.1%) for TATI; and 505/810
(62.3%) for HMFG2. Therefore the active disease prevalences in populations
assayed for each marker were similar.
The correlations between CA125 and the other markers in the stepwise
discriminant analysis were as follows: CA153 (n=184, r=0.455, p>0.05), CA199
(n=185, r=0.197, p>0.05), CA724 (n=69, r=0.403, p>0.05), TATI (n=357,
r=0.029, p<0.0001) and HMFG2 (n=810, r=0.183, p<0.005). Therefore, CA153,
CA199 and CA724 did not add significantly to the discriminatory capacity of
CA125, while TATI (p<0.0001) and HMFG2 (0.005) did add significantly to
CA125.
7.5.2 Series assay of markers in addition to CA125
Marker assays may be performed in a parallel or series manner (Galen and
Gambino, 1975). Samples assayed in parallel are simultaneously assayed for
each marker. To reduce the overall cost and labour intensity, samples may be
assayed in series. The most specific marker is assayed first and subsequent
assays are performed on samples which give negative results with this test. In
this instance, CA125 is also the most sensitive test compared to any of the
other markers, though this may not always be the case. The extent to which
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any of the markers in this study improved sensitivity, specificity, and predictive
values when assayed in CA125 negative samples compared to CA125 assay
alone is shown in table 7.5.
Table 7.5 Series analysis of each marker in addition to CA125
% change with additional assay of:
CA153 CA199 CA724 TATI hmfg2
No.samples 94 95 30 173 329
Sensitivity t 0.5 f 0.6 t 0.1 t 3.0 t 2.9
Specificity 4 3.4 1 6.7 0 1 11.8 4 17.3
Accuracy 4 0.1 4 0.3 4 0.7 4 0.3 4 3.0
PVP 4 0.4 4 0.8 0 4 2.3 4 6.5
PVN t 1.1 t 0.7 t 4.8 t 7.8 t 3.5
Different populations were assayed for each marker, hence direct comparisons
cannot be drawn between markers. Sensitivity, and concomitantly PVN, are
increased with the additional measurement of all markers compared to CA125
alone. CA153, CA199, and CA724 each improve sensitivity by < 1.0%, while
TATI and HMFG2 improve sensitivity by 3.0% and 2.9% respectively. While
sensitivity increases marginally, specificity is more markedly reduced resulting
an overall decrease in accuracy. TATI and HMFG2 reduced specificity overall
by 11.8% and 17.3% respectively.
To ascertain which patients might benefit from additional marker assay to
CA125, the changes in sensitivity and specificity resulting from TATI and HMFG2
assay compared to CA125 assay alone were examined in more detail. Patients
were given a negative score if CA125 and either TATI or HMFG2 were both
negative and a positive score if one or both markers were elevated. A true
negative score with CA125 alone became a false positive score in patients with
either false positive TATI or HMFG2 levels. A false negative score with CA125
alone became a true positive score in patients with either true positive TATI or
167
HMFG2 levels. The number of patients whose scores were converted from true
negative to false positive and false negative to true positive after series TATI
and HMFG2 assay are shown in table 7.6.
Table 7.6 Series addition of TATI and HMFG2 to CA125
No. patients with change in marker score:
Disease TATI HMFG2
characteristics FN - TP TN - FP FN - TP TN -
Stage I 1 2 2 7
II 1 5 2 5
III 5 3 6 11
IV 5 0 7 1
Type Serous 10 8 14 16
Adenocarcinoma 0 0 0 2
Endometrioid 1 1 3 4
Clear cell 0 0 1 1
Mucinous 1 0 0 1
Mixed 0 1 - -
Grade WD 1 1 1 4
MD 2 6 1 8
PD 8 3 12 8
Total 12 10 17 24
The number of patients whose marker scores were converted from false
negative to true positive outweigh the number of patients whose marker scores
changed from true negative to false positive when TATI and HMFG2 assays
were performed in series with CA125 only in those with advanced poorly
differentiated serous tumours.
In addition, 5/12 (41.6%) patients with true positive results using a combination
of CA125 and TATI had clinically evaluable disease at the time of marker assay.
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7/17 (41.2%) patients with true positive results using a combination of CA125
and HMFG2 had clinically evaluable disease at the time of marker assay.
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7.6 DISCUSSION
CA125 was elevated overall in 81% of patients in agreement with values found
in the literature (Jacobs and Bast, 1989). CA125 was elevated in a higher
proportion of patients with all disease stages (table 7.1) and histological tumour
types (table 7.2) than all the other markers assayed in this thesis, except for
CA724 which was elevated in a slightly higher percentage of patients with
mucinous tumours (although the number of patients was small). Apart from
CA125, HMFG2 was elevated in a greater proportion of patients with all stages
(table 7.1) and tumour types (table 7.2) than all other markers.
Ideally, the sensitivity of each marker for a particular stage or type of EOC
should be determined by assaying pre-operative samples. As these were
unavailable, the highest level obtained in serial samples from each patient was
chosen to approximate the number of patients who expressed each marker.
Using this approach, the "sensitivity" of CA125 for stages I, II, III, and IV disease
was 50%, 64%, 86%, and 98% respectively (table 7.1). Kenemans (1991), in a
review of the CA125 literature dating from 1983 to 1990, reported the
cumulative sensitivity of CA125 from 16 studies; 81/187 (43%) patients with
stage I, 58/68 (85%) patients with stage II, 430/463 (93%) patients with stage
III, and 141 /145 (97%) patients with stage IV disease had elevated pre-operative
CA125 levels. These figures agree with the results obtained in patients with
stages I and IV disease in this thesis. However, the "sensitivities" of CA125 for
stages II and III were underestimated, probably due to serological monitoring
of a minority of patients during remission, highlighting the limitations of this
approach to approximating sensitivity.
HMFG2 was elevated in a similar proportion of patients with stage I disease to
CA125, but was elevated in approximately 20% fewer patients with stages ll-IV
disease (table 7.1). The cut-off values used in this thesis were established by
the original investigators (chapter 4, table 4.9, p 114), except for HMFG2 which
was determined empirically. 5% of normal individuals had elevated HMFG2
levels using the 40 Urnl"1 cut-off value (figure 7.6). Using their own cut-off value,
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Ward and Cruickshank (1987b) reported a false positive rate of 8% in samples
from normal individuals, while Burchell et al. (1984) originally found a false
positive rate of 17%. Ward and Cruickshank (1987b) found elevated pre¬
operative levels of HMFG2 in 3/9 (33%) patients with stage I disease and 18/29
(62%) patients with stages II to IV disease (they did not distinguish between
different stages in patients with advanced disease). Different cut-off values were
not employed in this thesis, as the value chosen appeared to be optimal.
CA153, CA199, CA724, TATI and p185 were elevated overall in 46%, 33%, 41%,
43%, and 12% of patients in this study (table 7.1). All of these markers had very
poor "sensitivity" for early stage disease. Scambia et al. (1988) found elevated
pre-operative CA153 levels in 3/11 (27%) patients with stage I disease, similar
to the findings in this study (table 7.1). However, the sensitivity for advanced
disease was higher; 27/34 (79%) stage III and 11/13 (85%) stage IV patients
had elevated pre-operative CA153 (Scambia et al., 1988). CA199 has poorer
sensitivity than CA153, Canney et al. (1985) found pre-operative CA199
elevated in 29% of patients while Bast et al. (1984) found elevated CA199 in
only 17% of patients. Recently, Scambia et al. (1990) found elevated pre¬
operative levels of CA724 in 10/15 (67%) patients with stages I and II disease,
11/17 (65%) stage III and 8/12 (67%) stage IV patients. The sensitivity for stage
I disease was not reported in this study (Scambia et al., 1990). Kobayashi et
al. (1989) however reported pre-operative elevation of CA724 in 8.3% of
patients with stage I, 25% with stage II, 48% with stage III and 85.7% with stage
IV disease. Whilst Scambia et al. (1990) used a cut-off value of 7 Uml"1, higher
than the value employed in this study, Kobayashi et al. (1989) employed a
more generous cut-off value of 3.9 Umf1. Both of these studies reported a
higher overall frequency of CA724 elevation than found in this thesis. This is
most likely to have resulted from a bias towards assay of patients with negative
CA125 levels to determine if the sensitivity could be increased with use of a
panel of markers including CA724. This holds true for all of the commercially
available markers assayed in small numbers in this thesis. Halila et al. (1988)
found pre-operative TATI elevated overall in 12/45 (27%) patients, fewer than
in this study. The sensitivity of serum p185 for EOC has not been reported to
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date, but less than 5% of patients with stages I and II had elevated levels in this
study.
In general, tumour markers are elevated in fewer patients with early stage
disease, seriously limiting their value in screening for ovarian cancer alone
(Roulston, 1990). No tumour marker to date has a sensitivity of greater than
50% for stage I EOC; furthermore, the sensitivity for "true" early disease - stage
la - is unknown.
CA125 was elevated in the serum of patients with all histological tumour types;
fewer patients with mucinous and clear cell tumours had elevated levels than
those with serous, endometrioid and poorly differentiated adenocarcinoma
(table 7.2). Kenemans (1991), collated data from 21 papers and reported
elevated pre-treatment CA125 levels in; 560/597 (94%) patients with serous
tumours, 91/97 (94%) patients with undifferentiated tumours, 74/85 (87%)
patients with endometrioid tumours, 20/26 (77%) patients with clear cell
tumours, 70/119 (59%) patients with mucinous tumours, 10/10 (100%) patients
with mixed tumours, and 20/21 (95%) patients with unclassified tumours. The
cumulative literature values are slightly higher than the results obtained in this
study for reasons given previously. However, there is close agreement
regarding the subtypes of tumours that most frequently overexpress CA125.
HMFG2 was most frequently elevated in patients with in descending order
poorly differentiated adenocarcinomas, serous, clear cell, endometrioid, and
mucinous tumours (table 7.2). There are no data in the literature to compare
serum elevation of HMFG2 in patients with different histological types. P185 was
also most frequently elevated in patients with poorly differentiated
adenocarcinoma, and to a lesser degree in patients with the other subtypes.
In descending order, TATI was most frequently elevated in patients with PDA,
clear cell, serous, endometrioid and mucinous tumours. TATI has been
advocated as a marker of mucinous EOC (Halila etal., 1988, Mogensen etai,
1990), but fewer patients in this study with mucinous tumours had elevated
levels than those with non-mucinous tumours. CA153, CA199 and CA724 were
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all elevated in the same patient with poorly differentiated adenocarcinoma.
There were little data to draw conclusions about the proportions of patients with
other tumour types, however CA724 was elevated in a higher proportion of
patients with mucinous tumours. Scambia et al. (1988) found elevated pre¬
operative CA153 in 23/30 (77%) patients with serous, 5/10 (50%) with
mucinous, 11/14 (78%) with endometrioid, and 2/3 (67%) with undifferentiated
tumour types. The range of values was lowest in patients with mucinous
tumours. Kobayashi et al. (1989) found elevated levels of TAG 72 (CA724) in
39% patients with serous, 52% with mucinous, 44% with endometrioid and 33%
with clear cell tumours. The authors advocated CA724 as a marker of mucinous
EOC on this basis.
The association between tumour grade and serum marker elevation is not well
documented for CA125, or for the other markers. A few studies have reported
increasing pre-treatment CA125 levels with decreasing degree of differentiation
(Brioschi et al., 1987, Schwartz et al., 1987, Vergote et al., 1987, Zanaboni et
al., 1987a), although the correlation was not always statistically significant
(Brioschi et al., 1987, Zanaboni et al., 1987a). In this thesis, CA125 levels were
elevated in the same proportion of patients with well and moderately
differentiated tumours, and in a greater proportion of patients with poorly
differentiated tumours (table 7.3 and figure 7.8).
The proportion of patients with elevated serum CA153 and HMFG2 increased
with decreasing degree of differentiation (table 7.3 and figure 7.8). P185 was
also elevated in serum in substantially more patients with poorly differentiated
tumours than well and moderately differentiated tumours (table 7.3 and figure
7.8). CA724 however showed the inverse correlation; degree of expression fell
with increasing tumour grade. Both TATI and CA199 were most frequently
elevated in patients with moderately differentiated tumours, and in a similar
proportion of patients with well and poorly differentiated tumours (table 7.3 and
figure 7.8).
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The statistical significance of these observations (tables 7.1, 7.2 and 7.3) was
not tested because of the difficulties in comparing marker elevations in patients
assayed at different times during their illness. The results in this chapter,
discussed so far, are only intended to give an approximation of the distribution
of each of the above markers in patient populations with different stages, types
and grades of tumour. The problem of comparing marker data obtained from
patients at different phases in treatment is recurrent throughout this chapter.
Receiver operating characteristic (ROC) curves were plotted for each tumour
marker assay using all data available (figure 7.9). These curves may be useful
in determining the cut-off value of a diagnostic test depending on the purpose
of the test. As all samples were included in the construction of these curves, all
that can be concluded from them is that CA125 is, in general, a far better
marker of EOC than any of the other markers in this thesis. This is not
surprising, as CA125 was elevated in a greater proportion of EOC patients than
all of the other markers (table 7.1). There is little difference overall between the
other markers, except for p185 which has an accuracy that differs little from
chance observation.
ROC curves were also plotted for each histological type (not shown), and the
area below compared to determine if there were any significant differences
between the performance of each test for different EOC subtypes (Hanley and
McNeil, 1982). CA125, CA153, CA199, and TATI were all significantly more
sensitive and specific markers of poorly differentiated adenocarcinoma than
other types that were compared (see section 7.3.2). These results were to be
expected given that each marker was elevated most frequently in patients with
poorly differentiated adenocarcinomas (table 7.2), the majority of whom have
advanced stage disease. CA724 was most sensitive and specific for mucinous
tumours, although only three patients with mucinous tumours had serial CA724
assay. There were no significant differences in overall sensitivity and specificity
between HMFG2 or p185 for different histological types, neither of which has
been advocated for a particular histological type.
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ROC curves however tell nothing about the predictive value of a test; PVP and
PVN are heavily dependent on the disease prevalence in a population, unlike
sensitivity and specificity (chapter 3, section 3.4.7, pp. 68-71). Consequently,
the predictive value of a positive result for each marker assay would be
expected to be higher for disease in patients with poorly differentiated
adenocarcinomas, and indeed other histological types, than mucinous
cystadenocarcinomas, the disease prevalence of the latter being considerably
lower. Thus, the sensitivity and specificity of a test may be higher for mucinous
compared to non-mucinous tumours, but this does not imply a higher PVP
(chapter 3, section 3.4.7, pp. 70-71).
Given that no single test can accurately determine disease status in all patients,
"panels" or combinations of markers have been intensely sought for the past
eight years since the first clinical report of CA125 (Bast et ah, 1983). The value
of each marker in addition to CA125 was investigated in two ways in this thesis.
Firstly, a stepwise discriminant analysis was performed to determine if any
marker could add significantly to the ability of CA125 to discriminate between
"disease positive" and "disease negative" samples. If the correlation between
two markers is high there is no point assaying both markers; cost may be
reduced by assaying the best marker. The correlations between CA125 and
CA153 (r=0.455) and CA125 and CA724 (r=0.403) were relatively high, and
only TATI and HMFG2 were able to add significantly to CA125 in this analysis
(see section 7.4.1).
Cost was a major limiting factor in the evaluation of the commercially available
markers in this thesis, and is likely to pose problems should any panel of
markers be adopted routinely. One way of circumventing this problem without
reducing diagnostic capability is to assay the most specific marker first, and
perform subsequent assays on samples that prove negative with the first test.
As CA125 is far superior to any marker discovered to date, it would seem not
unreasonable to assay a panel of markers in this "series" manner (Galen and
Gambino, 1975) employing CA125 as the first test. Indeed, the majority of
studies of marker panels to date have included CA125 as the "gold standard"
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to which other markers are compared. This method of panel testing has been
adopted in screening studies involving pelvic examination, ultrasound and
CA125 assay (Jacobs et al., 1990a). For these purposes a marker may be
considered as any test or investigative procedure capable of producing a
simple dichotomous outcome in relation to disease presence and not
necessarily a quantitative serological assay.
Assay of each additional marker in series with CA125 increased overall
sensitivity by less than 1% with combinations of CA125 and CA153, CA125 and
CA199, and CA125 and CA724, and by 3% and 2.9% respectively with CA125
and TATI, and CA125 and HMFG2 compared to CA125 assay alone (table 7.5).
Specificity was more markedly reduced by each panel, except for CA125 and
CA724 as no false positive CA724 results were noted. Thus, CA153 reduced
specificity by 3.4%, CA199 by 6.7%, TATI by 11.8%, and HMFG2 by 17.3%
(table 7.5). There was a concomitant increase in PVN with a greater fall in PVP,
resulting in an overall decrease in accuracy using each panel compared to
CA125 assay alone.
Both TATI and HMFG2 increased sensitivity by a marginally greater percentage
than CA153, CA199 and CA724, and there were more patients with both CA125
and TATI, and CA125 and HMFG2 data to evaluate. When these marker
combinations were investigated in more detail, sensitivity increased, while the
specificity of CA125 assay alone was retained, only in patients with advanced
poorly differentiated serous tumours, over 40% of whom had clinically evaluable
disease at the time of marker assay. It follows that the majority of patients had
no clinical evidence of disease at the time TATI or HMFG2 were elevated in
CA125 negative samples. There is considerable disagreement in the literature
regarding the use of marker panels to improve marker sensitivity. Investigators
tend either to advocate the use of various combinations of markers including
CA125, or recommend CA125 alone as the optimal test.
Although assay of TATI and HMFG2 in addition to CA125 each improved the
detection rate in patients with advanced poorly differentiated serous tumours,
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they also generated an equal number of false positive results in patients with
other disease stages, types and grades of tumour. The specificity of both of
these markers is therefore not sufficiently high to warrant their inclusion in a
panel of markers for monitoring all EOC patients. Moreover, these marker
panels identified residual or recurrent disease in patients with either clinical
evidence of disease and/or limited therapeutic options.
Bast and colleagues concluded that CA125 assay alone was better than a
panel of CA125, CA199 and CEA for monitoring EOC a year after the first
clinical report of CA125 (Bast eta!., 1984). Scambia etal. (1990) concluded that
CA724 gave no useful additional information to CA125, while Halila etal. (1988)
concluded that TATI gave no additional information to CA125 in patients with
non-mucinous tumours. The number of patients in their study is too small to
conclude that TATI is a clinically useful addition to CA125 in patients with
mucinous tumours, although recently Mogensen et al. (1990) found pre¬
operative TATI and CA125 assay was able to improve the discrimination
between benign and malignant mucinous tumours. Earlier in this study, assay
of placental alkaline phosphatase was found to be no use in addition to CA125
due to the high false negative and false positive rate of PLAP assay (Fisken et
al., 1989), this was corroborated at the time by Haije et al. (1988). Ward et al.
(1987c) however, reported pre-treatment assay of PLAP and HMFG2 in addition
to CA125 to increase sensitivity with CA125 alone from 96% to 100% in 26
patients with advanced disease, and from 18% to 64% in 11 patients with early
stage disease. As the disease prevalence in the population with advanced EOC
is 100%, their study is worthless. A positive result was defined as elevation of
at least one marker in the panel (Ward et al., 1987c), also used in this thesis.
The PVP of both PLAP and HMFG2 are, however, not sufficiently high to assist
CA125 in screening for early stage disease.
One approach to improving the specificity for screening or diagnosis, and limit
the number of false positives that result in unnecessary investigation, is to
stipulate that all markers in all panel should be elevated instead of at least one
to constitute a positive result (i.e. parallel testing). This approach has been
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adopted in screening studies (Bast et a/., 1990) where the consequences of
false positive results have more immediate widespread implications (chapter 3,
section 3.4.8, pp. 71-72). Achieving adequate sensitivity, and not specificity, is
more of a problem in monitoring, while achieving adequate specificity is more
of a problem in screening. It is unlikely therefore that this approach would
improve the ability of markers to detect occult disease in patients with
established EOC. Unless markers with similar or superior sensitivity and
specificity to CA125 are discovered it is unlikely that marker panels will influence
clinical decision making more than CA125 measurement alone.
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CHAPTER 8




The purpose of this study was to evaluate the role of tumour markers in
patients with established epithelial ovarian cancer. Pre-operative tumour marker
assay may aid the differential diagnosis of an adnexal mass, which could lead
to a more appropriate operation in a substantial proportion of patients with
ovarian malignancy (Gadducci eta!., 1988, Yedema etai, 1988, Jacobs etal.,
1990, Kenemans, 1991, also see chapter 3, section 3.6, p 76). Unfortunately,
samples taken prior to primary diagnostic laparotomy were unavailable,
therefore the markers' usefulness in this respect could not be assessed.
Ideally, absolute tumour marker levels should reflect viable tumour burden and
changes in levels should reflect the response to therapy and course of disease.
The former was assessed (i) after primary laparotomy by determining the
correlation between post-operative tumour marker levels and residual disease
and (ii) before second-look by determining the correlation between pre-second-
look tumour marker levels and findings at second-look. The latter was assessed
by determining the correlation between the change from pre-treatment to post-
treatment levels and response to first-line chemotherapy.
The above correlations are well documented for CA125, but are less well
documented for the other tumour markers (for reviews see Jacobs and Bast,
1989, and Kenemans et al., 1991). This chapter investigates the clinical
correlates of each tumour marker. More data were available for CA125, TATI,
HMFG2, and c-neu p185, hence these were studied more in more detail than
CA153 and CA199. CA724 was excluded due to lack of data.
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8.2 CORRELATION OF MARKERS WITH POST-OPERATIVE RESIDUAL
DISEASE
The primary operative procedures and extent of debulking, in the 250 patients
included in this study, were shown in chapter 5 (tables 5.5-5.8, pp. 120-122).
Overall, optimal debulking (i.e. residual disease <2cm) was achieved in 129/250
(51.6%) patients; 46/46 (100%) with stage I, 23/27 (85.2%) with stage II, 52/139
(37.4%) with stage III, and 8/38 (21.1%) with stage IV disease had <2cm
residual disease. The rate of successful debulking decreased with increasing
tumour grade; 23/31 (74.2%) well, 33/55 (60%) moderately and 49/126 (38.9%)
poorly differentiated tumours were optimally debulked. Tumour histology also
influenced the success rate; 66/147 (44.9%) serous, 29/41 (70.7%)
endometrioid, 15/22 (68.2%) mucinous, 7/18 (38.9%) adenocarcinoma, 11/17
(64.7%) clear cell, 1/3 (33.3%) mixed, and 0/2 unknown tumour types were
optimally debulked.
It is well known that surgical resection may cause a transient rise in marker
levels (Van der Zee et ai, 1990). Correlations with tumour burden were
therefore assessed in patients who had samples taken 1 -4 weeks after primary
laparotomy, before the initiation of further therapy. The first blood sample taken
for serial monitoring was usually obtained the day before chemotherapy
started; approximately four weeks after primary laparotomy.
Seventy seven patients had blood had samples taken during this period.
Sixteen patients had stage I disease, nine had stage II, 37 had stage III and 15
had stage IV disease. In this group there were 44 serous, 15 endometrioid,
seven mucinous, seven clear cell, two adenocarcinoma, one mixed and one
unknown histological type. Twelve tumours were well differentiated, 13 were
moderately differentiated, 38 were poorly differentiated, four were variably
differentiated (exact compositions were unknown), and 10 were of unknown
grade. Complete debulking was achieved in 16 patients, 24 had residual
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disease <2cm, 14 had 2-5cm residual disease, nine had >5cm residual
disease, and 14 had gross residual disease after biopsy only procedures.
Not all of the patients who had samples taken during this period had every
tumour marker assayed. Table 8.1 shows CA125 levels in 76 patients who had
samples assayed 1-4 weeks (mean 17.8 days, median 18 days, and range 3-28
days) after primary laparotomy. A wide range of CA125 levels were found in
patients in all residual disease categories.
Elevated CA125 was seen in 73.3% of patients who were completely debulked,
87.5% who had <2cm disease, and all patients with >2cm disease. Mean and
median post-operative levels increased with residual tumour volume, and this
correlation was highly significant (p< 0.0001). Patients with >2cm disease had
significantly higher CA125 levels than those with <2cm disease (p< 0.0001).
Table 8.1 Post-operative CA125 levels
Residual No. patients with CA125 (Umr1)
disease elevated CA125 (%) Mean SD Median Range
None 11/15 (73.3) 58.0 46.3 55.5 14-210
< 2cm 21 / 24 (87.5) 238.1 224.0 129.3 17.8-798
2 - 5cm 14/14 (100) 472.8 456.6 383.5 50.2-1933
> 5cm 9/9 (100) 548.7 440.4 458.0 70-1553
Gross 14/14 (100) 480.2 473.4 403.2 88-2000
Table 8.2 shows CA153 levels in 13 patients who had samples assayed 1-4
weeks (mean 17.5 days, median 17 days, and range 7-28 days) after primary
laparotomy. CA153 levels increased with tumour burden, but the trend was not
significant. Fewer optimally debulked patients had elevated post-operative
CA153 levels (33.3%) than those with residual disease >2cm (50%).
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Table 8.2 Post-operative CA153 levels
Residual No. patients with CA153 (Urnl1)
disease elevated CA153 (%) Mean SD Median Range
None 0 /1 (0) *11.8
< 2cm 3 / 8 (37.5) 29.8 22.6 23.3 7.3-77.2
2 - 5cm 1 / 3 (33.3) 36.5 23.5 24.6 21.3-63.3
> 5cm 1 / 1 (100) *65.9
* n=1
Table 8.3 shows CA199 levels in the same 13 patients who had CA153 assay
1-4 weeks after primary surgery. One patient with no residual disease had
markedly elevated post-operative CA199. Post-operative levels of CA199
showed no trend with tumour burden.
Table 8.3 Post-operative CA199 levels
Residual No. patients with CA199 (Urnl1)
disease elevated CA199 (%) Mean SD Median Range
None 1 / 1 (100) *341
< 2cm 3/8 (37.5) 39.2 52.9 15.6 9-166.5
2-5cm 0/3 (0) 16.3 4.3 14.5 13.3-21.2
> 5cm 1 / 1 (100) *42.9
* n=1
Table 8.4 shows TATI levels in 28 patients who had samples assayed 1-4
weeks (mean 18 days, median 18 days, and range 3-28 days) after primary
laparotomy. A wide range of TATI levels were found in patients in all residual
disease categories; 9/22 (40.9%) optimally debulked patients and 3/6 (50%)
with residual disease >2cm had elevated levels. Post-operative TATI levels did
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not correlate significantly with residual tumour burden and no trends were
observed.
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Table 8.5 shows HMFG2 levels in 62 patients who had samples assayed 1-4
weeks (mean 17.3 days, median 18 days, and range 3-28 days) after primary
laparotomy. There was a wide range of HMFG2 levels in patients in all residual
disease categories; 11/34 (32.3%) optimally debulked patients, 2/11 (18.2%)
with 2-5cm disease, and 10/17 (58.8%) with >5cm disease had elevated levels.
Table 8.5 Post-operative HMFG2 levels
Residual No. patients with HMFG2 (Uml1)
disease elevated HMFG2 (%) Mean SD Median Range
None 3/16 (18.8) 26.1 22.5 22.3 5-83.3
< 2cm 8/18 (44.4) 38.7 42.4 36.5 5-146.5
2 - 5cm 2/11 (18.2) 22.1 21.2 18.3 5-64.6
> 5cm 3/6 (50.0) 65.1 52.1 48.3 26.6-166.6
Gross 7/11 (63.6) 142.9 151.8 103.2 5-500
With the exception of the partially debulked group, mean and median HMFG2
levels increased with residual tumour volume. This correlation was highly
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significant (p<0.005). Although HMFG2 levels were not significantly different in
patients with <5cm disease, patients with >5cm residual disease had
significantly higher levels than those with <5cm residual disease (p<0.005).
Table 8.6 shows p185 levels in 38 patients who had samples assayed 1-4
weeks (mean 16.5 days, median 17 days, and range 7-28 days) after primary
laparotomy. No patient had elevated p185 after surgery, and there was no
correlation with tumour burden, even within the normal range.
Table 8.6 Post-operative p185 levels
Residual No. patients with p185 (Uml1)
disease elevated p185 (%) Mean SD Median Range
None 0/10 (0) 1121 179 1033 925-1440
< 2cm 0/11 (0) 966 191 915 685-1350
2 - 5cm 0/5 (0) 1271 367 1260 785-1820
> 5cm 0/4 (0) 866 248 833 610-1190
Gross 0/8 (0) 1087 434 1013 605-1760
8.3 CORRELATION OF MARKERS WITH RESPONSE TO FIRST-LINE
CHEMOTHERAPY
Over the period of this study, up to 10 different chemotherapy regimes were in
use, see chapter 5 and Appendix C. Therefore, to ensure adequate sample
sizes, patients who received different regimes were grouped according to UICC
response; complete response (CR), partial response (PR), stable disease (SD),
and progressive disease (PD) (see chapter 1, table 1.4, p 27). The correlations
between each marker and response were assessed in patients with samples
taken immediately prior to first-line chemotherapy, who also had a sample
assayed within one month of completion of therapy.
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Blood samples were not always taken precisely when a drug regime was
completed or when UICC response was determined. Fewer patients who had
pre-treatment samples had both pre-treatment and post-treatment samples,
however, the majority of patients described in section 8.2 were included. In
addition, a few patients who had pre-treatment samples taken outside the 1 -4
week post-operative period, as well as post-treatment samples, were included.
The treatment of each patient group will be described in more detail in sections
8.3.1 to 8.3.5.
8.3.1 Change in CA125 levels from pre-treatment to post-treatment
Pre-treatment and post-treatment CA125 levels in patients who received first-line
chemotherapy are shown in table 8.7.
Table 8.7 CA125 levels before and after first-line chemotherapy
No. CA125 (Uml1)
Response patients Sample Mean SD Median Range
CR 23 pre-Rx 445.2 629.6 227.3 10-2499
post-Rx 48.6 79.4 30.0 5-330
PR 13 pre-Rx 317.3 245.8 244.0 58.3-865
post-Rx 31.3 20.6 30.0 7.1-84.2
SD 10 pre-Rx 422.6 257.3 388.7 100-996
post-Rx 322.6 316.5 219.6 34-1006
PD 14 pre-Rx 496.2 606.1 356.5 68-2410
post-Rx 1059 1445.8 367.0 27-4920
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Figure 8.1 shows the individual changes in CA125 from pre-treatment to post-
treatment in the patients in table 8.1, described below in each response
category. Overall, change in CA125 levels showed a highly significant
correlation with response to first-line chemotherapy (p<0.005).
Twenty three patients (stages 1-1, II-2, 111-18, IV-2) who achieved CR had pre-
treatment and post-treatment samples assayed for CA125. Seventeen patients
were debulked to <2cm, five were partially debulked, and one had >5cm
residual disease. Sixteen patients had cisplatin/prednimustine, three had
cisplatin alone, two had cisplatin/a-interferon, and one had 5-fluorouracil/
cisplatin/hexamethylmelamine/prednimustine (5-FU/P/H/P).lnthisgroup,CA125
levels fell 10-fold on average; individually they fell in 21/23 (91.3%) and
increased in 2/23 (8.7%) patients (figure 8.1). Pre-treatment CA125 levels were
significantly higher than post-treatment CA125 levels (p<0.0001). Upon
completion of therapy, 4/23 (17.4%) patients had false positive CA125 results.
Thirteen patients (stages 11-1, III-5, and IV-7) who achieved PR had pre-
treatment and post-treatment CA125 assay. Six patients were debulked to
<2cm, while seven had >5cm residual disease. Six patients had
cisplatin/prednimustine, three had chlorambucil, two had cisplatin alone, one
had prednimustine alone, and one had 5-FU/P/H/P. In this group, CA125 levels
also fell 10-fold on average; individually they fell in 12/13 (92.3%) and increased
in 1/13 (7.7%) patients (figure 8.1). Pre-treatment CA125 levels were significantly
higher than post-treatment CA125 levels (p< 0.002). However, there was no
significant difference in CA125 response between complete and partial
responders. Upon completion of therapy, 9/13 (69.2%) patients who achieved
PR had false negative CA125 results.
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(n = 23) (n = 13) (n = 10) (n = 14)
Response to first-line chemotherapy
Figure 8.1 Change in CA125 levels from pre-treatment to post-treatment
values in individual patients in each response category.
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Ten patients (stages 11-2,111-7, and IV-1) who remained stable had pre-treatment
and post-treatment CA125 assay. One patient was debulked to <2cm, five were
partially debulked, and four had residual disease >5cm. Five patients had
cisplatin/prednimustine, one had cisplatin, and four had chlorambucil. In this
group, CA125 levels remained unchanged in 7/10 (70%) and fell in 3/10 (30%)
patients (figure 8.1). There was no significant difference between pre-treatment
and post-treatment CA125 levels. Only one patient (10%) had a false negative
post-treatment CA125 result.
Fourteen patients (stages 111-10, and IV-4) who progressed had pre-treatment
and post-treatment CA125 assay. Three patients were debulked to <2cm, five
were partially debulked, and eight had residual disease >5cm. Six patients had
cisplatin/prednimustine, and eight had chlorambucil. In this group, CA125 levels
increased in 9/14 (64.2%) and fell in 5/14 (35.8%) patients (figure 8.1). The
mean post-treatment CA125 level was greater than double the mean pre-
treatment level (table 8.1), although this difference was not significant. Only one
patient (7.1%) had a false negative post-treatment CA125 result.
8.3.2 Change in CA153 and CA199 levels from pre-treatment to post-
treatment
CA153 and CA199 were assayed in the same six patients (stages 11-1, III-5), all
of whom had a complete response to chemotherapy. Five patients were
debulked to <2cm, and one was partially debulked. All six patients had
cisplatin/prednimustine therapy. There were insufficient data to test for statistical
significance.
Pre-treatment CA153 levels were; mean 29.9 Umf1, sd 23.6 Uml"1, median 24.6
Urnl"1, and range 7.3-74.2 Urnl"1. Post-treatment CA153 levels were; mean 21.5
Urnl"1, sd 11.7 Uml"1, median 23.5 Urnl"1, and range 9-36.9 Uml"1. CA153 levels
fell in 4/6 (66.7%) patients and were unchanged in 2/6 (33.3%) patients in this
group.
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Pre-treatment CA199 levels were; mean 22.7 Urnl"1, sd 14.2 Uml"1, median 15.9
llml"1, and range 9-41.5 Umf1. Post-treatment CA199 levels were; mean 56.5
Urnl"1, sd 62.1 Umf1, median 20.8 Uml"1, and range 8.4-137.7 Uml"1. CA199
levels increased in 4/6 (66.7%) patients and were unchanged in 2/6 (33.3%)
patients. There were two (33.3%) false positive CA199 results and one (16.7%)
false positive CA153 result post-treatment.
8.3.3 Change in TATI levels from pre-treatment to post-treatment
Pre-treatment and post-treatment TATI levels were measured only in patients
who achieved CR and PR, shown in table 8.8. There were insufficient data to
test for statistical significance.
Table 8.8 TATI levels before and after first-line chemotherapy
No. TATI (|j.gr1)
Response patients Sample Mean SD Median Range
CR 6 pre-Rx 30.8 18.4 27.8 9.3-56.6
post-Rx 13.9 3.7 12.9 11-19.2
PR 3 pre-Rx 68.5 44.5 59 29.5-117
post-Rx 72.9 98.6 16.3 15.7-186
Six patients (stages 1-1,11-1, and III-4) who achieved CR had pre-treatment and
post-treatment TATI assay. Five patients were debulked to <2cm, and one was
partially debulked. Five patients had cisplatin/prednimustine, and one had
cisplatin alone. In this group, TATI levels fell in 5/6 (83.3%) and increased in 1/6
(16.7%) patients. There were no false positive TATI results upon completion of
therapy.
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Three patients (stages 11-1 and IV-2) who achieved PR had pre-treatment and
post-treatment TATI assay. Two patients were debulked to <2cm, and one had
>5cm residual disease. One patient had cisplatin, and two had chlorambucil.
TATI levels fell in 2/3 (66.7%) and increased in 1/3 (33.3%) patients in this
group. Two patients (66.7%) had false negative TATI results after therapy.
8.3.4 Change in HMFG2 levels from pre-treatment to post-treatment
Table 8.9 shows HMFG2 levels before and after first-line chemotherapy. Figure
8.2 shows the individual changes in HMFG2 from pre-treatment to post-
treatment levels in the patients in table 8.9 described below in each response
category. Overall, changes in HMFG2 levels did not show a significant
association with response to chemotherapy.
Table 8.9 HMFG2 levels before and after first-line chemotherapy
No. HMFG2 (Urnl1)
Response patients Sample Mean SD Median Range
CR 15 pre-Rx 53.6 59.9 38.3 5-202
post-Rx 24.9 42.6 5.0 5-129.8
PR 9 pre-Rx 37.3 27.6 46.6 5-73.3
post-Rx 26.8 30.3 11.3 5-86.6
SD 9 pre-Rx 46.3 54.2 18.3 5-162.5
post-Rx 40.1 27.4 20.0 16.6-78.3
PD 11 pre-Rx 90.3 115.5 53.3 5-350
post-Rx 74.7 64.5 58.3 5-210
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Response to first-line chemotherapy
Figure 8.2 Change in HMFG2 levels from pre-treatment to post-treatment
values in individual patients in each response category.
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Fifteen patients (stages 1-1,111-13, and IV-1) who achieved CR had pre-treatment
and post-treatment HMFG2 assay. Eleven patients were debulked to <2cm,
three were partially debulked, and one had residual disease >5cm. Eleven
patients had cisplatin/prednimustine, two had cisplatin alone, and two had
cisplatin/a-interferon. In this group, HMFG2 levels fell in 8/15 (53.3%), increased
in 3/15 (20%) and were unchanged in 4/15 (26.7%) patients (figure 8.2). The
mean pre-treatment HMFG2 level was greater than double the mean post-
treatment level (table 8.9), this difference almost achieved significance (p<0.07).
Two patients (13.3%) had false positive HMFG2 results upon completion of
therapy.
Nine patients (stages 11-1, III-3, and IV-5) who achieved PR had pre-treatment
and post-treatment HMFG2 assay. Four patients were debulked to <2cm, and
five had residual disease >5cm. Four patients had cisplatin/prednimustine, two
had cisplatin alone, and three had chlorambucil. In this group, HMFG2 levels fell
in 5/9 (55.6%), increased in 2/9 (22.2%) and were unchanged in 2/9 (22.2%)
patients (figure 8.2). The mean post-treatment HMFG2 level was almost two-
thirds that of the mean pre-treatment level (table 8.9), although this difference
was not significant. Seven patients (77.8%) had false negative HMFG2 results
after therapy.
Nine patients (stages II-2, III-6, and IV-1) who remained stable had pre-
treatment and post-treatment HMFG2 assay. One patient was debulked to
<2cm, four were partially debulked and four had residual disease >5cm. Five
patients had cisplatin/prednimustine, one had cisplatin alone, and three had
chlorambucil. In this group, HMFG2 levels increased in 5/9 (55.6%), fell in 2/9
(22.2%) and were unchanged in 2/9 (22.2%) patients (figure 8.2). There was no
difference between pre-treatment and post-treatment HMFG2 levels (table 8.9).
Five patients (55.6%) had false negative HMFG2 results after therapy.
Eleven patients (stages III-8 and IV-3) who progressed had both pre-treatment
and post-treatment HMFG2 assay. Two patients were debulked to <2cm, two
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were partially debulked, and seven had residual disease >5cm. Five patients
had cisplatin/prednimustine and six had chlorambucil. In this group, HMFG2
levels increased in 4/11 (36.4%), fell in 3/11 (27.2%) and were unchanged in
4/11 (36.4%) patients (figure 8.2). The mean pre-treatment HMFG2 level was
slightly higher than the mean post-treatment level (table 8.9), although the
difference was not significant. Four (33.3%) patients had false negative HMFG2
results after therapy.
8.3.5 Change in p185 levels from pre-treatment to post-treatment
Table 8.10 shows p185 levels before and after first-line chemotherapy.
Figure 8.3 shows the individual changes in p185 from pre-treatment to post-
treatment levels in the patients in table 8.10 described below in each response
category. There were insufficient data to test for significance.
Table 8.10 p185 levels before and after first-line chemotherapy
No. p185 (Urnf1)
Response patients Sample Mean SD Median Range
CR 5 pre-Rx 929 152 885 795-1190
post-Rx 1275 198 1290 975-1500
PR 4 pre-Rx 1759 1309 1210 910-3705
post-Rx 1361 160 1443 1150-1535
SD 5 pre-Rx 1126 345 1000 820-1680
post-Rx 1361 185 1355 1135-1620
PD 7 pre-Rx 1336 636 940 915-2445
post-Rx 1230 445 1330 785-2020
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(n = 5) (n-4) (n = 5) (n = 7)
Response to first-line chemotherapy
Figure 8.3 Changes in c-neu p185 levels from pre-treatment to post-
treatment in individual patients in each response category.
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Five patients (stages 111-4 and IV-1) who achieved CR had pre-treatment and
post-treatment p185 assay. Two were debulked to <2cm, two were partially
debulked, and one had >5cm residual disease. Two patients had cisplatin/
prednimustine, two had cisplatin/a-interferon, and one had cisplatin alone.
Levels of p185 fell in 1/5 (20%) and increased in 4/5 (80%) patients in this
group, however, all values were within the normal range (figure 8.3).
Four patients (stages 111-1 and IV-3) who achieved PR had pre-treatment and
post-treatment p185 assay. One was debulked to <2cm, two had >5cm
residual disease, and one had gross residual disease. One patient had
cisplatin/prednimustine, two had cisplatin alone, and one had chlorambucil.
Levels of p185 fell in 1/4 (25%), increased in 2/4 (50%), and were unchanged
in 1/4 (25%) patients in this group. All patients had false negative p185 levels
after therapy (figure 8.3).
Five patients (stages III-4 and IV-1) who remained stable had pre-treatment and
post-treatment p185 assay. Three patients were partially debulked and two had
gross residual disease. Three patients received cisplatin/prednimustine, one
had cisplatin, and one had chlorambucil. Levels of p185 fell in 1/5 (20%) and
increased in 4/5 (80%), however, all levels were within the normal range (figure
8.3).
Seven patients (stages III-6 and IV-2) with progressive disease had pre-
treatment and post-treatment p185 assay. Three were debulked to <2cm, one
was partially debulked and three had gross residual disease. Three patients
received cisplatin/prednimustine and four had chlorambucil. Levels of p185
increased in 3/7 (42.8%) and fell in 4/7 (57.2%) patients (figure 8.3), all but one
patient had false negative p185 levels after therapy.
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8.3.6 Correlation of markers with UICC response to chemotherapy
Various criteria have been used to assess the correlation between the change
in tumour marker levels and response to chemotherapy. Generally, doubling or
halving of marker levels are considered "clinically significant" changes. The most
commonly used criteria for a positive correlation are as follows: CR - 50% or
greater decrease in levels; PR - 50% or greater decrease in levels; SD - less
than a 50% increase or decrease in levels; PD - 100% or greater increase in
levels (Beastall et a/., 1991). Using these criteria, the correlations between
change in marker level and UICC response in the patients described in sections
8.3.1 to 8.3.5 were determined, see table 8.11.
Table 8.11 Correlation of change in marker levels with UICC response
Tumour No. patients in whom markers correlate with UICC response:
marker CR PR SD PD Total
CA125 19/23 12/13 7/ 10 8/14 46 / 60 (76.7%)
CA153 1 / 6 - - - 1 / 6 (16.7%)
CA199 0/6 - - - 0 / 6 (0%)
TATI 2/6 1 / 3 - - 3 / 9 (33.3%)
hmfg2 7/15 4/9 3/9 4/ 12 18/45 (40.0%)
p185 0/5 1 / 4 0/5 0/7 1 / 21 (4.7%)
Overall, CA125 correlated with response to first-line chemotherapy in 46/60
(76.7%) patients (table 8.11). Changes in CA125 levels agreed with response
in 19/23 (82.6%) patients who achieved CR, 12/13 (92.3%) who achieved PR,
7/10 (70%) with SD, and 8/14 (57.1%) with PD. Although CA125 response
correlated with CR in 19/23 (82.6%) patients, levels fell in 21/23 (91.3%) patients
(figure 8.1); fewer than 21 patients had a CA125 fall of >50%. This applied to
changes in all markers in patients in all response categories.
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CA153 correlated with CR in 1/6 (16.7%) patients (table 8.11) although levels
fell in 4/6 (66.7%) patients. There was no correlation between the change in
CA199 levels in six patients who responded completely. Changes in TATI levels
correlated with response in 3/9 (33.3%) patients (table 8.11), although marker
levels fell in 7/9 (77.8%) patients. Overall, changes in HMFG2 levels correlated
with response in 18/45 (40%) patients; 7/15 (46.7%) who achieved CR, 4/9
(44.4%) who achieved PR, 3/9 (33.3%) with SD, and 4/12 (33.3%) with PD.
C-neu p185 only correlated with response in one patient who achieved a partial
response.
8.4 CORRELATION OF MARKERS WITH SECOND-LOOK OUTCOME
The findings at second-look laparotomy and laparoscopy were described in
chapter 5, tables 5.9, 5.10, and 5.17, pp. 125, 127, and 132 respectively. Of the
250 patients in this study, 107 underwent second-look surgery; 21/46 (45.7%)
had stage I, 14/27 (51.8%) had stage II, 65/139 (46.8%) had stage III, and 7/38
(18.4%) had stage IV disease at diagnosis. Second-look operation (laparotomy
and laparoscopy) revealed no disease in 10/21 (47.6%), microscopic disease
in 5/21 (23.8%), and macroscopic disease in 6/21 (28.6%) patients with stage
I disease. Second-look operation revealed no disease in 10/14 (71.4%) stage
II patients, microscopic disease in 3/14 (21.4%), and the findings were unknown
in one case. Second-look operation revealed no disease in 31/65 (47.6%) stage
III patients, microscopic disease in 8/65 (12.3%), macroscopic disease in 15/65
(23%), bulky disease in 10/65 (15.3%), and findings were unknown in one case.
Three (42.8%) stage IV patients had negative second-look, 2/7 (28.5%) had
microscopic disease, 1/7 (14.2%) had macroscopic disease, and 1/7 (14.2%)
had bulky disease.
Therefore, the numbers of patients in each outcome group were small. In total,
54 patients had a negative second-look, 18 had microscopic disease, 22 had
macroscopic disease, 11 had bulky disease at second-look, and the findings
were unknown in two cases. The number of samples taken immediately prior
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to second-look was poor; for example, 16/107 (14.9%) patients had blood
samples taken for CA125 assay within one month of second-look, 42/107
(39.3%) and 69/107 (64.5%) had CA125 assay within two and three months of
second-look respectively, see chapter 6, p 139. Therefore, marker levels in
samples taken after primary chemotherapy, up to three months prior to
second-look surgery, were assessed.
8.4.1 Marker levels prior to second-look laparoscopy
There were insufficient data to assess CA153 and CA199, and since p185
showed no correlation with either tumour burden or response to therapy, it was
not evaluated. Table 8.12 shows the pre-second-look laparoscopy levels of
CA125, TATI, and HMFG2 and outcomes in 13 patients (stages I-4, 11-1, III-7,
and IV-1) who had blood samples taken within three months prior to this
procedure (mean 29.4 days, median 21 days, and range 0-56 days). In this
group, second-look laparoscopy was performed on average 8.9 months after
primary laparotomy (median 8.5 months, and range 5.6-14.7 months). All
patients were optimally debulked at primary laparotomy, except for three
(patients 8 and 12 were partially debulked and patient 13 had >5cm residual
disease). Three patients had no post-operative chemotherapy (all had stage la),
one had adjuvant chlorambucil and one had adjuvant cisplatin/a-interferon, one
had prednimustine, while the remaining seven patients had
cisplatin/prednimustine. Eleven patients had a complete clinical response and
two had a partial clinical response to first-line chemotherapy. No patient had
clinically evaluable disease prior to laparoscopy, except for patient 13 who
achieved PR and had a true positive CA125 level prior to operation. Patient 11,
who also achieved PR, had false negative CA125 and HMFG2 levels eight days
prior to demonstration of microscopic disease. Patients 5 and 6 had false
positive CA125 levels before laparoscopy (table 8.12).
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Thus, CA125 assay was false negative in 1/13 (7.7%) and false positive in 2/13
(15.4%) patients prior to laparoscopy. TATI assay was true negative in three
patients with CR at laparoscopy. HMFG2 assay was false negative in 1/10 (10%)
patients and false positive in none prior to laparoscopy.
8.4.2 Marker levels prior to second-look laparotomy
Tables 8.13a and 8.13b show the pre-second-look marker levels in 32 patients
(stages I-5, II-2, III-20, and IV-5) who had blood samples taken within three
months of second-look laparotomy. This was performed on average 8.8 months
after primary laparotomy (median 8.4 months, and range 2.0-37.5 months).
Fifteen patients were optimally debulked, seven were partially debulked, nine
had >5cm residual disease, and one patient had unknown residual disease. Of
the seven patients who had biopsy only at primary laparotomy, secondary
debulking was performed in three (patients 11, 12 and 15). Patient 2 had no
post-operative chemotherapy (after completely resected stage la), three
patients had adjuvant chlorambucil, one (patient 6) had whole abdominal
radiotherapy, two had prednimustine, four had cisplatin alone, seven had 5-
FU/P/H/P, and 13 had cisplatin/prednimustine.
Thirteen patients achieved pathological CR, 12 achieved pathological PR, one
had SD, two had PD after first-line chemotherapy. Three patients were
inevaluable (patients 4, 15 and 16); patient 4 had early stage disease which
was completely debulked and had adjuvant post-operative chlorambucil,
although positive washings were found at second-look there was no cytological
assessment at primary laparotomy for comparison. The other two inevaluable
patients only had biopsy at primary laparotomy for diagnostic purposes; patient
15 was debulked at second-look and patient 16 had unresectable disease.
Before operation, 23/32 (71.8%) patients had no evaluable disease and 9/32
(28.1%) patients had evaluable disease.
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CA125 was assayed within three months (mean 46.7 days, median 54 days,
and range 0-85 days) of second-look laparotomy in all 32 patients shown in
table 8.13. CA125 was elevated in 11 patients; one had no disease, one had
microscopic disease, five had macroscopic disease, and four had bulky
disease. CA125 was normal in 21 patients; 12 had no disease, four had
microscopic disease, two had macroscopic disease, and three had bulky
disease. Thus, CA125 was false negative in 9/32 (28.1%) patients and false
positive in 1/32 (3.1%) patients prior to second-look laparotomy.
TATI was assayed within three months (mean 42 days, median 54 days, and
range 0-70 days) of second-look laparotomy in 11 /32 patients shown in table
8.12. TATI was elevated in three patients; one had no disease, and two had
bulky disease. TATI was normal in seven patients; three had no disease, one
had microscopic disease, and three had macroscopic disease. Thus, TATI was
false negative in 4/10 (40%) patients and false positive in 1/10 (10%) patients
prior to second-look laparotomy.
HMFG2 was assayed within three months (mean 46 days, median 52 days, and
range 0-70 days) of second-look laparotomy in 18/32 patients shown in table
8.13. HMFG2 was elevated in seven patients; one had no disease, one had
microscopic disease, two had macroscopic disease, and three had bulky
disease. HMFG2 was normal in 11 patients; five had no disease, one had
microscopic disease, four had macroscopic disease, and one had bulky
disease. Thus, HMFG2 was false negative in 6/18 (33.3%) patients and false
positive in 1/18 (5.5%) patients before second-look laparotomy.
8.4.3 Sensitivity, specificity, accuracy, and predictive values of
CA125, TATI, and HMFG2 for disease at second-look operation
The sensitivity, specificity, accuracy, and predictive values of CA125, TATI, and
HMFG2 in determining outcomes of second-look laparoscopy and laparotomy
were calculated in the patients shown in tables 8.12 and 8.13 and described in
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the previous sections (8.4.1 and 8.4.2). The results are shown in table 8.14 (the
formulae for calculating these parameters were given in section 3.4.7, pp. 68-
69). There were insufficient data to calculate these parameters for TATI results
prior to laparoscopy.
Table 8.14 Value of markers in determining second-look outcome
No. patients
Tumour Second-Look disease %
marker procedure positive (%) Sensitivity Specificity Accuracy PVP PVN
CA125 Laparoscopy 2/13 (15.4) 50 82 77 33 90
Laparotomy 19/32 (59.4) 53 92 69 91 57
TATI Laparotomy 6/10 (60.0) 33 75 50 67 43
HMFG2 Laparoscopy 1/10 (10.0) 0 100 90 100 90
Laparotomy 12/18 (66.7) 50 83 61 86 45
The sensitivity of CA125 for detecting disease prior to laparoscopy and
laparotomy were poor, 50% and 53% respectively. CA125 was negative prior
to laparoscopy in the one patient with microscopic disease. Prior to laparotomy
CA125 was negative in 5/6 (83.3%) patients with microscopic disease, 2/8
(25%) with macroscopic disease, and 3/7 (42.8%) with gross disease (these
three patients had consistently false negative CA125 values). Specificity was
slightly higher for disease at laparotomy than laparoscopy, 92% and 82%
respectively. Although the sensitivity and specificity of CA125 for disease at
second-look laparoscopy and laparotomy were similar, the predictive value of
a positive result was higher for the outcome of laparotomy and predictive value
of a negative result was higher for the outcome of laparoscopy. This was simply
a result of the higher disease prevalence in the patient group who underwent
second-look laparotomy.
TATI had a sensitivity of 33% and specificity of 75% for disease at laparotomy.
TATI was false negative in 1/1 and 3/3 patients with microscopic and
macroscopic disease respectively. There were insufficient data to calculate
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these parameters for laparoscopy, only three patients with CR had TATI assay
and all had normal levels (table 8.12).
The sensitivity of HMFG2 before laparoscopy was zero because the HMFG2
level was normal in the only patient with disease (patient 11 had microscopic
disease) had a normal HMFG2 level. PVP was 100% for laparoscopy outcome
simply because there were no false positive results and the disease prevalence
was low (10%). HMFG2 assay had a similar though slightly lower sensitivity and
specificity for disease at laparotomy (50% and 83% respectively) compared to
CA125 assay, reflecting a similar proportion of false negative and false positive
results. HMFG2 was false negative in 1/2 (50%) patients with microscopic




Post-operative levels of CA125 (table 8.1) and HMFG2 (table 8.5), but none of
the other markers, showed a significant correlation with residual tumour burden.
There was no correlation between p185 levels and tumour volume; levels were
within the normal range in all patients assayed post-operatively (table 8.6).
There were insufficient data to evaluate the correlation with tumour volume for
the other markers in this thesis.
Scambia etal. (1988), in a pilot study of CA153 in EOC patients using a cut-off
value of 30 Uml"1, found CA153 elevated in 0/5 patients with completely
resected tumour, while 5/10 (50%) and 10/14 (71%) patients with <2cm and
>2cm residual disease had elevated CA153 levels three weeks after
laparotomy. CA153 levels correlated with both pre-operative and post-operative
tumour volume in their study; patients with advanced disease had significantly
higher CA153 levels than those with stage I disease (Scambia et a!., 1988).
Scambia et at. (1990) later evaluated CA724 in EOC patients and found levels
elevated in 1/4 (25%) patients with no residual disease, 0/3 with <0.5cm
residual disease, and 5/12 (42%) patients with >0.5cm residual disease using
a cut-off value of 7 Urnl"1. Halila et al. (1988) did not assay TATI in samples
taken in the first month after surgery in their study, as Matsuda et al. (1985)
had previously shown transiently elevated levels of pancreatic secretory trypsin
inhibitor (PSTI), which is homologous to TATI, after surgery. There are no data
in the literature regarding post-operative serum TATI levels in EOC patients,
although in this thesis a higher proportion of patients with residual disease
>2cm had elevated post-operative levels than patients with <2cm residual
disease (table 8.4). Canney et al. (1985) found elevated CA199 after surgery
(exact length of time after surgery is unclear) in 4/18 (22%) patients with <2cm
residual disease, 5/13 (28%) patients with 2-10cm residual disease, and 7/24
(23%) patients with >10cm residual disease. CA199 levels showed no
correlation with residual tumour burden in their study (Canney et al., 1985).
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Thus, all tumour markers assayed in this study have been found elevated to
some degree after surgery.
CA125 was elevated in a high percentage of patients in all residual disease
categories, including all patients with >2cm residual disease (table 8.1).
Paradoxically, 73.3% of patients regarded as completely debulked had elevated
CA125 1-4 weeks after surgery. In the absence of other disease processes
which may cause marker elevation (for review see Kenemans, 1991, also see
sections 2.4.1 to 2.4.7, pp. 43-55), abnormal post-operative marker levels in
completely resected patients may reflect one or a combination of the following;
inaccurate measurement or recording of post-operative residual disease, a slow
plasma clearance or release caused by peritoneal trauma. Interestingly, levels
of both TATI and HMFG2 were lower in patients documented with 2-5 cm
residual disease (after partial debulking) than patients with <2cm disease. This
may reflect inaccurate assessment of residual disease, although this was not
the case with CA125. However, more patients in this category had CA125 assay
than TATI or HMFG2 assay, and there may be unintentional selection of patients
with inaccurate recording of residual disease for TATI and HMFG2 assay.
To date, several studies have investigated serum CA125 in the immediate post¬
operative phase. Redman et al. (1988) found elevated CA125 in peritoneal
lavage fluid but not in serum, however, they only studied six patients with a
post-operative follow-up of five days. Talbot et al. (1989) found rising CA125
levels following abdominal surgery in patients with a variety of benign and
malignant diseases. Declining post-operative levels were also found in patients
with elevated pre-operative CA125, suggesting the effect of laparotomy was
masked by removal of the CA125 shedding tumour in these patients (Talbot et
al., 1989). More recently, Van der Zee et al. (1990) studied post-operative
CA125 in three groups of patients, all with normal pre-operative levels, who
underwent abdominal surgery for either EOC, cervical cancer or aortic disease.
Post-operative CA125 was elevated in 82% of patients irrespective of primary
diagnosis. CA125 was measured daily for two weeks after surgery and then
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weekly for five weeks in EOC patients. The highest levels were found nine days
after laparotomy, gradually returning to normal 3-4 weeks after surgery (Van
der Zee et al., 1990). This agrees with the earlier findings of Crombach et at.
(1985) who reported a return to normal CA125 levels 3-6 weeks after
laparotomy in their patients. Thus, CA125, and possibly other markers elevated
after surgery, may have limited value in this period (see discussion of
prognostic value of early CA125 and HMFG2 assay in chapter 9, p 238).
Chemotherapy may also cause a transient elevation in serum markers. Canney
et al. (1984) found an acute rise in CA125 levels within the first week of
administration of chemotherapy. Such early serum "spikes" after treatment are
thought to reflect successful tumour cell lysis and antigen release, and
consequently predict a good response (Canney et al., 1984). As tumour
markers may take several weeks to return to "baseline" values in the intervening
time between surgery and chemotherapy and between cycles of chemotherapy,
the most appropriate time (and logistically the easiest) to take samples for
monitoring response to chemotherapy, is immediately prior to administration of
each cycle. In this thesis, patients had their first blood sample taken for marker
assay a median 18 days after laparotomy and within days of initiation of primary
chemotherapy. Subsequent samples were usually obtained the day before each
cycle of chemotherapy, or at each clinic or ward visit in patients off treatment
or in hospital for investigation or other treatment.
Patients were grouped according to UICC response to determine the
correlation between change in marker levels with response to first-line
chemotherapy. Each group consisted of patients with different stages, grades,
tumour types etc., and therefore represented heterogeneous populations. In
general, tumour markers were elevated in a greater proportion of patients with
advanced disease, poorly differentiated tumours and tumours of serous,
adenocarcinoma and clear cell types (see chapter 7, tables 7.1, 7.2, and 7.3,
pp. 152, 160 and 161 respectively). Comparisons between different markers
must therefore be drawn with caution.
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Only CA125 showed a statistically significant correlation with overall response
to first-line chemotherapy. Levels fell on average ten-fold in patients who
achieved CR and PR, were unchanged in patients with stable disease, and
increased two-fold in patients with progressive disease. Levels of CA153, TATI
and HMFG2 fell in the majority of responders. There were insufficient data to
fully evaluate the correlation with each response for all the other markers,
except for HMFG2 and p185. CA153, CA199, CA724 and TATI have been
evaluated in more detail by other investigators due to the commercial availability
of these tumour markers.
Scambia etal. (1988) found rising CA153 levels in 5/5 (100%) patients with PD,
and falling levels in 10/12 and 6/8 patients who achieved CR and PR
respectively. Levels were unchanged in the other four responders (Scambia et
al., 1988). These authors also monitored EOC with CA724 and found falling
levels in 10/11 responders and increasing levels in 2/7 non-responders. No
distinction was made between CR and PR or between SD and PD (Scambia et
al., 1990). Halila etal. (1988) found increasing TATI levels in 10/19 (53%) EOC
patients with PD, decreasing levels in 4/35 (11%) responders (CR and PR) and
unchanged levels in 5/7 (71 %) patients with stable disease. In a series of 55
EOC patients monitored with CA199, change in levels correlated with response
in 3/3 patients who responded to therapy and 9/9 non-responders in those
patients that initially overexpressed CA199 (Canney et al., 1985). In an earlier
report, Bast etal. (1984) found a correlation between CA199 and response to
therapy in only 2/6 (33%) patients with SD who had initially elevated levels.
Change in CA199 levels did not correlate with CR, PR or PD in any of their
patients (Bast et al., 1984).
In this thesis, HMFG2 levels fell two-fold on average in patients who achieved
CR, fell on average by one-third in patients who achieved PR, and were
unchanged in those with stable and progressive disease, although levels were
highest in patients with PD (table 8.9). To date there have been two studies of
HMFG in EOC patients, both involving small numbers of patients with poor
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follow-up. Ward and Cruickshank (1987), using the same HMFG2 antibody,
found HMFG2 elevated in 2/12 (15%) patients in complete remission and 16/20
(80%) patients at relapse, but they had insufficient samples and follow-up to
evaluate the effects response to therapy or course of disease on HMFG2 levels.
Patients with progressive disease however had significantly higher HMFG2
levels than those in remission (Ward and Cruickshank, 1987), as also observed
in this study. Ashorn et al. (1988) reported increasing levels of HMFG, using
their antibody designated HMFG III C12, in 6/7 patients with PD, stable levels
in 4/5 patients with stable disease, and decreasing levels in 1/5 responders (no
distinction was made between CR and PR). Their results were not significant
owing to the small number of patients (Ashorn etal., 1988). The authors of both
of these studies suggested that overexpression of HMFG may be indicative of
a poor prognosis, but did not quantitate their observations further.
P185 levels were elevated in serum from 17/21 (85%) patients with clinically
obvious progressive disease (mean CA125 levels in patients with elevated p185
were 1276 Uml"1, median 445 llml"1, range 14-7157 Uml"1). Not surprisingly,
p185 showed no correlation with response to therapy. Strong evidence exists
for roles for the oncogenes c-myc, K-ras, neu and their proteins in ovarian
cancer pathogenesis (Gullick, 1990), but p185 elevation in serum was of no use
in monitoring EOC patients.
In this thesis, 82.6% and 69.7% patients who achieved CR and PR respectively
had post-treatment CA125 levels <35 Urnl"1 (figure 8.1). HMFG2 showed a
similar false negative rate in partial responders; 86.7% and 77.8% of patients
who achieved CR and PR respectively had post-treatment HMFG2 levels below
the cut-off value (figure 8.2). There were no significant differences between pre-
treatment and post-treatment CA125 or HMFG2 levels in those who achieved
CR and PR. Thus, it was not possible to distinguish CR and PR. The first
longitudinal study by Bast etal. (1983) concluded that CA125 levels <35 Urnl"1
may or may not be associated with CR. Since the original report, several
authors have corroborated Bast's findings (Canney et al., 1984, Goldhirsch et
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al., 1988, and Onetto et a/., 1989). Two studies have shown, in addition, that
upon completion of primary chemotherapy, patients who were disease free
always had CA125 levels <35 Uml"1 within three months of initiation of therapy
(Brioschi etal., 1985, and Lavin et al., 1987).
Change in CA125 levels correlated with overall response in 76.7% of patients,
while change in HMFG2 levels correlated with overall response in 40% of
patients (table 8.11). The correlation between CA125 and course of disease in
earlier studies was consistently higher; CA125 correlated overall with response
in 94% (Bast etal., 1984), 91.3% (Canney etal., 1984), 89% (Crombach et al.,
1985), and 95.7% (Brioschi et al., 1987) of cases, although in a later review of
the literature Kenemans et al. (1988) report a range of 76% to 95% with an
overall correlation of 87%. These studies all used the same criteria for
correlation, i.e. a doubling or halving of levels were considered "significant"
since the magnitude of these changes are unlikely to be due to chance assay
variability. It is however possible that small changes in serum marker levels,
even within the normal range, may be an early indication of a changing tumour
volume. There were insufficient data to assess the overall correlation with
CA153, CA199, and TATI.
Scambia et al. (1988) reported a good overall correlation between CA153 and
response to therapy in 21/25 (84%) patients. Later they reported an overall
correlation between CA724 and response to therapy in 12/18 (66%) patients
(Scambia etal., 1990). The authors however use more lenient criteria to obtain
these correlations; defining a "significant" change in serum marker level as
greater than a 50% decrease or increase in levels (Scambia et al., 1988 and
1990). Halila et al. (1988) report an overall correlation between TATI and
response to therapy in 19/61 (31%) patients using the generally accepted
criteria applied in this thesis. Overall, the correlation between CA199 and
response is very poor as less than 30% of EOC patients express this marker
in their serum (Bast et al., 1984, Canney et al., 1985).
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The percentages of patients in whom CA125 and HMFG2 correlated with
response were higher in responders than non-responders (table 8.11).
Chemotherapy is thought to permit selective multiplication of cells which have
lost the ability to express markers in patients who develop drug resistance. This
would explain why levels are not often as high as may be expected in patients
with disease progression, and why there was a poorer correlation between
non-responders than responders in this study. Furthermore, the size and site
of persistent or recurrent lesions may have an influence on serum marker
levels.
It is generally accepted that rising CA125 levels are more predictive of
progressive disease than falling levels are of response (for reviews see
Lambert, 1987, Finkler et ai, 1988, and Kenemans, 1991). At first sight this
would appear to contradict the previous paragraph. For a "true" correlation, or
accurate reflection of post treatment disease status, post-treatment marker
levels should be below the cut-off value in patients with CR, and should either
remain elevated in patients with PR, SD, or PD, or become elevated with PD.
The majority of studies reported in the literature do not apply such strict criteria.
Markers returned to levels below the cut-off values upon completion of
chemotherapy in most patients who had either complete or partial response in
this thesis. It must be concluded that the definitions of response are at present
inadequate, as they make no attempt to distinguish between CR and PR.
"Marker response", like clinical response, does not equate with pathological
response. This is directly attributable to the lack of sensitivity of tumour markers
for small volume disease. This problem of definition of "marker" response is
currently being addressed by Rustin (personal communication).
At present, monthly CT scanning is the most reliable method of determining
disease status (Brioschi et at., 1985) but is insensitive for disease <1cm. The
only accurate method of determining response to chemotherapy is by second-
look surgery. In this study, 107/250 (42.8%) patients underwent second-look
operations. The majority of patients had no clinically evaluable disease prior to
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operation, although in total, 1/12 (8.3%) and 9/22 (40.9%) of those had residual
or recurrent disease at second-look laparoscopy (table 8.12) and laparotomy
(tables 8.13a and 8.13b) respectively.
The sensitivity and specificity of CA125 were similar for the outcome of both
second-look laparoscopy and laparotomy (table 8.14). PVP was higher for
laparotomy outcome (91%) than laparoscopy outcome (33%) due to the higher
disease prevalence in the patient group that underwent laparotomy. Conversely,
PVN was higher for the outcome of laparoscopy (90%) than laparotomy (57%)
due to the lower disease prevalence in the patient group that underwent
laparoscopy. TATI was less sensitive than CA125 for outcome at second-look
laparotomy (table 8.14). This was to be expected given the findings of a poorer
correlation between TATI levels and response to therapy. The results of HMFG2
prior to laparoscopy are inconclusive because a small number of patients were
assayed and only one was disease positive. Prior to laparotomy, HMFG2 was
slightly less sensitive and specific than CA125, consequently the PVP and PVN
were also lower (table 8.14).
The literature to date shows similar sensitivity and specificity for CA125 prior to
second-look operation to those found in this thesis. Niloff et al. (1985) first found
negative CA125 prior to second-look laparotomy in 22/36 (61%) patients with
residual or recurrent disease. Other authors have reported negative CA125
levels in 10/20 (50%) (Alvarez et al., 1987), 11/15 (73%) (Patsner et al., 1987),
9/20 (45%) (Zanaboni etal., 1987) patients with disease. Schilthius et a/. (1987)
found microscopic disease in 15/17 (88.2%) and macroscopic disease <2cm
in 11/13 (84.6%) patients with negative CA125 prior to second-look laparotomy.
Kenemans (1991), in a review of the CA125 literature to date, report a
cumulative false negative CA125 rate of 48% using cut-off values of 35 Urnl"1
and 65 Urnl"1. Increasing the cut-off value from 35 Urnl1 to 65 Urnl"1 lowered the
false positive rate from 5% to 0% (Kenemans, 1991).
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CA153 had a sensitivity of 33% and specificity of 100% prior to second-look
laparotomy; 2/2 patients with microscopic disease and 4/7 patients with
macroscopic disease had normal CA153 results (Scambia eta!., 1988). CA724
had a sensitivity of 38% and specificity of 100% prior to sceond-look
laparotomy; 3/3 patients with microscopic disease and 5/10 with macroscopic
disease had normal CA724 results (Scambia eta!., 1990). In addition, CA724
did not add to CA125 in Scambia's study. Halila etal. (1988) found serum TATI
elevated in 2/22 patients with no disease, 3/8 with microscopic disease and
3/18with macroscopic disease pre-sceond-look laparotomy; TATI therefore had
a sensitivity of only 19% and specificity of 91% for second-look outcome. No
data exists regarding the sensitivity and specificity of CA199 for disease at
second-look. Given that CA199 is expressed in fewer than 30% of EOC patients
and has shown no correlation with post-operative tumour burden (Canney et
a!., 1985), the correlation with disease at second-look is expected to be very
poor. Hence, none of the markers investigated to date is as sensitive as CA125
for occult disease.
Several alternative methods of determining disease status prior to second-look
laparotomy have been evaluated. Mogensen et al. (1988) found that pelvic
examination under anasthesia gave no additional information to CA125 assay.
Recently, Moskovic etal. (1991) have shown prospectively that CT scanning is
more sensitive than CA125 for detecting disease prior to second-look
laparotomy. Perkins et al. (1990), in a pilot study comparing novel scanning
methods to CA125 serum assay, found radioimmunoscintigraphy using 1311
labelled OC125 and magnetic resonance imaging both to be more sensitive
than CA125 assay.
Some investigators have advocated different tumour marker panels to increase
the sensitivity for disease prior to laparotomy. Lahousen et al. (1989) have
found a combination of CA125, ferritin, tissue polypeptide antigen (TPA) and
CEA useful for deciding whether or not to perform second-look laparotomy.
McGuckin et al. (1990) have recently developed two novel assays for the
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ovarian cancer-associated antigens OSA (ovarian serum antigen) and CASA
(cancer associated serum antigen) using the same catcher antibody BC-2 and
different tracer antibodies OM-1 and BC-3 for OSA and CASA respectively.
They report elevation of OSA and CASA in 82% and 76% of 80 samples
compared to 82% elevation with CA125 assay (McGuckin et al., 1990). In
addition, the authors claim these assays are more sensitive for occult disease
at second-look than CA125, meriting further investigation.
Tumour markers however cannot replace second-look laparotomy as the
definitive technique for determining response to chemotherapy and disease
status. In the only prospective randomised trial of it's kind, Luesley etal. (1988)
showed conclusively that second-look has no impact on overall survival. Most
authors would agree with the conclusions of Chambers et al. (1988) that
second-look laparotomy should be reserved for trial situations only, where
accurate documen-tation of response (pathological as opposed to clinical) is
necessary. However, Lippman et al. (1988) argued that resection to <2cm
resulted in a significant improvement in survival compared to those patients
resected to >2cm at second-look laparotomy. The decreasing trend in recent
years in the performance of second-look laparotomy owes more to the
demonstration that it lacks survival benefit, rather than the growing use of
markers to determine response to first-line therapy. Undoubtedly certain
patients do benefit from this procedure. Unless cytoreductive surgery is
contemplated, second-look surgery may be avoided in patients with persistently
elevated serum tumour markers.
The inability to distinguish CR from PR in patients with no clinically evaluable
disease has important implications. It is often possible to convert a partial to a
complete response by continuation of therapy. This may improve disease free
survival in these patients and ultimately overall survival. Also, patients who
respond completely, but who are at a high risk of early relapse, may benefit
from consolidation therapy. Up to 30% of patients with negative second-look
relapse within five years of operation (Gershenson et al., 1985, Podratz et al.,
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1988). Prognostic factors that would help identify such patients would be useful




The Prognostic Value of CA125 and HMFG2
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9.1 INTRODUCTION
Prognostic factors are sought not only to help understand the natural history
of a disease, but also to assist in the guidance and information given to
patients, and ultimately to help select treatment. Numerous factors of
prognostic importance have been identified in epithelial ovarian cancer patients.
These include: age (Bjorkholm et a/., 1982, Dembo and Bush, 1982, Schray et
al., 1983, Sevelda et ai, 1990), performance status (Swenerton etal., 1985,
Heintz et al., 1988 and 1990), ascites (Heintz et al., 1988 and 1990), stage
(Bjorkholm et al., 1982, Redman et al., 1986, Slotman et al., 1990), diameter
of primary tumour (Heintz et al., 1990), diameter of largest metastasis
(Heintz etal., 1990), site of metastases (Heintz etal., 1990), residual disease
(for reviews see Webb, 1989 and Voest etal., 1989), histological tumour type
(Bjorkholm etal., 1982), tumour grade (Dembo and Bush, 1982, Schray etal.,
1983, Swenerton etal., 1985, Slotman etal., 1990, Sevelda et al., 1990), ploidy
(Friedlander et al., 1988, Kallioniemi et al., 1988, Klemi et al., 1988),
psammomabody content (Kuhn et al., 1988), oestrogen receptor content
(Leake and Owens, 1990), progesterone receptor content (Leake and Owens,
1990, Slotman etal., 1990, Sevelda etal., 1990), transforming growth factor
a (Artega et al., 1988), and epidermal growth factor receptor (Bauknecht et
al., 1988). These studies have shown that response to treatment and survival
are vastly influenced by a variety of inter-connected disease and patient related
factors.
Earlier studies of prognostic factors were generally based on univariate analysis
(Richardson et al., 1985) which failed to account for the interactions of related
variables. Griffiths (1975) was the first to use multivariate analysis to decipher
the effects of several factors. Over the past 15 years, there has been growing
use of multivariate analysis to identify unrelated factors with the greatest impact
on survival. Such independent prognostic factors can be modelled to predict
the risk category of an individual patient and are essential for comparison, or
stratification, of clinical studies.
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Many authors have reported the prognostic significance of early CA125 assay
(chapter 3, section 3.7.5, p82). Thus, pre-operative measurement (Lavin eta!.,
1987, Vergote eta!., 1987), post-operative measurement (Redman etal., 1990,
Rosen etal., 1990), absolute levels after one (Rosen etal., 1990), two (Sevelda
et al., 1989, Redman et al., 1990), and three (Lavin et al., 1987) cycles of
primary chemotherapy, the half-life (Van der Burg etal., 1988, Hawkins et al.,
1989), and rate of fall (Rustin et al., 1989) after the first cycle of chemotherapy
have all been advocated as useful prognostic indicators. However, there is no
consensus yet as to which is the most useful indicator. Clarification of the
prognostic value of CA125 is essential if this information is to help early
treatment decisions. To date, the prognostic value of serum HMFG2 assay has
not been determined in ovarian cancer, although Ward and Cruickshank
(1987b) and Ashorn et al. (1988) suggested overexpression may be a poor
prognostic factor.
The sensitivity of CA125 for occult disease is poor. Nevertheless, CA125
provides a lead time to clinical relapse or recurrence in the majority of patients
(for review see Kenemans, 1988). The ability of HMFG2 to provide clinical lead
times is unknown. The impact on survival of therapeutic intervention at pre¬
clinical "serological" diagnosis of relapse however remains to be addressed.
This chapter investigates the prognostic value of early CA125 and HMFG2
assay and the ability of both markers to provide lead times in patients who
have responded to their first course of chemotherapy. In addition, the relative
importance of routine CA125 assay compared to conventional methods of
assessing disease progression is evaluated. The implications for clinical
decision making are discussed.
9.2 PROGNOSTIC FACTORS FOR EOC
The initial disease characteristics of the 250 patients included in this study were
shown in chapter 5, table 5.1, p 117. During case note review, available
prognostic factors ofmajor importance were recorded. These included; residual
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disease, stage, tumour grade, histological type, age at diagnosis, performance
status (before initiation of chemotherapy), and whether ascites and adhesions
were present at primary laparotomy. The prognostic significance of CA125 and
HMFG2 together with the above factors were investigated by univariate analysis
in patients with advanced disease (FIGO stages III and IV), and the relative
importance of each determined using multivariate analysis (Univariate and
multivariate analyses were performed using the SAS Lifetest procedure which
determines the x2 statistic for the Wilcoxon test. Cox's proportional hazard
model was not available on SAS.) All histological types were combined because
of the small numbers of patients with non-serous tumours. There were
insufficient data to analyse prognostic factors in patients with stages I and II
disease.
The prognostic significance of each factor was determined in the immediate
post-operative period and after each cycle of first-line chemotherapy (irres¬
pective of regime) for its duration. Samples taken from patients after completion
of six cycles of therapy were excluded due to insufficient numbers. Samples
were usually assayed for markers the day before, and therefore three weeks
after, each cycle was administered. One hundred and twenty seven patients
had blood samples taken during this period. Not all patients however had
samples taken after surgery and after each cycle of chemotherapy. Therefore,
different patient groups were assessed at each time point, although there was
an overlap of approximately 50% between each group. Consequently, the
significance levels quoted at different times are not directly comparable. Section
9.3 will examine one of these patient groups in more detail.
9.2.1 Factors influencing progression free survival in patients with
advanced disease
The progression free survival (PFS) of patients with stages III and IV were
shown in chapter 5, table 5.18, p 113. True dates of progression depend on the
methods and frequency of patient monitoring, and are inevitably earlier than
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recorded progression dates. The results of univariate analysis are shown in
table 9.1. The number of patients in each group are shown in brackets.
Table 9.1 Factors influencing progression free survival during first-line
chemotherapy in patients with advanced disease













CA125 ns 0.0005 0.01 0.0005 0.0005 0.05
hmfg2 ns 0.05 0.005 0.01 ns ns
*RD 0.0005 0.05 0.005 ns 0.002 0.05
Grade ns ns ns ns ns ns
Ascites ns ns ns ns ns ns
Adhesions ns ns ns ns ns ns
*PS 0.005 0.005 ns 0.05 ns ns
Age 0.0005 0.01 ns ns ns ns
* RD - Residual disease, PS - Performance status
After primary surgery, before the start of chemotherapy, the extent of residual
disease (p<0.0005), age at diagnosis (p<0.0005), and performance status
(p< 0.005) were the most significant predictors of PFS. No other factors were
significant at this time. Tumour grade, and presence of ascites or adhesions
were not significant predictors of PFS at any time. After one cycle of therapy
(approximately two months after surgery), CA125 (p<0.0005) was by far the
most significant predictor of PFS; performance status (p<0.005), residual
disease (p<0.05), HMFG2 (p<0.05), and age at diagnosis (p<0.01) were also
significantly associated with PFS. After two cycles, residual disease (p<0.005),
HMFG2 (p<0.005), and CA125 (p<0.01) were significant. After three cycles,
CA125 (p<0.0005), HMFG2 (p<0.01), and performance status (p<0.05) were
significant. After four cycles, CA125 (p< 0.0005) and residual disease (p< 0.002)
were significant. After five cycles, CA125 (p<0.05) and residual disease
(p<0.05) were significant. Thus, CA125 and HMFG2 were both significant
predictors of PFS after one cycle of primary chemotherapy, and remained
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significant for a further four and two cycles respectively. Table 9.2 shows the
results of multivariate analysis of these factors.
Table 9.2 Multivariate analysis of prognostic factors influencing
progression free survival
Post cycle Most significant Additional independent
number prognostic factor prognostic factor(s)
Pre-Rx Age at diagnosis (p< 0.0005) Performance status (p<0.05)
1 CA125 (p<0.0005) none
2 HMFG2 (p<0.005) Performance status (p<0.05)
3 CA125 (p< 0.0005) none
4 CA125 (p< 0.0005) none
5 Residual disease (p<0.05) none
After surgery, age at diagnosis was the most significant predictor of PFS
(p<0.0005), independent of performance status (p<0.05). No other factor
achieved significance. After one cycle of chemotherapy, CA125 was the most
significant predictor of PFS (p< 0.0005). No other factor achieved significance
independently of CA125. After two cycles, HMFG2 was the most significant
predictor of PFS (p<0.005), independent of performance status (p<0.05). After
three and four cycles, CA125 was the most significant predictor of PFS
(p< 0.0005). No other factor achieved significance independently of CA125.
After five cycles of chemotherapy, residual disease was the most significant
predictor of PFS (p<0.05), and no other factor achieved significance.
9.2.2 Factors influencing survival in patients with advanced disease
The survival of the total population was described in chapter 5, table 5.19,
p 134. The results of univariate analyses of the above factors are shown in table
9.3. The number of patients in each group are shown in brackets.
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Table 9.3 Factors influencing survival during first-line chemotherapy in
patients with advanced disease













CA125 ns 0.005 0.005 0.0005 0.0002 0.05
hmfg2 ns 0.05 0.005 0.002 ns ns
*RD 0.01 0.02 0.05 ns 0.02 0.05
Grade ns ns ns ns ns ns
Ascites ns 0.05 ns ns ns ns
Adhesions ns 0.02 ns ns ns ns
*PS 0.005 0.001 0.05 0.02 0.02 0.05
Age 0.002 0.05 ns ns ns ns
* RD - Residual disease, PS - Performance status
After primary surgery, before the start of chemotherapy, age at diagnosis
(p<0.002), performance status (p<0.005) and the extent of residual disease
(p<0.01) were significant predictors of survival. Tumour grade was not
significant at any time. After one cycle of chemotherapy, performance status
(p<0.001), CA125 (p<0.005), residual disease (p<0.02), adhesions (p<0.02),
age at diagnosis (p<0.05), ascites (p<0.05), and HMFG2 (P<0.05) were all
significant. After two cycles, CA125 (p<0.0005), HMFG2 (p<0.0005), residual
disease (p<0.05), and performance status (p<0.05) were significant. After three
cycles, CA125 (p<0.0005), HMFG2 (p< 0.002), and performance status
(p<0.02) were significant. After four cycles, CA125 (p<0.0002), performance
status (p<0.02), and residual disease (p<0.02) were significant. After five
cycles, CA125 (p<0.05), performance status (p<0.05) and residual disease
(p<0.05) were significant. Thus, CA125 and HMFG2 were significant predictors
of overall survival, like progression free survival, after the first cycle of primary
chemotherapy and for a further four and two cycles respectively. Table 9.4
shows the results of multivariate analysis of these factors.
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Table 9.4 Multivariate analysis of prognostic factors influencing
survival
Post cycle Most significant Additional independent
number prognostic factor prognostic factor(s)
Pre-Rx Age at diagnosis (p< 0.002) Performance status (p< 0.05)
1 Performance status (p< 0.0001) none
2 HMFG2 (p<0.005) Performance status(p<0.005)
3 CA125 (p<0.0005) none
4 CA125 (p< 0.0002) none
5 CA125 (p< 0.005) none
After surgery, age at diagnosis was the most significant predictor of survival
(p<0.002) independent of performance status (p<0.05). No other factor
achieved significance. After one cycle of chemotherapy, performance status
was the most significant predictor of survival (p<0.0001), and no other factor
achieved significance. After two cycles, HMFG2 was the most significant
predictor of survival (p<0.005), independent of performance status (p<0.005).
After three, four, and five cycles, CA125 was the most significant predictor of
survival (p<0.0005, p<0.0002, and p<0.005 respectively). No other factors
achieved statistical significance at these times.
9.3 VALUE OF CA125 AND HMFG2 MEASUREMENT AFTER ONE CYCLE
OF PRIMARY CHEMOTHERAPY
Prognostic information that may assist treatment decisions early during
chemotherapy could be extremely useful in two respects. If those patients who
are unlikely to respond could be identified early in treatment, unnecessary
toxicity could be avoided and valuable resources re-allocated. Alternatively,
patients with a good outlook may benefit from dose intensification, thereby
shortening the time spent on therapy - possibly improving response rates.
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Both CA125 and HMFG2 were significant predictors of total and progression
free survival after the first cycle of primary chemotherapy. Fifty seven patients
had samples taken at this time; 46 had stage III and 13 had stage IV disease.
Forty two patients had serous tumours, nine had endometrioid tumours, three
had poorly differentiated adenocarcinomas, one had a clear cell tumour, one
had a mucinous tumour, and one had mixed tumour histology. Forty one
tumours were poorly differentiated, eight were moderately differentiated and
eight were well differentiated. None of these patients had macroscopic tumour
clearance at primary laparotomy; 13 had inoperable disease, six had residual
disease >5cm, 17 had 2-5 cm residual disease, and 21 had <2cm residual
disease. Thirty seven patients had ascites at diagnosis and 49 had adhesions.
Twenty six patients had a performance status (PS) of 0, 22 had a PS of 1,
seven had a PS of 2, and two patients had a PS of 3 prior to chemotherapy.
Patients who survived for less than six months had markedly high levels of both
CA125 and HMFG2 two months after surgery. These patients represented
approximately the upper quartile of this group. Consequently, the total group
was divided into quartiles on the basis of marker levels to determine if further
prognostic groups could be identified.
9.3.1 Identification of patient groups with distinct periods of progression
free survival
Dates of progression were obtained for 38 patients who had samples taken
after the first cycle of therapy. These patients were divided into quartiles on the
basis of CA125 levels, see table 9.5, and PFS curves plotted for each quartile,
see figure 9.1.
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Table 9.5 CA125 levels in patients with poor, intermediate and good
progression free survival
Median No. Patients CA125 (Urn!"1)
PFS progression free
Group n (months) at 1 year (%) mean median range
A 10 4.5 2/10 (20.0%) 1308 532 480-6183
B 10 8.5 3/10 (30.0%) 390 418.9 252-472
C 9 12.0 4/10 (40.0%) 149.9 117.9 66.4-250.9
D 9 19.0 5/10 (50.0%) 39.2 35 6-62.9
Patients in group A had a median PFS of 4.5 months, and only two (20%)
remained progression free (PF) after one year of follow-up. Patients in group
B had a median PFS of 8.5 months, and three (30%) remained progression free
at one year. Patients in group C had a median PFS of 12 months, and four
(40%) remained progression free at one year. Patients in group D had a
median PFS of 19 months, and five (50%) were progression free at one year.
Figure 9.1 shows three distinct prognostic groups; groups A, B and C, and D
with poor, intermediate and good PFS respectively (these definitions are
arbitrary). The difference between the PFS curves was significant using the Log
Rank test fo2=9.48, df=3, p<0.02). Patients in group A had significantly poorer
PFS than those in groups B fo2=4.27, df=1, p<0.05), C fo2=4.72, df=1,
p<0.05), and D (^2=8.33, df=1, p<0.005). There was no difference in PFS
between groups B and C. Patients in group D had significantly better PFS than
those in groups A fc2=8.33, df=1, p<0.005), B fo2=4.76, df=1, p<0.05), and
C (*2=5.21, df=1, p<0.02).
Patients in the poor prognostic group had CA125 levels >480 Urnl"1 (median
532 Urnl1), those in the intermediate prognostic group had CA125 levels in the
range 66.4-472 Urnl"1 (median 252 Uml"1), and those in the good prognostic
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Figure 9.1 Progression free survival ofpatients according to CA125 levels
after one cycle ofprimary chemotherapy. Patients in group A (•)
had a mean CA125 level of 1308 Uml"1, patients in group B (a) had
a mean CA125 level of 390 Uml"1, patients in group C (o) had a
mean CA125 level of 150 Uml"1, and those in group D (x) had a
mean CA125 level of 39 Uml"1, see table 9.5. The difference
between the four survival curves was significant (^2=9.48, df=3,
p<0.02).
228
Twenty eight patients with progression dates available had HMFG2 assayed
after the first cycle of chemotherapy. This group was divided into quartiles on
the basis of HMFG2 results, see table 9.6, and progression free survival curves
plotted for each quartile, see figure 9.2.
Patients in all groups had poor median survivals. Thus, groups A, B, C and D
had median survival times of four months, six months, nine months and nine
months respectively. HMFG2 levels ranged from 5-433 Uml"1 in these groups,
see table 9.6. There were no significant differences in PFS using the Log Rank
test between any two groups with different HMFG2 values.
Table 9.6 HMFG2 levels in patients after one cycle of chemotherapy
according to progression free survival
Median No. patients HMFG2 (Umr1)
PFS progression free
Group n (months) at 1 year (%) mean median range
A 7 4.0 1/7 (14.3%) 178.2 83.3 73-433
B 7 6.0 3 / 7 (42.9%) 55.2 54.9 45-65
C 7 9.0 3 / 7 (42.9%) 32.5 37.6 10-45
D 7 9.0 1/7 (14.3%) 6.1 5 5-10
9.3.2 Identification of patient groups with distinct survival periods
The total group of 57 patients were divided into quartiles on the basis of CA125
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Figure 9.2 Progression free survival of patients according to HMFG2
levels after one cycle of primary chemotherapy. Patients in
group A (•) had a mean HMFG2 level of 83,3 Urnl"1, patients in
group B (±) had a mean HMFG2 level of 55.2 Urnl"1, patients in
group C (o) had a mean HMFG2 level of 32.5 Urnl"1, and those in
group D (x) had a mean HMFG2 level of 6.1 Urnl"1, see table 9.6.
The difference between the four survival curves was not significant.
230
Table 9.7 CA125 levels in poor, intermediate and good prognostic
groups
Median No. patients CA125 (Urnl1)
survival alive
Group n (months) at 1 year (%) mean median range
A 15 7 3/15 (20.0%) 1109 500 450-6183
B 14 15 10/14 (71.4%) 340 364 228-434
C 14 16 11 / 14 (78.6%) 103 102 58-221
D 14 23 13/14 (92.9%) 29 31 6-55
Patients in group A had a very poor median survival of 7 months, only 3 (20%)
patients were still alive after one year of follow-up. Patients in groups B and C
had similar median survivals of 15 and 16 months respectively. Ten (71.4%) and
11 (78.6%) patients in groups B and C were alive at one year. Patients in group
D had a median survival of 23 months, 13 (92.9%) were alive at one year.
Figure 9.3 shows three distinct prognostic groups based on CA125 values at
this time. The difference between the survival curves was significant using the
Log Rank test O(2=14.70, df=3, p<0.005). Patients in group A had a signific¬
antly poorer survival than those in groups B (^2=8.12, df=1, p<0.005),
C (x2=8.00, df=1, p<0.005), and D 0c2= 13.91, df=1, p<0.001). There was no
difference in survival between patients in groups B and C. Patients in group D
had significantly better survival than those in groups A (^2= 13.91, df=1,
p<0.001), B (x2=6.67, df=1, p0.01), and C fe2=6.58, df=1, p<0.02).
Patients in the poor prognostic group had CA125 levels >450 Uml"1 (median
500 llml"1), those in the intermediate prognostic group had CA125 levels in the
range 58-434 llml"1 (median 224 Uml"1), and those in the good prognostic
group had CA125 levels <55 Urnl"1 (median 31 Uml"1, all but one patient had
normal levels).
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Figure 9.3 Survival of patients according to CA125 levels after one cycle
of primary chemotherapy. Patients in group A (•) had a mean
CA125 level of 1109 Urnl"1, patients in group B (a) had a mean
CA125 level of 340 Urnl"1, patients in group C (o) had a mean
CA125 level of 103 Uml"1, and those in group D (x) had a mean
CA125 level of 29 Uml'1, see table 9.7. The difference between the
four survival curves was significant (^2=14.7, df=3, p< 0.005).
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Forty four patients with HMFG2 results after one cycle of therapy were divided
into quartiles on the basis of HMFG2 levels, see table 9.8. Survival curves were
plotted for each quartile, see figure 9.4.
Table 9.8 HMFG2 levels in patients after one cycle of chemotherapy
Median No. patients HMFG2 (Urnl1)
survival alive
Group n (months) at 1 year (%) mean median range
A 11 5 4/11 (36.6%) 154 90 65-433
B 11 16 8/11 (72.7%) 49 48.3 40-64
C 11 13 8/11 (72.7%) 24 23.3 10-39
D 11 15 8/11 (72.7%) 7 5 5-10
Patients in group A had a poor median survival of five months, while those in
groups B, C and D had similar median survivals of 16, 13, and 15 months
respectively. There were no significant differences in survival using the Log
Rank test between any two patient groups.
9.4 CLINICAL LEAD TIMES TO RELAPSE
Twenty patients were followed serologically from complete (n=10) or partial
(n=10) response until clinical relapse. CA125 was assayed in samples from all
20 patients, while HMFG2 was assayed in samples from 15 patients; the stages
and histological types of the two groups are shown in table 9.9. The lead time
to relapse was calculated in months as the number of days from the first rise
in marker levels until the date of appearance of new symptoms divided by 30.
Table 9.9 shows the patients with CA125 and HMFG2 lead times. CA125 gave
a mean lead time of 8.6 months (median 9.6 months, range 2.0 -14.8 months)
in 14/20 (70%) patients, while HMFG2 gave a mean lead time of 8.6 months
(median 9.2 months, range 1.2 - 14.8 months) in 7/15 (47%) patients. Thus,
HMFG2 gave similar lead times as CA125 but in fewer patients.
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Figure 9.4 Survival of patients according to HMFG2 levels after one cycle
of primary chemotherapy. Patients in group A (•) had a mean
HMFG2 level of 154 Uml"1, patients in group B (a) had a mean
HMFG2 level of 49 Urnl"1, patients in group C (o) had a mean
HMFG2 level of 24 Uml"1, and those in group D (x) had a mean
HMFG2 level of 7 Urnl"1, see table 9.8. The differences between the
four survival curves were not significant.
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Table 9.9 CA125 and HMFG2 lead times to clinical relapse
Disease Patients with marker lead time
characteristic CA125 HMFG2
Stage I 1 n (100%) 0/1 (0%)
II 3/3 (100%) 2/3 (66.7%)
III 7/14 (50.0%) 5/10 (50.0%)
IV 3/4 (75.0%) 0/1 (0%)
Histology Serous 10/14 (71.4%) 6/10 (60.0%)
Endometrioid 2/2 (100%) 1 n (100%)
*PDA 2/4 (50.0%) 0/4 (0%)
Total 14/20 (70.0%) 7/15 (46.7%)
*
Poorly differentiated adenocarcinoma
CA125 gave clinical lead times in patients with disease stages I - IV at
diagnosis, while HMFG2 only gave lead times in those with stages II and III,
although the numbers in each group were small. CA125 gave a lead time in
patients with serous tumours, poorly differentiated adenocarcinoma and
endometrioid tumours, while HMFG2 gave a lead time in those with serous and
endometrioid tumours. Both markers gave lead times in the same patients,
except for one patient with stage III poorly differentiated serous disease who
had false negative CA125 and an HMFG2 lead time of 4.6 months. Sampling
and follow-up were insufficient to demonstrate lead times in patients with clear
cell or mucinous tumours.
9.5 ASSESSMENT OF DISEASE PROGRESSION
One or more methods of assessment, clinical, radiological, surgical or
biochemical, may alert the oncologist to the possibility of disease progression.
The predominant methods of assessment recorded in the case notes of 154
patients with progressive disease until July 1989 are shown in table 9.10.
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Table 9.10 Methods of assessing disease progression















Disease progression was most frequently diagnosed during clinical
examination; 83 (53.9%) patients were assessed in this manner. Similar
numbers, 27 (17.5%) and 23 (14.9%), were diagnosed on CT scan and US
scan respectively, while eight (5.2%) patients had disease progression
diagnosed by X-ray. Second-look laparotomy and laparoscopy detected nine
(5.8%) cases and two (1.3%) cases respectively. CA125 levels led to suspicion
of disease progression in only two (1.3%) patients; one had no clinically
evaluable disease and no evidence of disease on a recent CT scan, while the




After surgery, residual disease, age and performance status were ail significant
predictors of progression free survival and overall survival. All published studies
agree upon the importance of residual disease (Griffiths, 1975, Swenerton et
al., 1985, Webb, 1989, Marsoni etal., 1990), while other prognostic factors vary
in significance. These variations may be accounted for by the small sample
sizes, generally less than 200 patients, and the different "cocktails" of factors
considered in different studies. In addition, the majority of studies, including this
thesis, have analysed prognostic factors in patients with advanced disease
owing to the greater number of patients who present late.
Several authors, using Cox's proportional hazard model for multivariate
analysis, have reported a maximal combination of three or four independent
prognostic factors. Thus, Bjorkholm et al. (1982) found stage, age, and
histological type, Dembo and Bush (1982) found residual disease, stage, age,
and tumour grade, and Schray et al. (1983) found residual disease, age and
tumour grade to be independent predictors of survival in their studies. None of
these studies took performance status into consideration. A later, larger study
by Swenerton et al. (1985), that retrospectively assessed 16 characteristics in
556 patients, found residual disease, tumour grade and performance status to
be independent prognostic factors. Swenerton et al. (1985) also reported
prognostic factor variation with disease stage. Tumour grade was most
important in stages I and II, residual disease was most important in stage III
and no other factor was independent of stage IV in predicting survival. Dembo
et al. (1990) also found tumour grade to be the most powerful predictor of
relapse in patients with early stage disease. Although residual disease is the
most important prognostic factor in ovarian cancer, it is not surprising that it is
of no importance in patients with early stage disease, the majority of whom are
optimally debulked.
The prognostic significance of tumour grade has been consistently reported to
date. However, it was not significant in this thesis, owing to the bias towards
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inclusion of patients with poorly differentiated tumours; less than 30% of
patients had well and moderately differentiated tumours at any given time.
Recently, McGuire (1991) has published a series of guidelines for evaluating
prognostic factors. Patient selection bias is a common problem that may mask
important factors. Small sample size, a notorious cause of statistical
insignificance in randomised trials of chemotherapy regimes, is also a potential
problem. Although the sample populations in this thesis are small, the
prognostic significance of residual disease, performance status, age, and
CA125 are fairly consistent throughout treatment - emphasizing the importance
of these factors.
In a large study, Marsoni et al. (1990) identified residual disease, stage, age,
and tumour type as independent predictors of survival in 514 patients. They
also found performance status to be a strong independent factor nullifying the
effect of stage and age. Performance status, although a subjective assessment,
may therefore represent a "comprehensive" marker of the relationship between
a patient's general well-being and the extent of disease expressed by a
combination of factors such as stage and age.
Neither CA125 nor HMFG2 were significant predictors of total or progression
free survival immediately after surgery. It is well known that surgical intervention
causes a transient rise in CA125 (see discussion, chapter 8, p 208). In a recent
study, Van der Zee etal. (1990) found elevated post-operative levels of CA125
in 82% of patients who underwent abdominal surgery, with normal pre-operative
levels, regardless of primary diagnosis. CA125 levels took 3-4 weeks to return
to normal in their patients. In this thesis, 82% and 100% of optimally debulked
and sub-optimally debulked patients had elevated post-operative CA125 levels
(see table 8.1). Although post-operative CA125 levels correlated significantly
with residual tumour burden in our study, elevation in serum levels as a result
of surgical intervention may partially explain the lack of prognostic significance
of CA125 at this time. The same might apply to HMFG2, and indeed other
markers, although the prognostic significance of post-operative CA125 has
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been found in other studies (Redman et al., 1990, Rosen et a!., 1990, Rustin,
personal communication).
CA125 was a highly significant predictor of total and progression free survival
after one cycle and remained significant throughout primary chemotherapy
(tables 9.1 and 9.3). HMFG2 was also significant in this respect after one, two
and three cycles of primary chemotherapy. As the length of progression free
survival is predictive of overall survival, it not surprising that similar results were
obtained in prediction of both, either with the markers or other factors
previously discussed. It would be useful to know how the prognostic value of
each factor changes with time and disease course, and hence when the most
useful information can be obtained.
Information relating to prognosis is desirable as early as possible especially if
it can influence treatment for the benefit of the patient. Patients with "advanced"
ovarian cancer represent a heterogeneous group, with five year survival varying
from as much as 7% to 62% (Marsoni et al., 1990). The knowledge that
advanced ovarian cancer patients can be assigned to groups with distinct
prognostic characteristics may serve oncologists as a guideline for a more
accurate estimate of the trade-off between toxicity and survival offered by
chemotherapy. Treating patients with aggressive chemotherapy regimes would
not be justified if a poor outcome could be predicted. Although prognostic
factors are essential for stratification in clinical studies and to help guide
treatment, they cannot however predict how a patient will respond to a
particular therapy.
The survival benefits of chemotherapy, in particular platinum combination
regimes, are a contentious issue. Population sample sizes are often too small
to reveal statistically significant differences in survival between treatment arms.
Recently, the MRC Gynaecological Cancer Working Party have initiated an
overview of ovarian cancer chemotherapy; by January 1990 they had identified
53 relevant randomised controlled trials with a total of nearly 10,000 patients,
to address this issue (MRC Gynaecological Cancer Working Party, 1991).
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Many authors have reported the prognostic significance of early CA125 assay,
however, there is no consensus yet as to the most useful measurement. There
is conflicting evidence regarding the significance of pre-operative CA125 assay;
Vergote et al. (1987) and Van der Burg et al. (1988) found an inverse
correlation with survival, while Cruickshank et al. (1987) found no correlation,
and Sevelda et al. (1989) report that CA125 gave no additional information to
residual disease and tumour grade. Extensive debulking is likely to override the
association between pre-operative CA125 and survival, giving added credence
to Sevelda's conclusion.
It was possible to distinguish significantly between three prognostic groups,
with relatively poor, intermediate and good PFS and survival (figures 9.1 and
9.3), based on absolute CA125 levels after one cycle of chemotherapy, but not
HMFG2. Thus, in approximation, patients with normal CA125 levels had a good
prognosis, those with elevated levels but <500 Umf1 had an intermediate
prognosis, and those with CA125 levels >500 llml"1 had a poor prognosis (see
tables 9.7 and 9.9 for exact values). Fewer patients had HMFG2 assayed, and
the total group was slightly biased towards those with a poorer prognosis,
again illustrating the problem of selection bias outlined in McGuire's guidelines.
Indeed, HMFG2 only just achieved significance at this time (p<0.05). Hence,
more data are required to assess the prognostic value of HMFG2 in patients
with a wider range of prognoses.
Rustin et al. (1989) were able to discriminate between different prognostic
groups using a seven-fold fall in CA125 levels from pre-treatment to post-
treatment, using progression free survival as the endpoint in 54 patients with
advanced disease. 58% of patients with greater than a seven-fold fall and 9%
of patients with less than a seven-fold fall were disease free after two years of
follow-up. Van der Burg et al. (1988) found a serum CA125 half-life of greater
than 20 days more predictive of a favourable prognosis than a half-life of less
than 20 days. There are as yet no data to substantiate these findings.
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After two cycles of chemotherapy, Sevelda et al. (1989) and Redman et al.
(1990) found CA125 to be the most significant predictor of survival in 163 and
50 patients respectively. The results of this thesis agree with their findings, in
addition HMFG2 and performance status were highly significant at this time.
Redman et al. (1990) claim to have been able retrospectively to predict
outcome with an overall accuracy of 93%; 96% of patients alive at one year
were correctly predicted, while 85% dead at one year were correctly predicted.
Although CA125 levels may be used to discriminate significantly between
different prognostic groups, they tell us nothing about the accuracy of
predicting outcome in the individual patient. Longer follow-up in a larger patient
series is necessary to refine the predictive value of CA125. No single biological
parameter will give an accurate prediction in all patients due to tumour
heterogeneity (Leake and Owens, 1990). Although CA125 was the most
significant predictor of PFS in this thesis, it was not independent of
performance status in predicting overall survival (table 9.6). Sevelda and
Redman did not consider performance status in their evaluations. Of the four
patient groups, those in group A with the highest CA125 levels also had at least
three other poor prognostic factors. The majority of patients in group A had
inoperable bulky disease, poorly differentiated tumours, and a performance
status of 2 or 3. At the other end of the spectrum, all patients in group D were
optimally debulked and the majority had a performance status of 0. Therefore,
although CA125 strongly correlates with outcome, it does not necessarily
provide prognostic information that is not either clinically obvious or
determinable by several other factors.
Given an accurate prognosis, treatment decisions are still more likely to be
influenced by patient desire for active therapy (Cody and Slevin, 1989), by
limitations of current drug regimes, and increasingly by financial considerations
(Rees, 1991). When deciding whether to stop treatment in patients with no
change in markedly elevated CA125 levels after one cycle of primary
chemotherapy, Rustin et al. (1989) urge caution. Up to 10% of such patients
may respond eventually to therapy, and it would be wrong, they argue, to deny
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patients this chance however slight. Unfortunately response to chemotherapy
rarely results in a significant improvement in long-term survival.
CA125 gave a lead time to clinical recurrence in 70% of responders in this
study, while the literature reports indicate up to 87% of responders have a
CA125 lead time to relapse (for review see Kenemans, 1988). Both CA125 and
HMFG2 gave similar clinical lead times to relapse, HMFG2 in fewer patients. This
does not necessarily imply that HMFG2 has similar sensitivity for occult disease
to CA125. Indeed, after primary laparotomy, CA125 levels were significantly
higher in patients with >2cm compared to those with <2cm residual disease,
while HMFG2 levels were significantly higher in patients with >5cm compared
to <5cm residual disease (chapter 8, tables 8.1, p 182 and 8.5, p 184).
Sampling was performed relatively infrequently, i.e. every few months, in the
majority of patients who had marker lead times in this study. It is possible that
more frequent sampling would have resulted in longer marker lead times.
Marker elevation during chemotherapy may prompt further investigation leading
to discontinuation of treatment, change of treatment, or no action. Marker
elevation after chemotherapy may lead to re-initiation of treatment or no action,
while elevation in a previously untreated patient may result in initiation of
treatment or no action. The course of action given a lead time to relapse or
recurrence in a patient with EOC depends ultimately on the available remaining
therapeutic options for that patient. No study has yet addressed the question
of whether earlier detection of recurrent disease by CA125 monitoring translates
into an improved outlook for the patient. As the results of treatment of recurrent
disease are so poor, it is doubtful that earlier initiation of therapy would have
any impact in the majority of patients. There is understandable reluctance to
initiate therapy on the basis of rising marker levels in patients who are
otherwise well. It is current practice to wait until other evidence of recurrent
disease presents before beginning new therapy.
This caution is underlined by the fact that the predominant method of
determining disease progression was clinical examination (table 9.2). This
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situation prevailed until two years ago when there was less experience with
CA125. Patients diagnosed with early stage disease, completely resected at
laparotomy, previously untreated with cisplatin based regimes however may
benefit from early treatment of recurrent disease. The impact on survival of
therapeutic intervention at pre-clinical "serological" diagnosis of relapse can only
be determined by prospective randomised controlled trials.
Similarly, the influence of CA125 upon clinical decision making, whether during
first-line or subsequent treatments or during follow-up, can only be addressed
in a prospective manner. In what claims to be the first prospective study, the
authors at the Royal Marsden Hospital, London, have addressed the influence
of scanning techniques on patient management (Gore et a/., 1989). In their
study, US and CT scans each differed from clinical assessment in 45% of
cases, although clinical decision making was influenced in only 10% and 18%
of cases respectively. Patient management was more frequently altered when
scans were performed for suspicion of relapse rather than for measurement of
response or at routine follow-up.
Knowledge of "what is going on" is claimed to be valuable, giving clinicians
confidence in treating their patients. This concept has been challenged by Gore
etal. (1989), begging the question of how important routine CA125 assay is in
patient management. This has yet to be addressed and, together with the
previous considerations, may have important implications for timing of CA125
assay and allocation of precious Health Board resources. At present there is
sufficient information and experience with CA125 to proceed to address these
issues.
All the marker evaluations in this thesis have been performed retrospectively.
The principal reservation about conclusions drawn from retrospective analyses
are that they usually result from "a look to see what the data show" rather than
the formal testing of a previous hypothesis. Statistically significant observations
may be peculiar to the data set that has been explored retrospectively and may
not be open to generalisation. Proof of generalisation of inferences requires that
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they be validated on a separate set of patients. Large prospective studies are
needed to generate common criteria for defining and reporting risk groups to
facilitate comparisons between investigators. Justification of wider routine
adoption of the CA125 assay in EOC patient monitoring will be dependent upon





Conclusions and Future Prospects
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10.1 CONCLUSIONS
CA125, on its own, is not sensitive or specific enough to screen women for ovarian
cancer (Fisken etal., 1989b, Rouslton, 1990). A large research effort, however, has
established a role for CA125 in monitoring epithelial ovarian cancer patients. Its
value lies mainly in determining response to chemotherapy and providing lead
times to clinical relapse or recurrence. Many serum assays using monoclonal
antibodies directed to PEM detect elevated marker levels in a high proportion of
EOC patients, in particular HMFG2. Over 60% of EOC patients in this thesis had
elevated HMFG2 serum levels. However, none discovered to date is as sensitive
and specific as CA125. Moreover, no marker has proved a clinically useful addition
to CA125 in patient monitoring (Fisken et ai, 1991). In this study, although both
HMFG2 and TATI added significantly to the discrimination of CA125, neither marker
was able to provide accurate information in patients with early stage disease with
no clinical or radiological evidence of disease.
Although several of the markers assayed in this thesis have been advocated as
markers of mucinous tumours, these studies have been based on small numbers
of patients. As the incidence of mucinous EOC is far lower than serous EOC it is
difficult to obtain sufficient samples for meaningful analysis in any one centre. This
also applies to any other non-serous histological types of EOC. In addition,
patients with mucinous tumours tend to present at an earlier stage, have better
differentiated tumours and a better prognosis in general. Consequently, long-term
multicentre studies are necessary to fully evaluate markers such as CA724, TATI,
and CA199 in patients with mucinous ovarian carcinomas.
Although CA125 is useful in monitoring response to chemotherapy, the results of
many studies, including this thesis (see chapter 8, section 8.3.1, pp. 186-189), have
demonstrated that CA125 response cannot discriminate between complete and
partial response. CA125 had a sensitivity of 53% in this study for disease at
second-look laparotomy, similar to values previously reported in the literature. In
addition, neither HMFG2 nor TATI were more sensitive for disease at second-look
compared to CA125. Second-look laparotomy remains the most accurate way of
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determining true pathological response as opposed to clinical response. This is
important, as prognosis may differ substantially between patients with clinical
complete response and those with pathological complete response.
CA125 gives a lead time to relapse in the majority of patients. However, clinical
examination was the most frequently documented means of determining disease
progression in this thesis (see chapter 9, table 9.10, p 236). Prospective
randomised trials are needed to determine whether pre-clinical "serological"
diagnosis of relapse can be translated into an improved outlook for the patient. At
present, tumour markers are limited by currently available drug regimes. Although
responses to second-line treatments are poor, patients diagnosed with early stage
disease and treated with a first-line platinum regime prior to clinical relapse may
benefit in terms of prolonged survival. Until, either more sensitive, widely applicable
diagnostic techniques or better treatments become available significant
improvements in survival do not appear likely.
Radioimmunoscintigraphy is routinely performed in some oncology units, and has
been shown to detect recurrence before serum marker elevation (Granowska et
al., 1988). This technique may also be a useful inclusion in a prospective
intervention trial. Should such a trial be initiated, the frequency of monitoring would
also need to be determined. The demand for CA125 assay in the Immunoassay
section of Edinburgh Royal Infirmary has more than doubled over the past two
years at considerable cost to the Health Board. Cost may be reduced if an "in-
house" assay were available. Wilson and Kalirai (1991) have recently reported the
development of an "in-house" ELISA for CA125 with this objective in mind. The
correlation coefficient between this assay and a commercial IRMA is 0.7. Further
studies using this assay are needed before routine adoption is warranted.
Alternatively, new techniques in monoclonal antibody production using plasmid
vectors (Winter and Milstein, 1991) may substantially reduce cost, as the most
expensive part of any immunoassay is usually the production cost of the
antibodies.
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Problems regarding standardisation are likely to arise unless one assay method
is adopted for either screening or monitoring (Fisken et a/., 1989). The MRC
Working Party on CA125, coordinated by Dr.G.Rustin, have experienced major
difficulties pooling CA125 results from the eight centres involved (including
Edinburgh), partly because of discrepancies resulting from the use of different
assay kits. In addition, standardisation of clinical information has proved a major
problem. The last report of the Working Party agree with the findings in this thesis
regarding the prognostic significance of CA125. Prognostic factors are sought to
help guide treatment and the information that is given to patients. Both early CA125
and HMFG2 assay were prognostically significant. Each marker was a statistically
significant predictor of progression free survival and total survival after the first
cycle of primary chemotherapy and throughout first-line treatment (see chapter 9,
sections 9.2.1 and 9.2.2, p 221 and p 225 respectively). Statistical significance
however, does not necessarily equate with clinical significance, as evidenced in this
thesis by the lack of clinical value of series assay of HMFG2 and TATI in addition
to CA125 for example. Examination of one of these patient populations revealed
that CA125 did not give any additional information to several other clinical
parameters, including performance status, age and residual disease.
CA125 may therefore confirm what the clinician already knows or suspects. The
value of such confirmatory information is perhaps impossible to determine,
although Gore et al. (1989) at the Royal Marsden Hospital, London, have
challenged a similar concept concerning the value of ultrasound and CT scanning
in EOC management. At present, patient management is likely to continue along
conventional lines, although routine adoption of novel techniques is becoming
more widespread. In this climate of NHS reform, clinicians will increasingly be
forced to rationalise their treatments of patients with far advanced cancer (Rees,
1991). Threats to treatment of advanced cancer patients have recently been
highlighted in the media in the wake of cuts at Guy's Hospital, London, after opting
for trust status.
The best chance an ovarian cancer patient has at present is optimal surgical
management. Approximately half of the patients in this thesis were optimally
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debulked, although Hacker et al. (1989) estimated 85% of all patients may feasibly
be optimally resected. This problem has also been recently highlighted in the
media. AWorking Party was established by the Department of Health to investigate
regional treatment variation and define acceptable surgical practices for a number
of malignant conditions. Significant differences in five and ten year survival rates
of patients with early stage ovarian cancer treated at local and specialist centres
in the West of Scotland ("The Cancer Lottery" shown on Panorama, April 1991).
Sophisticated management strategies should be available to all patients;
unfortunately centres differ widely in the expertise they have to offer and
consequently varaitions in outcome are to be expected.
10.2 FUTURE PROSPECTS
A better understanding of the pathogenesis of epithelial ovarian cancer will allow
new treatment strategies to be developed. The most interesting in this respect is
the work being carried out at the molecular level. Study of the molecular genetics
of ovarian cancer is still in its infancy compared to breast, lung and colon cancer.
This is not surprising given the large numbers of tumour specimens that need to
be collected and the enormous effort required to isolate genetic alterations. A
number of genetic abnormalities have been found in ovarian cancer, many in
common with those found in breast cancer (for review see Steel, 1991). The
tumour suppressor gene, p53, discovered by Lane in 1979, has been intensively
studied in breast cancer, and is now receiving much attention in ovarian cancer.
Eccles et al. (1990) recently reported a high incidence of p53 loss in patients with
advanced serous EOC. Russell et al. (1990) also report a high incidence of
deletion of chromosome 17 in EOC patients. In addition to needing a greater
understanding of ovarian cancer pathogenesis, prospective randomised controlled
trials addressing the value of CA125 in pre-clinical "serological" and radiological
diagnosis of relapse are warranted. Intervention based on rising CA125 levels in
the absence of other signs of progression in patients either previously untreated
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UKCCCR RECOMMENDATIONS FOR SCREENING FOR EOC
1. Screening for ovarian cancer is of unproven benefit, and should not in the
light of current knowledge, be offered as a routine test.
2. Further studies would be necessary before it could be stated whether
ovarian cancer screening is effective in reducing deaths from this disease
or what is the optimum combination and frequency of tests.
3. Further studies are required to identify high-risk groups. Famlilies identified
as being "high-risk" should be referred to centres with a specific interest
in the genetic aspects of the disease.
4. Screening of a high-risk group could provide results more quickly and
less expensively than screening of a large population of average risk.
5. Any proposed study of a large population would have to be properly
structured from the outset, piloted for patient acceptability and carefully
monitored and would require extensive funding.
6. There is need for basic research into the malignant potential of benign
and borderline ovarian tumours.
7. Every effort should be made to stage ovarian cancer accurately at
diagnosis.
8. Patients suspected of having the disease should have a laparotomy




ADDRESSES OF IMMUNOASSAY KIT SUPPLIERS
CA125, CA153, CA199, and CA724 Immunoradiometric assays
CIS U.K. Ltd.
Unit 5, Lincoln Park,
Business Centre, Lincoln Rd.,


















ADDRESSES OF HMFG2 ASSAY REAGENT SUPPLIERS
Sigma Chemincal Co. Ltd., Poole, Dorset, U.K.
Horseradish peroxidase (HRP), Tween 20 (polyoxyethylene sorbitan
monolaurate), o-phenylenediamine, sulphuricacid (H2S04), sodium borohydride
(NaBHJ, sodium m-periodate (NalOJ, hydrogen fluoride, thimerosal, bovine
serum albumin (BSA), cyanogen bromide activated-sepharose.
BDH Chemicals Ltd., Glasgow, U.K.
Sodium acetate, acetic acid, citric acid, sodium carbonate (Na2C03), sodium
hydrogen carbonate (NaHC03), sodium chloride (NaCI), potassium chloride
(KCI), di-sodium hydrogen phosphate (Na2HP04), potassium di-hydrogen
phosphate (KH2P04), di-sodium hydrogen phosphate (Na2HP04).
Pharmacia (Laboratory Separation Division), Milton Keynes, Bucks.
Protein A (affinity chromatography).
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APPENDIX C
CHEMOTHERAPY REGIMES GIVEN TO EOC PATIENTS
(with typical doses)
Cisplatinum - 160mg/m2 i.v. every 21 days.
Cisplatinum/Prednimustine - 160mg/m2 i.v. cisplatinum every 28 days,
prednimustine orally days 1 -5.
Cispaltinum/a-interferon (i.p.) - 160mg/m2 i.v. cisplatinum with 25 mu i.p.
a-interferon every 21 days.
Prednimustine - 160 mg/m2 orally days 1-5 every 21 days.
Chlorambucil - 10mg orally for 5-7 days every 21 days.
Carboplatin - 400 mg/m2 i.v. every 21 days.
5-Fluorouracil/Prednimustine/Hexamethylmelamine/Cisplatin - 600 mg/2 i.v.
5-fluorouracil days 1 and 8,15mg/m2 oral prednimustine days 2-14,150 mg/m2
oral hexamethylmelamine days 2-14, and 30mg/m2 i.v. cisplatinum days 1 and
8. Cycles repeated every 28 days.
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APPENDIX D
SCORING OF TUMOUR MARKER RESULTS
Tumour marker results were retrospectively scored true positive (TP), true
negative (TN), false positive (FP) or false negative (FN). A marker result was
positive if the level obtained was higher than the assigned cut-off value and
negative if the level obtained was lower than the assigned cut-off value.
Results were scored at least six months in retrospect using all clinical,
radiological and surgical information available at the time of marker assay and
proceeding marker assay. If a patient had no clinical, radiological or surgical
evidence of disease at the time of marker assay and remained in remission for
the following six months, marker levels within the normal range were scored
true negative and elevated marker levels were scored as false positive. If a
patient had clinical, radiological or surgical evidence of disease at the time of
marker assay or relapsed in the proceeding six months, elevated marker levels
were scored true positive, and marker levels within the normal range during this
time were scored as false negative.
It must be stressed that six months was an arbitrary cut-off point in time.
After complete surgical resection, the majority of patients, who had elevated
pre-operative marker levels, also have elevated post-operative marker levels.
Surgical intervention often causes transient rises in serum marker levels which
may take weeks to return to the normal range (see chapter 8, section 8.2,
p 181). In addition, marker levels often become elevated in patients longer than
six months before clinical or other evidence of relapse presents (see chapter
9, section 9.4, p 233). Long-term follow-up of patients is necessary to determine
true marker scores. Consequently, a change in marker levels is more




Publications arising from this project:
Roulston,J.E.,Fisken,J.,Leonard,R.C.F.(1988). Screening for ovarian cancer
using CA125 assays. Lancet;ii: 171 -172 (letter to the editor).
Fisken,J.,Leonard, R.C.F.,Shaw,G.,Bowman,A.,Roulston,J.E. (1989). Serum
placental-like alkaline phosphatase (PLAP): a novel combined enzyme linked
immunoassay for monitoring ovarian cancer. J.Clin.Pathol.;42:40-45.
Fisken,J..Loenard,R.C.F..Roulston,J.E.(1989). Immunoassay of CA125 in
epithelial ovarian cancer: a comparison of three assays for use in diagnosis and
monitoring. Dis.Markers;7:61-67.
Fisken,J.,Leonard,R.C.F.,Badley,A.,Jonrup, I. ,Aspinall,L.,Sturgeon,C.,
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arrhvthmia or torsade de pointes. On the tenth day, replacement
therapy with thyroxine, 25 pg progressively increased to 100 pg
daily, and hydrocortisone, 30 mg daily, was started. One month
later, the Q-T interval had shortened to 420 ms (Q-T 392 ms,
52/min) and peripheral thyroid hormone levels were normal. She
had no palpitation, dizziness, or syncope during nine months of
follow-up and the Q-T interval remained normal (400 ms) on the
same treatment.
Torsade de pointes related toQ-T prolongationmay be a cause of
ventricular arrhythmias during hypothyroidism, as demonstrated
in our patient and in the case reported by Kumar et ai.2 However,
these two patients had secondary hypothyroidism due to
panhypopituitarism. By contrast, the case reported by Guthrie et al1
had peripheral hypothyroidism. Whether the association with other
pituitary deficiencies increases the risk of torsade de pointes inQ-T
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The mechanism is said to be differing repolarisarion times in
different areas of the ventricle. A cellular defect would therefore
have to be patchy to produce this effect. In ischaemic heart disease,
when similar changes are found,2 sympathetic imbalance is at least
as likely a cause as the myocardial damage. Similarly in alcoholic
heart disease, an autonomic neuropathy could be the explanation for
Q-T prolongation.
In the hereditary long Q-T syndromes, necropsy studies have
failed to demonstrate a consistent abnormality, although James et al
have described inflammation or degeneration of the intracardiac
nerves and sinoatrial node.3 There are several reasons for
supposing, therefore, that the underlying abnormality may be an
imbalance of sympathetic innervation rather than a myocardial
cellular defect, at least on current evidence.
Woodend General Hospital,
Aberdeen AB9 2YS JOHN C. S. DEAN
1. Schwartz PJ. Idiopathic long QT syndrome: Progress and questions. Am Heart J
1985; 109: 399-415.
2. Ahnve S. QT interval prolongation in acutemyocardial infarction. Eur HeartJ1985; 6
(suppl D): 85-95.
3. James TN, Froggatt P, AtkinsonWJ, et al. Observanons on the pathophysiology ofthe
long QT syndromes with special reference to the neuropathology of the heart.
Circulation 1978; 57: 1221-31.
1. Guthrie GP Jr, Hunsaker JC, O'Connor WN. Sudden death in hypothyroidism.
N EnglJMed 1987; 317:1291.
2. Kumar A, Bhandari AK, Rahimtooia SH. Torsade de pointes and marked QT
proionganon in association with hypothyroidism. Arm Intern Med 1987; 106:
712-13.
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TWAVES IN LONG Q-T SYNDROMES
Sir,—Dr Attwell and Dr Lee (May 21, p 1136) emphasise the
measurement of the corrected Q-T interval and its variation with
heart rate in the diagnosis of a predisposition to arrhythmias. No
mention was made, however, of the fact that in the hereditary
prolonged Q-T syndromes, T waves with abnormal morphology
are commonly found on the standard electrocardiogram (ECG),1
and these can be a helpful pointer to the diagnosis.
The figure illustrates the ECG of a 12-year-old girl with
Romano-Ward syndrome. These waves have been described as
triphasic, bifid, or notched and may also be variably inverted. This
abnormality is often much more striking at first glance than the
prolongation of theQ-T interval, whichmay only become apparent
after careful measurement and correction with Bazett's formula.
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Abnormal T waves in case ofhereditary long Q-T syndrome.
I
SCREENING FOR EARLY OVARIAN CANCER
Sir,—Professor Campbell and colleagues (Mar 26, p 710) report
their preliminary analysis of ultrasound screening for ovarian
cancer. They acknowledge that the specificity of the screen was low,
but suggest that the high detection rate and predictive value of a
negative result "constitute the most important criteria for the
evaluation of any screen for a lethal disease". As their screening
programme detected all 5 cases ofovarian cancer which occurred in
the study populaton during up to 2-vears' follow-up, they conclude
that ultrasound is "acceptable and effective".
Mthough high sensitivity is one essential attribute of a screen for
cancer, other equally important criteria must be satisfied before a
test"becomes acceptable. Campbell et al report a specificity of94-6%
and that there was no evidence ofmorbidity ormortality among the
305 patients (300 false positives) who underwent laparoscopy or
laparotomy. They did not, however, consider the psychological
morbidity associated with recall for investigation of a positive
screening test or the morbidity of laparoscopy or laparotomy even
when uncomplicated.
In addition the complication rate of diagnostic laparoscopy is
299/1000 (major complication rate 3-9/1000).' The annual
incidence ofovarian cancer among women over 45 years in the UK
is 40/100 000.2 If these figures are accurate a test with 96-4
specificity used to screen 100 000 women over 45 years ofagewould
detect 40 cases (assuming 100% sensitivity) and produce 5398 false
positive results requiring diagnostic surgery. Apart from the cost
implications and the difficulty of persuading clinicians to act on a
test with such a low positive predictive value, this would result in
over 150 complications (21 major), if all patients with positive
results were subjected to laparoscopy. Unless the specificity of
ultrasound can be improved or benign ovarian tumours are shown
to have malignant potential our contention (Feb 6, p 268) that
ultrasound alone is unacceptable as a screen for ovarian cancer
remains valid.
London Hospital,
London El ibb ian jacobs
1. Chamberlain G, Brown JC, cds. Gynaecological laparoscopy. the report of the
Working Party of the Confidential Enquiry in Gynaecological Laparoscopy.
London: Royal College ofObstetricians and Gynaecologists, 1978.
2. OPCS cancer stansties, registrations. Cases of diagnosed cancer registered in England
and Wales. London: HM Stationery Office, 1983.
Sir,—Jacobs et al1-2 reported a sensitivity and specificity of 100%
for identifying eariy ovarian cancer with a combination of serum
CA-125 over 30 U/ml, positive vaginal examination, and abnormal
pelvic ultrasound. However, because of the insensitivity of vaginal
examination all subjects with CA-125 over 30 U/ml (31/1010) were
examined by ultrasound. 3 were abnormal and were operated on,
but only 1 had ovarian cancer—a positive predictive value (PPV)
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(true posidves/ail positives) of 33% in those needing surgery to
confirm the diagnosis. In prospective studies thePFVmay be lower
soil; defining a cut-offvalue on the hn.i. of a population group and
then applying that value back to the same group is always likely to
increase apparent discrimination.0 Furthermore, with the interassay
coefficient ofvananon of9-1%, the 95% confidence interval about
their one true positive (inwhom CA-125 was 32 U/mi) would be26
to 38—an equivocal result to say the least. The more usual cut-off
value established'' is 35 U/mi; in that case their sensitivity of 100%
(1/1) would fall to 0% (0/1).
Ovarian cancer has a prevalence of 15/100 000.' Therefore a test
with 100% sensitivity and 99-9% specificitywill still yield a PFV of
oniv 13%. Cruickshank* suggested a marker panel of CA-125,
HMFG., and placental alkaline phosphatase (PLAP) as more
appropriate for screening, and has found an increase in detection
rate in panents with localised disease to 64%.7 He also makes the
vital point that such an approach "may increase the false positive
rate". Tr is nnr riiffimlr rn .p.. ....sensitivity fry
assays; tossing a coin four nmw will yield a pick-up of 93% in a
disease-positive group like those studied by Cruickshank and his
colleagues.The problem is that specificity will fall with equal
sharpness. In our hands PLAP assay did not increase the PPV
obtained with CA-125 alone, whether analysed in parallel or in
series.' Furthermore we find HMFG, assay in serum to be
disturbingly non-reproducible.
A comparative study between the principal CA-125 assays, as
suggested by Cruickshank,4 has been undertaken,' the results
indicated a discrepancy in standardisation bccwu-n the CHS and
Abbott assays. This difference does not help to establish true
cut-offs. Screening for eariy ovarian cancer, in the absence of a
perfect system, will be hindered by the iow disease prevalence and
wtil thereby lead to unacccptabiy high numbers of false-positives,
some ofwhom, as we have seen, end up in the operating theatre.
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MECHANISM OFNITRATE VASODILATORS
Sir.—Dr Yusuf and colleagues (May 14, p 1088) present
evidence from an overview ofclinical trials that intravenous nitrates
reduce mortality in acute myocardial infarction, ,4the reduction
being non-sigmficantiy greater with nitroglycerin than with
rutroprusside." The lesser effect ofmtropnisside has implications
about themechanism ofacconof "nitrovasodilators" inmyocardial
int'arcnon. The nitrovasodilators relax vascular smooth muscle by
the action of their aenve moiety, nitric oxide, on soluble guanyiare
cyclase.1 Platelet aggreganon is also inhibited by elevation of cyclic
GMP levels.-*3 Nitroprusside and nitroglycerin induce similar
vasodilator effects at therapeudc concentrations, but platelet
aggregation imeasured ex vivo and in vitro) is inhibited only by
nitroprusside t ref 4 and our unpublished observanons), probably
because platelets generate nitric oxide from nitroglycerin only at
concentrations far in excess of those achieved therapcudcally. This
suggests rhar the bcncficiai effect of mirovasodilators in
myocardial infarction isnot attributable to a directacnon on i
function.
Departments ofCardiology
sad Pharmacology and Therapeutics.
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EXTREMELABILEBLOOD PRESSURE IN
GUILLAXN-BARRE SYNDROME
Sir,—Hypertension is acommonmanifestationofthe autc
disturbances sometimes asvx-iarrri with Gniilain-Bam: svn,
Lichtenfeld' noted impressive lability of blood pressure
penoriiory measured in hours or days. We report here a
whose biood pressure fluctuated over seconds.
A 14 kg, 4-year-old boy presented with diplopia, araria..
developing paralysis, and areflexia. He was ventilated and :
with CDiazemuisr) CSFprotein subsequently ros;
g/L He eventually recovered fully.
Antrum.!,"- disnirbances included profuse salivation,
gaxtromtestmai mooliry, various arrhythmias, and hypert;
On the nforh day of his iiinm. he had a seizure, manifest c
slight twitching of one hand, an obtunded level of oonsoo
and fine, rapid eye luuvoiinu on fimdoscopy. His serum s
was 131 mmoi/1; gi""—, calcium,magnesium, and phospna:
ail normal, as was a computerised tomographic scan. Papiilc
was absrnr Direct artemi monitoring revealed the spec
lability ofhis blood pressure. The accompanying figure lilt
blood-pressure rhamjr. over 3 min; these changes
■SpnnTanrrm. and rvrwml Hi-tynr. infiiimni nfmnrpnin. i f
midazolam 2 mg/h, hydralazine 2 mg/h, and prop
2mg/h. 24 h urinary hydrorymethyimandeiic acid (HMM
22 pmoi, three rimes the upper limit for a normal 14 kg
Further seizures were noted on EEG, rhnngn these we
rlmirally appatnti because of the paiaivsis.
Control of the seizures was achieved by control ofblood p:
and aniiiiininiim. (phenobarfaitonc jhH law pher.
Autonomic dysfunction improved in parallel with neurc
icuivery. At follow-up there was no neurological deficit an
blood pressure and urinary HMMA levds were normal.
Despite the 3hw»-.» of papiiloedema we concluded tf
seizures were secondary to hypertensive encephalopathy









Direct artenml pranur prim-out illustratmr extreme lab
bleed pressure over 3 minperiod,without stixnuiaaon and
tedadoo and annhyperteiixivemedication
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Serum placental-like alkaline phosphatase (PLAP): a
novel combined enzyme linked immunoassay for
monitoring ovarian cancer
JFISKEN*, R C F LEONARD, G SHAW,* A BOWMAN, J E ROULSTON*
From the University Departments of *Clinical Chemistry and Clinical Oncology, Royal Infirmary, Edinburgh
summary A new combined enzyme linked immunoassay (ELISA) was developed to measure both
serum placental-like alkaline phosphatase (PLAP) activity (PLAP A) and concentration (PLAP C) in
the same microtitre plate using an Imperial Cancer Research Fund monoclonal antibody, designated
H17E2. PLAP A and PLAP C were determined together with an existingmarker, CA125, in 397 serial
samples from 87 patients with epithelial ovarian cancer. Retrospective assessment showed the
sensitivity to increase from 73% with CA125 alone, to 88% using CA125 and PLAP A, and to 93%
with all three markers in 261 samples from the patients with known active disease at the time of
sampling. When the results for all 397 samples were included in the analysis, however, the specificity,
sensitivity, accuracy and predictive powers of this monoclonal antibody were not sufficiently high to
assist in the prospective follow up of patients with ovarian cancer. This was due to a significant
number of false positive and false negative results.
Our data indicate that PLAP A or PLAP C estimation with H17E2 may, therefore, only be ofvalue
in the management of those patients with known active disease who are already known to be "marker
positive" for this antigen.
Ovarian cancer produces few local symptoms and
presents late in most cases; consequently the mortality
is high. Attempts to improve the detection of early
stage disease have foundered on the lack of a reliable
clinical or radiological screening test. In the past five
years screening work has focused on the identification
of serological tumour markers which could facilitate
earlier diagnosis and disease monitoring, a vital step
towards improving the survival of these patients.
Although numerous tumour markers have been iden¬
tified to date,1 none is specific enough to warrant its use
as a primary diagnostic tool, but several have proved
useful for monitoring the course of disease.2 Since the
publication of the initial report by Bast et al,3 CA125
has become the accepted testwith which other markers
are compared.
There has been considerable interest shown recently
in the application of placental-like alkaline phos¬
phatase (PLAP) as a marker of epithelial ovarian
cancer (EOC). Ectopic expression of PLAP was first
discovered in a patient with squamous cell carcinoma
of the lung4 and has subsequently been found in
Accepted for publication 4 August 1988
various malignancies5 including ovarian cancer.
Raised serum concentrations of this oncofetal antigen
have been found in 44%,5 35%,6 and 40%7 of patients
with ovarian cancer.
PLAP is normally produced by the syncytiotro-
phoblast of the placenta and has been detected in sera
as early as 9 weeks' gestation, increasing considerably
during the second half of pregnancy.8 It is normally
undetectable in the sera of healthy subjects and it is
this difference between normal adults and patients
with cancer which affords it marker potential. Smok¬
ing, however, is an established cause of false positive
results.9
Serum PLAP activity (PLAP A) and concentration
(PLAP C) were determined in 387 healthy volunteers
and 397 serial samples from 87 patients using a novel
combined enzyme linked immunoassay (ELISA),
developed by modification of two existing separate
assays for PLAP A10 and PLAP C.11 Serum CA125 was
also determined in all samples and evaluated with
PLAP A and PLAP C in the patients with ovarian
cancer. Both PLAP A and PLAP C were measured to
investigate a recent report" that PLAP A decreased
and PLAP C increased simultaneously with progres¬
sion of disease.
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Subjects and methods
The Imperial Cancer Research Fund (ICRF) murine
monoclonal antibody H17E2 used in this study was
produced by immunisation with term placental mem¬
branes.12 It reacts with a heat stable alkaline phos¬
phatase that is more resistant to inhibition by L-Leu
than Phe-Ala-Gly-Gly, confirming its recognition of
term PLAP as opposed to other isoenzymes of the
same family.12
Three hundred and ninety seven serial blood sam¬
ples were collected from 87 patients with EOC over
three years. The samples were separated by centrifuga-
tion at 1500 g- for 10 min at 20°C and each serum
sample stored in 0-5 ml portions at — 20°C. Each
sample was thawed once and assayed for PLAP A and
PLAP C. A separate portion was assayed for CA125
using CIS ELSA-CA kits (CIS (UK) Ltd, High
Wycombe, Buckinghamshire).
Upper limits of normal, defined as the 95th centile
for PLAP A and PLAP C were established by assaying
samples from 387 healthy blood donors after obtain¬
ing informed consent. Smoking habits were noted. All
samples were tested in duplicate using a near term
pregnancy serum pool as quality control material.
combined PLAP A and C ELISA
MicroELISA plates (M129B, Dynatech, Billingshurst,
Kent) were coated overnight at 4°C with 100 /d/well
1 0 fig ml"1 H17E2 monoclonal antibody (supplied by
courtesy of the ICRF, Lincoln's Inn Fields, London)
in 50 mM carbonate buffer, pH 9-6. The plates were
washed three times in 015 M phosphate buffered
saline (PBS), pH 7-4, containing 0 05% v/v Tween 20
(PBS/Tween 20) to remove unbound antibody; 100 p\
serum were then added and incubated for two hours at
room temperature. After washing four times in PBS/
Tween 20 100 /d phosphatase substrate: 5 mmol 1"'
disodium p-nitrophenylphosphate (Sigma, Poole,
Dorset) in 0-2 mmol 1"' diethanolamine buffer (BDH,
Glasgow, Scotland) containing 0-5mmoll~' MgCL
(pH 9-8) were added and incubated for two hours at
37°C. Optical density was measured at 405 nm using a
Titertek Multiskan MCC/340 spectrophotometer
(Flow Laboratories, Irvine, Scotland) to determine
PLAP A. The plates were then washed four times and
100^1 rabbit anti-human PLAP (Dakopatts, Den¬
mark) at 1/250 dilution in PBS containing 0-5% w/v
bovine serum albumin (BSA) were added and incu¬
bated for 30 minutes at room temperature. After
washing three times in PBS/Tween 20 100 /d peroxi-
dase-conjugated goat anti-rabbit IgG (Sigma, Poole,
Dorset) at 1/1000 dilution in PBS/0-5% BSA were
added and incubated for 30 minutes at room tem¬
perature. The plates were finally washed three times
and incubated at room temperature for 45 minutes
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with 100 /d peroxidase substrate: 0 04% w/v o-
phenylenediamine and 0 012% v/v H,0; in 0-15 M
citrate-phosphate buffer (pH 5 0) H:S04 (50 /d 2-5 M)
were added to stop the reaction and PLAP concentra¬
tion determined by measuring optical density at
492 nm using a Titertek Multiskan MCC/340.
All patient samples were scored true or false by
correlating the clinical state at the time of sampling
with the antigen titre. Presence of disease was defined
on clinical, radiological, or surgical grounds
(laparotomy). Clinical disease activity was defined
temporally as declared disease progression or reac¬
tivated disease within six months of assay. From this
the sensitivity, specificity, accuracy and predictive
values of PLAP were determined, alone and in com¬
bination with CA125.
discrete PLAP C assay
PLAP C was determined separately to show that pre¬
incubation with phosphate substrate for the activity
assay did not have any deleterious effects on sub¬
sequent PLAP C assay performance in the combined
assay.
The plates were coated in the same manner as in the
combined assay. After the serum incubation step the
plates were washed three times and rabbit anti-human
PLAP added. The remainder of the assay was identical
with that of the combined concentration assay.
Results
assay performance
The correlation between the combined and discrete
PLAP C assay was high (n = 34, r = 0-97, y = 1-4 x,
p < 0 001) (fig 1), supporting the use of a combined
assay.
Based on results from the near term pregnancy
serum pool, the between (n = 160) and within
(n = 46) assay coefficients of variation were: 16% and
7-5% for PLAP A assay, 8-2% and 3-8% for combined
PLAP C assay, and 13% and 4-4% for discrete PLAP
C assay, respectively.
correlation between PLAP A and C in
blood donors
Using the results from 397 blood donors, PLAP A and
C were poorly associated (n = 387, r = 0-56,
y = 0-16 x, p < 0-001), although still significantly
correlated.
PLAP A did not seem to be influenced by smoking
in either male or female blood donors (p > 0-05).
PLAP C, however, did seem to be increased by
smoking in both male and female donors (p < 0-001).
reference range for PLAP A and C
PLAP A and PLAP C were not normally distributed in
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Placental-like alkaline phosphatase concentration
optical density at 492nm (discrete assay)
Fig 1 Correlation between PLAP concentration measured
atone and after activity in combined technique.
the control population, neither did they normalise
following logarithmic transformation as tested by
Kolmogorov-Smirnov Goodness of Fit Test
(p < 0 05). Therefore, the 95th centiles of the control
population, 0-400 and 0-085 for PLAP A and PLAP C,
respectively, were used as cut off values. In smokers,
however, the 95th centile of the PLAP C reference
interval was 0-185; for PLAP A it was unchanged from
the non-smokers' value. Therefore, PLAP C abnor¬
mality was defined as a value greater than halfway
between the 95th centile for non-smokers and smokers
Table 1 Proportion ofsamples with raised marker values
Fisken, Leonard, Shaw, Bowman, Roulston
because the smoking habits were known in only 10%
of the patient population. Assigned cut off values were
therefore 0-400 and 0-135 optical density units for
PLAP A and PLAP C, respectively.
CORRELATION BETWEEN PLAP A AND C IN
PATIENTS WITH CANCER
The correlation between PLAP A and C in patients
with ovarian cancer (n = 397, r = 0-18, p < 0-001)
was poorer than that for the blood donors, although
still significant.
PLAP A, PLAP C AND CA125
CONCENTRATIONS
The proportion of samples with raised values ofPLAP
A, PLAP C, and CA125 are shown in table 1. Patients
were divided according to the Federation Inter¬
national de Gynecologie et Obstetrique (FIGO) stage
and histopathology. Abnormal values were seen in all
stages, but were more numerous in advanced (FIGO
stages III and IV) disease.
The sensitivity, specificity, and accuracy of PLAP
A, PLAP C, and CA 125 for each stage and histopath-
ological type are shown in table 2. Using these criteria
PLAP A was more sensitive but less specific than
PLAP C for stages III and IV disease, although both
performed less well than CA125.
The sensitivity, specificity, accuracy and predictive
values of a positive result (PVP) and of a negative
result (PVN) for each marker are shown in table 3: all
three markers were tested in all 397 samples. This
would be the case in a prospective analysis of all
sample results.
Table 4 shows the above indices when the combina¬
tion of all three markers are considered together; A
No ofsample results evaluated (TP and FP)
No ofsubjects No ofsamples PLAP A (OD > 0-4) PLAP C (OD > 015) CA125 (35 Ulmlt
Blood donors 387 387 18(5%) 5(1%)
Patients:
Stage I:
Serous 5 20 11 9 1
Mucinous 1 5 2 0 0
PDA 1 3 1 2 0
Stage II:
Serous 4 19 6 2 4
Mucinous 1 3 2 0 0
Stage III
Serous 40 204 122 81 108
Mucinous 3 12 9 6 3
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Table 2 Marker performance as assessed by histopathology
and FIGO staging
Tumour Sensitivity Specificity Accuracy
Stage (FIGO) marker (%) (%) (%)
I PLAP A 20 43 39
PLAPC 60 65 64
CA125 20 100 86
II PLAP A 0 60 55
PLAPC 0 90 91
CA125 100 90 91
III PLAP A 61 51 58
PLAPC 37 69 46
CA125 70 96 78
IV PLAP A 78 67 76
PLAPC 38 93 48
CAI25 83 93 85
I + II PLAP A 14 51 46
PLAPC 43 77 72
CA125 43 95 88
III + IV PLAP A 66 53 63
PLAPC 37 73 46
CA125 74 96 80
Histological type
(stages I-IV):
Serous PLAP A 65 51 60
PLAPC 42 71 51
CA125 74 95 81
Mucinous PLAP A 71 38 50
PLAPC 14 62 45
CA125 43 100 80
Poorly differentiated adenocarcinoma:
PLAP A 63 65 64
PLAPC 21 95 44
CA125 73 95 80
Table 3 Individual CAI25, PLAP A, and PLAP C results
CA125 PLAP A PLAPC
Sensitivity 190/262(73%) 169/262(65%) 98/262(37%)
Specificity 130/135(96%) 71/135(53%) 99/135(73%)
Accuracy 320/397(81%) 240/397(60%) 197/397(50%)
PVP 190/196(97%) 169/233 (73%) 98/133(74%)
PVN 130/201 (65%) 71/164(43%) 99/264(38%)
shows positive marker state where one or more than
one marker in the panel was increased, and B shows
the same indices when PLAP was tested only in the
samples which were CA125 negative (so called "series
testing").
SERIAL ANTIGEN TITRES IN TWO PATIENTS
Two patients were chosen after analysis of their serial
antigen titres. (fig 2) to illustrate retrospectively if
PLAP A and PLAP C had been useful for predicting
relapse. In case 1 CA125 had been negative until well
after clinically evident relapse, and in case 2 an
increase in CA125, although preceding relapse, was a
late event. An increase in PLAP A in case 1 and an
increase in PLAP C in case 2 would have been earlier
predictors of relapse. Both patients were followed up
after a positive second look laparotomy. Case 1 was
receiving chlorambucil when each sample was taken
and case 2 received three cycles of Cis-platinum












Jc " - -








Fig 2 Case I: stage III adenocarcinoma. Case 2: stage III
serous papillary adenocarcinoma.
Table 4 CAI25, PLAP A, and PLAP Cpanel results
Sensitivity Specificity Accuracy PVP PVN
A: CAI25, PLAP A and PLAP C 43/261 (93%) 57/136(42%) 300/397(76%) 243/322(75%) 57/75 (76%)
where $ I marker is positive




Determination of both PLAP A and C in a combined
assay has several advantages over separate assays.
These include reduced expense (in particular halved
monoclonal antibody costs) and reduced operator
time and error due to sampling variation. The correla¬
tion between the combined and discrete PLAP C assay
was high, supporting the use of the combined assay.
The gradient of the slope was greater than 10,
however, for which the reasons are unclear. The
greater absorbance in the combined assay was not due
to residual p-nitrophenyl phosphate substrate, which
showed zero absorbance at wavelengths greater than
470 nm. In the combined assay the catalytic reaction
may have induced a conformational change in PLAP
which results in enhanced recognition and binding by
the rabbit anti-human PLAP.
The data show that PLAP A and PLAP C assays,
individually and in combination, are insufficiently
sensitive and specific (tables 2 and 3) for the man¬
agement of women with epithelial ovarian cancer.
Several reasons for the .failure of PLAP to fulfil
expectations may be postulated. Changes in antigen
expression during disease progression and increasing
tumour dedifferentiation are complex, substantiated
by the lack ofclose correlation we have found between
PLAP A and PLAP C in cancer patients when
compared with normal controls. These findings con¬
trast with reports from another group who used a
different monoclonal antibody raised against PLAP.'4
Numerous factors influence the expression of
PLAP, including smoking, which induces PLAP-like
alkaline phosphatase synthesis and secretion by lung
alveoli.15 H17E2 recognises this isoenzyme,16 which
may in part account for a high proportion of false
positive results in our series of patients. Whether a
"smoking effect" was a source of error in this series is
uncertain. The control sera showed a significant
increase in the reference interval only in the PLAP C
assay; in the patients' sera many more false positive
results were seen with PLAP A than with the PLAP C
assay. For PLAP C the use ofa correction factor based
on observations in the large control group might
reasonably be expected to have reduced the false
positive results associated with smoking. Unfortun¬
ately, information on the smoking habits in most
patients was unobtainable, hence the effect ofsmoking
on the patients' PLAP values could not be assessed
properly.
PLAP has not previously been evaluated in terms
of sensitivity, specificity, accuracy and predictive
power,16 although numerous reports advocate its use
as a tumour marker in ovarian cancer.5-81"4 When
results for PLAP A and PLAP C were combined with
CA125 results the overall sensitivity increased from
Fisken, Leonard, Shaw, Bowman, Roulston
73% with CA125 alone to 93% with all three markers,
where at least one gave a positive result (table 4a).
Combining results in this way, however, resulted in a
considerable loss of specificity, from 96% for CA125
alone to 42% for the combined results. This loss of
specificity is better seen in terms of the relative
predictive powers of the test. The PVP ofCA125 alone
was 97% with a PVN of 65% (table 3), whereas the
combined results showed a fall of PVP to 75% and
only a relatively small rise in PVN to 76% (tables 4a
and b).
PLAP may be assayed in series17 with CA125. This
reduces the total number of PLAP assays required as
only CA125-negative samples would require retesting,
allowing the PVP ofCA125 alone to be retained. Serial
analysis of the patients' data (table 4b) showed that the
use of PLAP A and PLAP C on samples negative for
CA125 (n = 201) gave a PVP of both assays together
ofonly 42%, with PVN remaining unchanged at 76%.
It is clear, therefore, that assay of PLAP A and PLAP"
C did not add significantly to the predictive value of
CA125 in these negative samples in which the active
disease prevalence, as assessed clinically, was 71/201
(35%).
These data indicate that PLAP, as measured with
this monoclonal antibody, confused the interpretation
of CA125 results in this cohort of patients. CA125
assay used on its own would seem to be more helpful in
clinical decision making. The results of this study
agree with those ofa recent report by Haije et a/,18 who
also assayed PLAP activity and concentration by
immunoreactivity, but found neither to be useful for
general patient follow up and management.
Tucker et al have found determination of PLAP
activity using H17E2 useful in the follow up of
testicular germ cell tumours, particularly seminomas.10
The applicability of the simple combined assay
deserves to be tested in this and possibly other cancers.
The combined assay, using a more specific mono¬
clonal antibody, one which does not react with PLAP
induced by smoking,6 may prove useful in the follow
up of patients with ovarian cancer. Increased
specificity would then be obtained, possibly at the
expense of sensitivity—an acceptable modification in
the context of a panel of markers where specificity of
each marker is the most important criterion.
Although measurement of PLAP was not found to
be generally helpful, a few patients may have benefited
from additional PLAP assay (fig 2). It is impossible at
this stage to judge which patients will benefit most
from prospective serial measurement of PLAP.
Appropriate patient selection is essential ifPLAP is to
be of use in future as an adjunct in monitoring ovarian
cancer.
Unfortunately, insufficient preoperative samples
were available in this study to assess the value ofPLAP
Combined ELISA for monitoring ovarian cancer
assays in the untreated patient. Preoperative
measurement of PLAP may provide a helpful
indicator of patients who will benefit from further
serial measurement in a manner analogous to CA125
where assay at the time the disease presents helps in the
selection of "secretors".'9
Despite initial promising investigations of PLAP as
a tumour marker in ovarian cancer this study and
others18 20 have failed to corroborate them. Work is
currently under way using various monoclonal
antibodies to investigate further the PLAP molecules
and epitopes in conjunction with assay development
for other promising markers such as mucin antigens."
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SUMMARY
There is increasing evidence to support the use ofCA125 in the follow-up and management of
patients with ovarian cancer and several commercial kits are now available for its measure¬
ment. This study investigated and compared the performance of three of them: an enzyme
immunoassay (EIA) and an immunoradiometric assay (IRMA) from Abbott Diagnostics,
and an IRMA from CIS, U.K.
One hundred and thirty-two serum samples from 42 patients with advanced epithelial
ovarian cancer were thawed once and assayed for CA125 using each kit. Both IRMAs
performed better than the EIA in terms of CV, sensitivity, specificity, and accuracy. The
results confirm the usefulness of CA125 as a marker for ovarian cancer. However, discrep¬
ancies between results using different kits suggest the need for improved standardization.
keywords Ovarian cancer ELISA Immunoradiometric assay Sensitivity
Specificity CA125
INTRODUCTION
Since the development of the CA125 immunoradiometric assay (IRMA) using the
monoclonal antibody (MoAb) OC125 by Bast etal. (1983), many investigators have
corroborated their initial findings, establishing CA125 as a useful tumour marker
for ovarian epithelial cancer.
CA125 has been found in various tissues, both malignant and non-malignant
(Bast et al., 1983). Although not specific for ovarian cancer, CA125 is extremely
useful in the follow-up of ovarian cancer patients. Serum antigen levels tend to
correlate well with tumour burden and disease status (Lambert, 1987); rising levels
are associated with disease progression, whilst falling levels are associated with
disease regression. However, a negative result does not preclude the presence of
disease (Lambert, 1987); up to 25-30 per cent may be false negative. This is particu¬
larly true with mucinous ovarian epithelial carcinomas, where greater than 50 per
cent may be false negative (Bast et al., 1983). An increasing level of CA125 was
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found to precede clinical recurrence by a median lead-time of 3 months in one study
(Niloff et al., 1986). Recently, the significance of pre-operative CA125 has been
reported. It has been suggested that a low pre-operative serum CA125 level is
indicative of a favourable prognosis, while a high pre-operative CA125 carries
a poorer prognosis (Cruickshank et al., 1987). Pre-operative assay also aids in
the selection of 'secretors' whose management may be aided by further serial
measurement.
As a result of the relatively low false positive rate in comparison to other markers,
CA125 assay is being investigated as a screening test for earlier diagnosis in the 'at
risk' population, namely post-menopausal women. Preliminary results from the
first U.K. study where an abnormal CA125 and vaginal examination were followed
up by pelvic ultrasound have led the authors to suggest the need for further
randomized trials (Jacobs et al., 1987, 1988).
Our study investigates and evaluates the performance of three of the commercial
assays currently available—an enzyme immunoassay (EIA) and an IRMA from
Abbott Diagnostics, and an IRMA from CIS (U.K.)—when used in the assay of
samples from patients with ovarian cancer. The results are evaluated in the context
ofmonitoring patients with advanced disease and consideration is also given to the
implications of screening for early diagnosis using the CA125 assay.
PATIENTS AND METHODS
Patients
One hundred and thirty-two serial serum samples from 42 patients with FIGOt
stage I-IV epithelial ovarian cancer were assayed for CA125 using the kits de¬
scribed. The majority of patients had FIGO stage III and IV disease. All samples
were obtained in the post-operative follow-up period.
Methods
The assays were carried out according to manufacturers' instructions supplied
with each kit. All kits operate on the same principle: a monoclonal sandwich is
formed between fixed OC125 MoAb, CA125 present in the sample, and a radio-
labelled (IRMA) or enzyme-labelled (EIA) OC125 tracer MoAb. The antigen con¬
centration is therefore proportional to the amount of tracer bound. All results are
interpolated from a standard dose-response curve. The IRMA data were subjected
to computer curve fit and analysis by the RIA-Calc program (LKB). The EIA data
were analysed and evaluated manually.
The antigen results were scored retrospectively (true or false and positive or
negative) according to disease status at the time of sampling. A positive CA125 by
any assay was defined as >35 U ml-', following the initial recommendations of
tFederation International de Gynecologie et Obstetrique.
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Table 1. Summary of assay performance
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% Abbott IRMA CIS IRMA Abbott EIA
Sensitivity 90-7 80 83-3
Specificity 81-3 92-5 78-8
Accuracy 85-3 87-4 80-6
C.V. 6-10 6-10 10-15
PVP 77-8 88 74-5
PVN 92-4 88 88
Bast et al. (1983). Disease status was assessed clinically or surgically (second-look
laparotomy).
The sensitivity, specificity, and accuracy of each kit were defined by aggregating
the frequencies of true positive (TP), true negative (TN), false positive (FP), and
false negative (FN) results. Thus,
TP
Sensitivity = x 100%
TP+ FN
TN
Specificity = x 100%
TN+ FP
TP+TN
Accuracy = x 100%
TP+ TN+ FP+ FN
For prospective assay and subsequent clinical usage, it is necessary to know the
predictive value of a test, i.e. the chance that a test result is correct. The predictive
value of a positive result (PVP) and negative result (PVN) were calculated using the
following formulae:
TP TN
PVP = x 100% PVN = x 100%
TP+FP TN + FN
The sensitivity, specificity, accuracy, coefficient ofvariation, and predictive values
of each kit are shown in Table 1.
RESULTS
Assay Performance
The CVs for each kit (Table 1) show that the IRMAs operate with satisfactory
reproducibility within the working range. In terms of precision, both IRMAs were
significantly better than the EIA.
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Figure I. Correlation between Abbott IRMA (x axis) and CIS IRMA (y axis)
The results were correlated using Spearman's Rank Correlation coefficient. The
correlation between the IRMAs was good («= 132, r= 0-93,/>< 0-001, y = 0-86x+
10-7) but the slope was significantly less than 1 0 (Figure 1). The EIA correlated less
well with the IRMAs (r = 0-85, Figure 2, and r= 0-86, Figure 3).
With a slope of less than 10 for the correlation between the Abbott IRMA and
CIS IRMA, the CIS IRMA consistently gave lower antigen levels than the Abbott
IRMA. As the upper limit of normal is the same for both IRMAs, this gave rise to
discrepancies in 11/132 (8 per cent) of sample results. Thus, of 11/132 samples
judged negative by CIS IRMA but positive with Abbott, five were TP, three were
FP, and three (recent samples) need further clinical follow-up.
DISCUSSION
Both IRMA perform better than the EIA in terms of CV, sensitivity, specificity,
accuracy, and predictive values (Table 1). In addition, the IRMAs are less time-
consuming and cumbersome to carry out than the EIA. Therefore, the IRMA is our
method of choice for the CA125 assay. However, although the correlation between
the Abbott and CIS IRMAs was good (Figure 1) the slope of the correlation line was
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Figure 2. Correlation between Abbott EIA (x axis) and Abbott IRMA (y axis)
significantly less than 10, which led to some samples being erroneously classified.
Both IRMA manufacturers recommend 35 U ml"' as the upper limit of normal,
suggesting a discrepancy in standardization and a need for re-definition of the
cut-off value.
The major problem with CA125 assay is the relatively high proportion of false
negative results; these reduce overall assay sensitivity (Schilthius et al., 1987), and
were particularly noticeable in the CIS IRMA. Although CA125 is not specific to
ovarian cancer, false positives are rarely seen in this population and do not consti¬
tute a major problem since this marker's main use is in monitoring the progress of
established ovarian cancer patients during follow-up therapy. The highest predic¬
tive value of a positive test (PVP) was 88 per cent in this study using the CIS IRMA.
This would have to be greatly improved to avoid unnecessary trauma to individuals
with false positive results, if use of the test were to be extended for profiling lower-
risk groups, i.e. if it were to be used for purposes other than the management of
known cancer patients. Recent reports (Jacobs et al., 1987, 1988) have, however,
suggested such a role for CA125 as part of a multimodal screening system for early
diagnosis, but these conclusions have been called into question (Cruickshank, 1988;
Roulston et al., 1988).
Ovarian cancer has a prevalence of 15/100 000 of the population (Piver, 1983),
therefore a test with 100 per cent sensitivity and 99.9 per cent specificity will produce
an unacceptably low PVP of 13 per cent.
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Figure 3. Correlation between Abbott EIA (x axis) and CIS IRMA (y axis)
In the light of our investigation, improved standardization of the CA125 assay
may be advantageous in that it may lead to increased sensitivity when used alone or
with a panel ofmarkers as in the current trend (Bast et al., 1984; Dhokia et al., 1986;
Knauf et al., 1985; Ward et al., 1987). This may facilitate earlier detection of recur¬
rence and consequently improve management of established ovarian cancer
patients.
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